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ABSTRACT

Vascular health plays a major role in several human disorders, particularly in
cardiovascular diseases (CVD) (1,2). The endothelium can be considered an organ that
regulates vascular homeostasis by maintaining an appropriate vascular tone, platelet activity,
leukocyte adhesion and angiogenesis. When one or more of these components is compromised
due to impaired endothelial vascular signalling, endothelial dysfunction (ED) may occur (1).
One of the main key metabolic manifestations of ED is reduced nitric oxide (NO)
bioavailability. NO is an important signalling molecule that regulates various vascular
processes, including through its main role as a vasodilator, acting through relaxation of smooth
muscle cells (2,3). Impaired bioavailability of NO and up-regulation of various molecules
involved in vascular function are partly explained by the cooperative and synergistic action of
inflammation and oxidative stress on ED (4–6). This is particularly evident in older adults, as
several studies support a new immune-metabolic viewpoint for age-related diseases, termed
“inflammaging” which is characterized by a chronic low-grade inflammation (7). Thus,
interventions aiming to regulate the immune response and to prevent the accumulation of
deleterious reactive species, have been considered to be a relevant therapeutic target to improve
vascular health (8).
Nutrition plays a major role in regulating the inflammatory state and enhancing
endogenous antioxidant defences (9). Many dietary patterns have been associated with the
prevention of diseases associated with inflammation in epidemiological studies (10), while at
the same time a large range of dietary interventions have been explored in clinical practice to
treat pathological conditions such as ED (11). Flavonoids, a class of dietary polyphenols, are
bioactive compounds that have potential to both prevent and treat conditions related to a proinflammatory and oxidative stress state (12,13). Meta-analysis of controlled trials and cohort
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studies demonstrate a protective effect of flavonoid intake on CVD (14–18), particularly on
hypertension (19,20). Anthocyanins, a subclass of flavonoids, are emerging as a potential
therapeutic option for CVD risk factors (21). Anthocyanins are the largest class of watersoluble plant pigments, that are responsible for the blue, purple and red colour of many fruits
and vegetables, such as blueberries, blackberries, red grapes, plums and eggplants (22). The
beneficial effects of anthocyanins on CVD risk factors are related to their antioxidant and
immunomodulatory effects, thereby attenuating the synergistic deleterious effects of oxidative
stress and inflammation in CVD (21,23). In humans, anthocyanin intake has been shown to be
associated with a lower risk of cardiovascular events (24,25). Intervention studies using
anthocyanins have demonstrated improvements in vascular function (26) and biomarkers
related to oxidative stress (27–30), as well as antioxidant status (28,30–32), lipid profile (33–
35) and inflammatory response (36,37) in both long-term and acute designs.
Despite these promising findings, there are still several gaps in the literature regarding
the potential health benefits of flavonoids and anthocyanins. At the epidemiological level, a
few populations have been investigated in appropriate large-scale studies. Epidemiological
studies require a specific approach to quantify flavonoid content in foods due to significant
variation between crops grown in different geographic areas, as well as consideration of the
variety of diet patterns, both within and between countries. At the clinical level, a number of
studies have investigated the potential effect of anthocyanins in attenuating and preventing
pathological conditions. The immediate effect of anthocyanins in the postprandial state has
been evaluated in several studies using a high-fat high-energy meal challenge. Acute feeding
studies allow investigation of the ability of these bioactive compounds to attenuate the
deleterious effects following a stressor meal; however, the findings have not been adequately
collated to facilitate translation into dietary guidance. Such studies have not included a robust
investigation of sensitive measures of vascular function in the postprandial state, which along
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with the immune response are important predictors of CVD. Additionally, there are still several
gaps to be addressed regarding the effect of anthocyanins on vascular health and inflammation
in older adults, especially among those with neurodegenerative conditions, such as mild
cognitive impairment (MCI), which share risk factors with CVD.
This thesis addresses the following research questions:
1. Is dietary intake of flavonoids, including anthocyanins, associated with the
incidence of hypertension in Australian women?
2. What is the current level of evidence on the postprandial effects of anthocyanins on
CVD risk factors in high-fat high energy (HFHE) meal challenge studies?
3. What are the post-prandial effects of anthocyanins on micro- and vascular function,
and other CVD risk factors in overweight older adults following a HFHE challenge?
4. What are the chronic effects of anthocyanins on microvascular function,
inflammatory biomarkers and 24 h ambulatory blood pressure in older adults with
diagnosis of MCI?

Four studies were conducted to address these research questions. At the
epidemiological level, nationally representative cohort study data was used to estimate the total
dietary intake of flavonoids and their subclasses in Australian women. This provided novel
data that demonstrated an association between flavonoids subclasses with a lower risk of
hypertension in Australian women. This contributes to the body of evidence that informs
nutrition messaging and policies for improved cardiovascular health in this population.
At the clinical level, knowledge synthesis was conducted using a systematic literature
review approach to collate information on the postprandial effects of anthocyanins on CVD
risk factors in high-fat meal challenge studies. A total of 13 eligible randomized clinical trials
reported beneficial effects of anthocyanins, with most the promising results evident for the
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attenuation of deleterious postprandial effects on oxidative stress and antioxidant status,
triacylglycerol and total cholesterol concentrations, vascular endothelial function and
inflammatory biomarkers. Post-prandial changes in blood pressure and lipoproteins were least
affected by acute anthocyanin consumption.
A randomised crossover, placebo controlled clinical trial was subsequently designed to
investigate the postprandial effects of anthocyanins following a HFHE meal challenge, but
using a novel and robust evaluation of vascular function, namely macro and microvascular
parameters. Methodologies combined both classical techniques (flow-mediated dilatation
(FMD) with the novel imaging technology Laser Speckle Contrast Imaging (LSCI). To our
knowledge, this is the first study to conduct this type of protocol in studies of nutritional
interventions. Fruit-based anthocyanins attenuated the postprandial detrimental effects of a
HFHE challenge on parameters of vascular and microvascular function, and inflammatory
biomarkers in 16 overweight older adults.
A second randomised, placebo controlled clinical trial was conducted to investigate the
longer term effects (8 weeks) of two different doses of anthocyanins provided by Queen Garnet
plum on inflammatory markers associated with CVD risk factors, along with analysis of
microvascular function and 24-hour ABP. The innovative aim of this study was to investigate
such parameters in an older population diagnosed with mild cognitive impairment (MCI), a
neurodegenerative condition that shares pathological mechanisms with CVD. A daily high dose
(201 mg/day) of fruit-based anthocyanins consumed for 8 weeks significantly reduced tumour
necrosis alpha (TNF-α), but did not alter interleulin-6 (IL-6), interleukin-1 beta (IL-1β), highsensitivity C-reactive protein (hs-CRP), microvascular function nor blood pressure parameters.
No effects were observed in the low dose (45mg/day) group.
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This body of research contributes novel data on the role of flavonoids, and specifically
anthocyanins, on vascular function, inflammation and CVD risk across various levels of
evidence, including:
•

Epidemiological evidence: analytical work conducted in national representative
cohort of Australian women.

•

Knowledge synthesis: systematic literature review.

•

Experimental evidence: Two randomised controlled clinical trials with
innovative design that allows interpretation of both acute and chronic effects of
anthocyanin intake.
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CHAPTER 1: Introduction
1.1

Vascular function and cardiovascular diseases

The health of the vascular system plays a major role in several human disorders,
particularly in CVD (1,2). CVD is a major cause of mortality globally and is the leading cause
of death for Australian men and women, responsible for over 43,500 deaths (27%) in the year
2017 (38). Following a pattern that is also similar worldwide, about 1 in 3 Australians aged 18
years and over (34%) have high blood pressure, comprised of 23% adults with uncontrolled
high blood pressure and 11% whose blood pressure was controlled using medication (39).
A common characteristic among CVDs is the alteration of vascular function and/or
structure. The endothelium, which is comprised of cells that line the internal surface of the
lumen of blood vessels, is an organ that regulates vascular homeostasis by maintaining an
appropriate vascular tone, platelet activity, leukocyte adhesion and angiogenesis through the
controlled release of mediators such as NO and other regulatory factors (3,40). When one or
more of these components becomes dysregulated due to impaired endothelial vascular
signalling, a pathological state named endothelial dysfunction (ED) occurs. In the case of ED,
there is attenuated vasodilation, augmented vasoconstriction, and remodelling of the vessel
structure that occurs simultaneously in multiple vascular beds (3,41).
Determining the aetiology of ED is complex issue, as this condition shares causes and
outcomes with several other diseases. For example, classical CVD risk factors such as smoking,
high blood pressure, obesity, dyslipidaemia and glucose intolerance are associated with the
occurrence of ED (1,40). Furthermore, because the degeneration of vascular beds occurs over
time, ageing is an independent risk factor for ED (42). After ED manifests, it worsens the
clinical status in people who have pre-existing diseases such as diabetes, peripheral vascular
diseases, stroke and other vascular events, hypertension and atherosclerosis (1,2). In CVD for
24

instance, ED is involved in its pathogenesis by increasing its coexistent risk factors, correlating
with disease progression and predicting cardiovascular events (43–47).
One of the main key metabolic manifestations of ED is the partial functional loss of
endothelial-derived vasodilators, such as NO, in which an aberrant accumulation of reactive
oxygen species (ROS) is one of the leading causes (3). The bioavailability of NO depends on
its proper synthesis, which involves the enzyme nitric oxide synthase (NOS). NOS is a family
of enzymes that catalyse a complex reaction involving L-arginine, NADPH, H+ and O2 into
citrullline, H2O, NADP and NO, besides other cofactors. Endothelial production of nitric oxide
synthase (eNOS) is key to the maintenance of vascular health. In a state of exacerbated
oxidative stress, several intracellular interactions may occur in the endothelium, resulting in a
phenomenon called “eNOS uncoupling”. This attenuated and/or altered activity of the enzyme
leads to a switch from the generation of NO to the generation of superoxide anions and
hydrogen peroxide, thus creating a vicious cycle in regard to the production of ROS and downregulation of eNOS (5,48). The outcome of this process is an endothelial phenotype consisting
of arterial stiffness, altered vasomotion, increased cytokine synthesis, chemokine secretion,
leucocyte adherence, LDL oxidation, platelet activation, smooth cell proliferation and
migration and up-regulation of adhesion molecules. This dysregulation in eNOS signalling and
remodelling of vasculature are the earliest pathological findings in atherosclerosis, a first step
to CVD development(49,50).

1.2

Inflammation and oxidative stress: Implications for vascular health

and cardiovascular diseases

Despite the development of successful treatments for dyslipidaemia and hypertension,
and knowledge of well-established risk factors, CVD still accounts for one third of all deaths
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worldwide. The multifactorial background makes it difficult to detect initial pathological
events, which are usually subclinical during the early phase of disease (51). Oxidative stress
and inflammation are known to contribute to endothelial dysfunction and vascular damage, and
their roles in the pathophysiology of hypertension and atherosclerosis are now well accepted
(52,53).
Inflammation is a complex series of coordinated events regulated by a diverse number
of features of the immune system including cytokines, enzymes, lipid mediators and vasoactive
mediators. In non-diseased conditions, inflammatory responses are resolved when proinflammatory factors are no longer active, resulting in maintenance of a highly active and wellregulated balanced state. However, in certain conditions, inflammation may not be completely
resolved, resulting in persistent and low intensity stimulation that produces continuous
inflammatory responses (54,55). This sustained pro-inflammatory state, also called low-grade
inflammation, can enhance ED (55). ED is an early marker and one of most predominant risk
factors in the development of atherosclerosis and can be detected before any structural change
affects the vessel walls (3,40,56).
The traditional view is that atherosclerosis represents a consequence of lipid
accumulation as a degenerative process associated with ageing, where cholesterol is
indisputably recognized as an environmental and genetic driver of the disease. However, this
does not explain the entire pathophysiological process. Robust evidence shows that
inflammation participates centrally in all stages of the disease, from initial lesions to end-stage
thrombotic complications, and current research is addressing questions about which
inflammatory mechanisms are involved, as well as identification of therapeutic interventions
(53,57,58). As the endothelium progresses to a dysfunctional state, anti-thrombotic properties
and endothelial permeability are impaired, along with upregulation of pro-inflammatory
cytokines and expression of adhesion molecules, thereby facilitating leukocyte adhesion to the
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endothelium. Subsequently, leukocytes cross the endothelium and migrate into the intima,
mediated by chemo-attractants. Upon reaching the intima, monocytes transform into
macrophages and express receptors that facilitate uptake of lipids, leading to the transformation
into foam cells, which initiate an atherosclerotic lesion (59,60).
In addition to the more specific vascular inflammatory process described above, which
involve several mediators such as vascular adhesion molecules (intercellular adhesion
molecule 1 and vascular adhesion molecule 1), proteases (plasminogen activator inhibitor-1
and metalloproteinases), endothelins, chemokines (monocyte chemo-attractant protein-1) and
others, the role of peripheral inflammatory biomarkers such as C-reactive protein (CRP),
tumour necrosis alpha (TNF-α), interleukin-6 (IL-6) and interleukin-1 beta (IL-1β) have been
associated with an increased CVD risk (55,61,62). This is particularly evident in older adults,
as several studies support a new immune-metabolic viewpoint for age-related diseases, termed
“inflammaging”, which is characterized by a chronic, low-grade inflammatory response in the
absence of a pathogen (7). Additionally, excessive adiposity across all ages is associated with
an up-regulation of a pro-inflammatory state, as the accumulation of adipose tissue mass
promotes the secretion and release of inflammatory mediators, including C-reactive protein
(CRP), interleukin-6 (IL-6), interleukin 1 beta (IL-1β) and tumour necrosis factor alpha (TNFα) (63,64). This process also leads to chronic low-grade inflammation that is driven by a
nutrient excess and/or overnutrition and has the same mechanisms as those underpinning
“inflammaging” (7).
CRP has emerged as a major marker of vascular inflammation, playing a direct role in
promoting ED (65,66) and the development of CVD (67,68). CRP is an acute-phase reactant
considered to be a reliable biomarker of underlying systemic inflammation due its long halflife and clinically-available bioassay (53). Although CRP levels may increase up to 1000-fold
in response to trauma or relevant infections, levels are remarkably stable over long periods of
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time when measured in asymptomatic individuals, and a high-normal range concentration of
CRP has been identified as an independent predictor of future vascular events (55). Increasing
evidence suggests that CRP directly participates in the inflammatory process of atherogenesis,
with a high expression in the atherosclerotic plaque and an important role in plaque
vulnerability (69). In a study of 302 autopsies of an atherosclerosis phenotype, it was found
that the lowest high-sensitivity c-reactive protein (hs-CRP) concentrations were observed in
those who had died of non-cardiac causes (70). Stable plaques showed a modest elevation,
while erosive plaques showed a greater elevation, and a marked elevation in hs-CRP was seen
in ruptured plaques. The highest quartile of hs-CRP concentration was associated with a 1.5 to
1.7-fold increase in relative risk of symptomatic atherosclerosis. In all cases of sudden cardiac
death, high concentrations of hs-CRP were identified, regardless of the presence or absence of
thrombosis, suggesting that hs-CRP identifies lesions rich in lipids and macrophages, and that
it is associated with a risk of a vascular event, even in patients with clinically stable coronary
heart disease (70).
CRP levels may be useful for short-term prognosis and long-term risk assessment after
a cardiovascular event (69). Therefore, several studies have investigated associations between
CRP levels and the risk of a wide range of CVD events. A number of studies have investigated
the predictive role of CRP in myocardial infarction (MI).The Honolulu Heart Study found that
the odds of MI increased in the first few years of follow-up in participants with high CRP
concentrations, and that trend was similar after 20 years of follow-up, showing that
inflammation may play both an early and late role in the atherosclerotic process (71). In another
study, among 1,086 men followed up for over 8 years, those with the highest quartile of hsCRP had a 2.9-fold greater relative risk for MI (p < 0.001) and 1.9-fold greater relative risk for
stroke (p = 0.02) compared to men in the lowest quartile, that was independent of traditional
cardiovascular risk factors (72). Another study conducted in 82,544 adults [66,796 men and
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15,748 women; mean (SD) age 55.1 (9.86) y] without prior cardiovascular diseases or cancer
at baseline reported 714 incident MI cases over 6 years of follow-up (61). Higher baseline and
cumulative average concentrations of hs-CRP were consistently associated with increased risk
of MI (p<0.001 for both). A longitudinal increase in hs-CRP was also associated with a higher
future risk of MI, after adjustment for baseline values and other covariates (p<0.001). Each
1mg/L increment per year in hs-CRP was associated with a 9.3% increase in risk for future MI
[hazard ratio (HR) = 1.09, 95% CI, 1.03; 1.17]. Participants with high-grade inflammatory
status (hs-CRP ≥10 mg/L) had a higher risk of MI occurring <3 months versus those compared
with those that had hs-CRP concentrations <0.5 mg/L (HR = 6.64; 95% CI, 1.49-29.6), and
with MI occurring ≥4 years (HR = 2.95; 95% CI, 0.90, 9.65) (61). A meta-analysis investigated
the ability of CRP to predict major cardiovascular events in 5401 individuals with peripheral
arterial disease (PAD). PAD patients with higher CRP had a significantly higher risk of major
cardiovascular events compared with those with lower CRP concentrations (HR 2.26, 95% CI
1.65 to 3.09, p < 0.001). The HR for major cardiovascular events was 1.38 (95% CI 1.16 to1.63,
p < 0.001) per unit increase in CRP concentration (73). Concerning coronary heart disease
(CHD), a meta-analysis was conducted presenting a body of evidence of good quality,
consistency, and applicability. For studies that adjusted for all Framingham risk variables, the
relative risk for incident CHD was 1.58 (95% CI, 1.37 to 1.83) for CRP levels greater than 3.0
mg/L compared with levels less than 1.0 mg/L(74).
TNF-α is a cytokine with a wide range of pro-inflammatory activities and is primarily
produced by macrophages, endothelial cells, and smooth muscle cells of atherosclerotic arteries
(75). TNF-α may influence the atherosclerotic process both by causing metabolic perturbations
and by increasing the expression of surface leukocyte adhesion molecules, chemokines and
enhancing the production of other cytokines and growth factors. TNF-α also stimulates new
vessel formation and induces features characteristic of developing atheroma. High
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concentrations of TNF-α have been associated with premature coronary artery disease, acute
MI, peripheral arterial disease, and congestive heart failure (75). Concerning the predictive role
of TNF-α in CVD, a case-cohort study comprising 105 coronary artery disease (CAD) cases
and 638 individuals randomly selected from a cohort of 5,404 participants aged 35–74 years
(mean follow-up of 6.1 years) reported that TNF-α was significantly and independently
associated with CAD (adjusted HRs=1.87;1.31–2.66) (75). Furthermore, there is evidence from
a large-scale prospective cohort study (2225 participants aged 70-79 years old without baseline
CVD) that were assessed for incident coronary heart disease, stroke and congestive heart failure
events during an average follow-up of 3.6 years. TNF-α was significantly associated with CHD
(per TNF-α SD increase: RR, 1.22; 95% CI, 1.04-1.43) and congestive heart failure (per TNFα SD increase: RR, 1.59; 95% CI, 1.30 to 1.95) (76).
IL-6 is a pleiotropic cytokine with both anti and pro-inflammatory roles that regulates
a plethora of immune and metabolic responses; however, high concentrations of this cytokine
have been associated with CVD and mortality (76,77). IL-6 is highly expressed by the vascular
endothelium and the pharmacological inhibition of IL-6 improves endothelial function (78)
Such findings are clinically meaningful considering the predictive roles of IL-6 concentrations
in CVD risk supported by a number of studies. Hazard ratios of 1.80 have been reported
according to each 1-SD increase in IL-6 for risk of first-ever cerebrovascular events in
individuals with vascular risk factors but without any pre-existing cardiovascular disease (79).
Further, in a meta-analysis of 17 prospective studies investigating clinical coronary outcomes
(i.e., myocardial infarction or coronary death), an odds ratio of 1.61 (95% CI 1.42–1.83) was
found per 2 SD increase in baseline IL-6 (80). Another meta-analysis of 17 studies comprising
288,738 healthy individuals reported significantly higher IL-6 concentration in CVD cases
compared to non-CVD controls [standardized mean difference of 0.14, (95% CI) 0.090.20]/mean difference of 0.36 [0.28-0.44] pg/mL) (81).
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IL-1β also plays a central role in CVD development, representing one of the most potent
inducers of innate immunity and acts as an upstream regulator in the inflammatory cascade
(82). IL-1β synthesis is significantly upregulated after cardiovascular events such as
myocardial infarction, as well as in advanced plaque formations in atherosclerotic disease, thus
it has been investigated as a therapeutic option in secondary and tertiary prevention of CVD
(83). Intrinsic vascular wall cells and lesional leukocytes alike can produce this cytokine. Local
stimuli in the plaque induce the generation of active IL-1β through the action of a molecular
assembly known as the inflammasome (84). The convincing links between IL-1β and proinflammatory diseases, such as atherosclerosis, indicates this cytokine to be a potential
therapeutic target to improve cardiovascular outcomes (84). In this matter, an anti-IL-1β
therapy was investigated in a large randomized, double-blind, placebo-controlled trial of
including 10,061 patients (median follow-up of 3.7y) with a history of myocardial infarction
and CRP concentrations ≥ 2 mg/L. The treatment with canakinumab (anti-IL-1β monoclonal
antibody) led to 15% reduction in major adverse cardiovascular events (p=0.007) (85).
Furthermore, a meta-analysis including 6 cohort studies with 1,855 CVD cases and 18,745 noncases with (follow-up times between 5-16y) investigated the effect on incident CVD of an
Interleukin-1 receptor antagonist (IL-1RA), which counter-regulates IL-1β as an endogenous
inhibitor in vivo by blocking the binding site for IL-1β. A pooled standardized hazard ratio
(95% CI) for incident CVD of 1.11 (1.06–1.17) was found after adjustment for age, sex,
anthropometric, metabolic, and lifestyle factors (P<0.0001) (82).
Oxidative metabolism is essential for aerobic life, as nutrients provide energy through
oxidative phosphorylation, while intermediary metabolism adds direct incorporation of oxygen
atoms from molecular oxygen (O2) into biomolecules. Any molecules or atoms generated by
this process containing 1 or more unpaired electrons (free radical) are highly reactive (86). This
biological process involving generation of oxidative breakdown products can interact and lead
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to oxidation of DNA, proteins, carbohydrates and lipids. On the other hand, the human
metabolism has several strategies of defence against oxidative damage, such as enzymatic and
non-enzymatic antioxidants, besides adaptive responses (87,88).
The imbalance between oxidants and antioxidants in favour of oxidants, potentially
leading to tissue damage and/or triggering cell death pathways, is called oxidative stress (50).
Reactive species or free radicals include reactive oxygen and nitrogen species (RNS), which
are also important components of intracellular signalling cascades. Thus, the deleterious
oxidative overload in cells, organs or the entire organism is a condition that can be
characterized not only by an aberrant quantity, but also by the quality (source) of these
molecules, as aforementioned in the eNOS uncoupling example (5,88).
ROS molecules include free oxygen radicals, such as superoxide, hydroxyl and peroxyl,
as well as non-radicals, such as hydrogen peroxide. The non-radicals are either oxidizing agents
or are easily converted into radicals. RNS are molecules containing nitrogen such as NO,
peroxynitrite, and nitrogen dioxide. The source of these molecules may be from by-products
of endogenous compounds or xenobiotics through mechanisms, such as the electron transport
chain, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, xanthine oxidase
(XO), metabolism of the arachidonic acid and cytochrome P-450 (89,90).
In a normal physiological state, a sufficient supply of antioxidants is provided during
metabolic processes, as well from dietary sources, that neutralizes harmful activity of reactive
species. However, several factors can increase the concentration of such harmful molecules by
depleting antioxidant defences leading to oxidative stress. These include smoking, sleep
deprivation, acute microbial infections, being overweight, high sugar and/or fat intake, and
exposure to metals and air pollutants (5,87). Oxidative stress can lead to injury of the
endothelium and impairment of NO bioavailability, as well as reduce other functions, such as
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regulation of blood clotting, local immune responses, control of the fluid volume and
transportation of electrolytes and other substances between blood vessels and tissues (1,91).
The immune response plays a major role in ED pathogenesis and also acts directly in
oxidative balance. Myeloid cells and T lymphocytes protect the host organism from pathogens
by attacking with bursts of ROS. While these ROS may help to preserve the vascular tone, an
aberrant production of ROS triggered by immune cells in the absence of any hemodynamic
insult can lead to damage to the endothelium. Nonetheless, an oxidative stressed state in
cardiovascular control organs may likewise potentiate inflammatory responses and augment
ED. Therefore, inflammation and oxidative stress act as cooperative and synergistic partners
in the pathogenesis of ED (4,5).

1.3

Assessment of vascular and microvascular function

There is increased interest in methods to assess ED to better understand the
pathogenesis of CVD and other diseases. With the simultaneous advance of knowledge and
technology in this field, there are already many non-invasive options available in both clinical
practice and research. Traditional techniques, such as flow-mediated vasodilation (FMD),
pulse wave velocity (PWV), and carotid intima media thickness are highly correlated with
cardiovascular outcomes and are useful to track disease progression and assess the efficacy of
therapeutic interventions in overall vascular health (11). The CVD risk prediction of FMD was
addressed in a meta-analysis of 23 studies that included 14,753 subjects finding an overall 8 %
reduction in CVD risk (RR= 0.92; 95%CI: 0.88; 0.95) for each percentage increase in FMD
(92). However, these methods evaluate conduit artery function, therefore providing limited
information with regard to mechanisms of systemic microvascular physiopathology.
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The microcirculation comprises arteries with low resistance, arterioles, capillaries, and
venules. While the capillary network acts on nutrient and gas exchanges between blood and
tissues, arterioles play a major role in blood flow regulation by mechanisms including arteriolar
myogenic response, flow-induced vasodilation, metabolic and neural mediators (93). These
mechanisms, as well as pathological processes that might affect them are evident in the
cutaneous microcirculation and can represent ED features and mechanisms upon other vascular
beds. Therefore, considering that the skin is readily accessible, several imaging techniques have
been developed in order to use cutaneous microcirculation to investigate the mechanisms of
systemic microcirculatory function and dysfunction in various diseases (94,95).
The first imaging techniques for this purpose were developed using Laser Doppler
technology. Laser Doppler flowmetry (LDF) assesses blood flow over a small volume (<
1mm3) and detects and quantifies relative changes in skin blood flow in response to a given
stimulus. However, this technique presents a relatively poor reproducibility due to the
significant spatial variability by a heterogenic capture of skin perfusion. Laser Doppler Imaging
(LDI), the subsequent developed technology, decreased this spatial variability drawback, but it
is much slower than LDF, thereby, recording rapid changes in skin blood flow over the larger
areas becomes particularly challenging (95,96). Laser Speckle Contrast Imaging (LSCI) is a
recent technique based on speckle contrast analysis that provides an index of blood flow. LSCI
supports a continuous rate of high frame assessment of skin perfusion over wide areas,
combining advantages of LDF and LDI, and thereby providing good reproducibility of tests
such as the post-occlusive reactive hyperaemia (PORH) and local thermal heating (LTH)
challenges (97,98).
Microvascular reactivity is assessed by stimulating microvessels with various
physiological or pharmacological challenges. The most common tests that are used in
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combination with imaging techniques are iontophoresis of vasoactive drugs, such as
acetylcholine and sodium nitroprusside, PORH and thermal challenges, such as LTH (93).
Iontophoresis is a non-invasive method of transdermal delivery of drugs based on the
transfer of charged molecules using electric currents. Acetylcholine and sodium nitroprusside
iontophoresis have been widely used to assess endothelial-dependent and -independent
microvascular vasodilation, respectively (95,99). Exact proportions of mechanisms that are
predominant in the acetylcholine-induced vasodilation are still not clear; however, C-fiber
(axon reflexes), COX-dependent pathways and NO contribute to this response. In addition,
endothelial-derived hyperpolarization also contributes to acetylcholine-mediated vasodilation
in a dose dependent manner (100). In order to avoid non-specific vasodilatory effects, one
group of researchers reviewed several protocols of iontophoresis of acetylcholine and sodium
nitroprusside, showing that the type of diluent used for each vasoactive agent, intensity of
current and the method of electrical current delivery are important to maintain good
reproducibility (101).
PORH is a microvascular reactivity test commonly conducted in the forearm when a
transient increase in cutaneous blood flow occurs following release of a brief occlusion in the
brachial artery. There is still no standardized protocol for this test; however, most studies use
a method in which a cuff, placed above the antecubital fossa, is inflated 50-60mmHg above
systolic pressure for 2-5 minutes (93). The mechanisms involved in this induced vasodilation
are still being elucidated, with some studies showing inconsistent results. Many mediators seem
to contribute to PORH vasodilation and although most of these responses are endothelialdependent, NO and COX pathways appear not to exert significant influence (102,103). The
major contributors to peak and time course of this microvascular reactivity are sensory nerves
through an axon reflex response (96). The endothelium-derived hyperpolarizing factors
(EDHF) are also involved, including activity of large-conductance calcium activated potassium
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channels (BKCa) by epoxyeicosatrienoic acids (95,104). In addition to the abovementioned
endothelial challenges that allow the evaluation of specific mechanisms, the postprandial state
is a condition that presents a particular modulation of endothelial function.
There is emerging evidence that metabolic imbalances in the postprandial state,
particularly after a high-energy meal rich in fat, are important contributing factors to
development of CVD (105,106). Overall, the underlying mechanism involves a sharp increase
in triacylglycerol along with an aberrant production of pro-oxidant molecules leading to an
oxidative stress state. This may impair vascular and endothelial functions, and mediate the
onset of an inflammatory response, which further contributes to the generation of more free
radicals, thus creating a deleterious vicious cycle (105–107). Dietary fats comprise
heterogeneous molecules with diverse structures, which affect diverse cell processes such as
transcription regulation, cellular and organelle membrane structure and function, ion channel
activity and electrophysiology. Responses vary depending on both the fatty acid composition
of the food source, as well interactions with accompanying nutrients, the food matrix and
process (108). Modification of the type of dietary fat in a food or overall meal has been shown
to result in postprandial effects on appetite (109), lipaemia and markers for inflammation and
endothelial activity (110).
The high-fat meal (HFM) challenge is one way to investigate the imbalances that are
promoted on a daily basis in Western diets (105). Considering that a significant part of the day,
usually two thirds of day time, is spent in the postprandial state, this is an important focus for
therapeutic investigations. Further details of this type of study and its implications in CVD are
provided in Chapter 3 of this thesis.
Taken together, the assessment of macro and microvascular function, including
techniques that evaluate structural changes in these vascular beds, such as FMD and PORH
combined with LSCI technology, along with evaluation of biomarkers related to the immune
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response and oxidative stress, provide reliable information to investigate prediction, severity
and responsiveness of treatment of several diseases, in particular CVD. Using these methods,
a wide range of dietary interventions can be explored as potential therapeutic options.

1.4

Flavonoids and implication on cardiovascular diseases
Diet is one of the most important factors in modulating metabolic and immune

responses by its direct effect on bioenergetics, body weight, gut microbiota and many other
systemic body regulation mechanisms. Among different dietary components, polyphenols are
bioactive compounds that naturally occur in various fruits, vegetables, cereals and beverages.
They partly contribute to the bitterness, astringency, colour, flavour, odour and oxidative
stability of such foods (111). Among the vast number of phenolic compounds, the most
common and widely distributed class are flavonoids, present virtually present in all plants. In
foods, flavonoids occur as aglycones, methylated derivatives and mostly as glycosides, also
providing prevention of fat oxidation and protection of vitamins and enzymes. There are more
than 9,000 flavonoids present in nature with different physical, chemical and physiological
properties, characteristics that delineate their biological activities. They are found in subclasses
such as flavanols, flavonols, flavanones, flavones, isoflavones and anthocyanins(112).
Dietary intake of flavonoids have been associated with the prevention and incidence of
several diseases in epidemiological studies. Dietary flavonoid interventions have been
explored in clinical trials to treat pathological conditions, such as ED (12,13). In the
endothelium, dietary flavonoids can exert physiological effects as both antioxidant and as
signalling molecules. The antioxidant activity is due to their ability to donate hydrogen, bind
metal ions, resonance stabilization of phenoxyl radicals, thereby acting as reducing agents,
metal chelators, ROS scavengers, chain-breaking antioxidants, quenchers of singlet oxygen
formation and protectors of endogenous ascorbic acid. The signalling properties of flavonoids
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are attributed to interactions with enzymes, kinases and cellular receptors in regulatory
pathways mediating physiological responses or altering gene expressions (113,114). For
instance, certain types of flavonoids can modify protein kinase-mediated signal transduction
and up-regulate antioxidant and anti-inflammatory gene expression (115,116), as well as downregulate inflammatory gene expression and improve blood pressure (117).
The association between dietary flavonoid intake and potential health benefits in large
studies can present methodological challenges. Besides the fact that flavonoid content in foods
is likely to be influenced by seasonality and geographical areas, there are some relevant
discrepancies between food composition databases with regard to flavonoid content in foods.
Additionally, the methods used to assess dietary intake of participants are generally insensitive
to accurately characterise flavonoid consumption (118). Nonetheless, some large prospective
studies and pooled analyses of clinical trials show positive results in relation to total dietary
flavonoid and certain subclasses. In a total of 2,087 fatal coronary heart disease (CHD) events
among 7 prospective cohorts, subjects in the higher tertile of dietary flavonol intake presented
a combined risk ratio of 0.80 in comparison to subjects in the lower tertile, after adjustment for
disease and dietary factors. The main flavonol sources that could be extracted from these
cohorts were from a small number of fruits and vegetables, tea and red wine (16). A metaanalysis of ten studies investigated mortality by CVD events. The relative risk (RR) of allcause mortality among subjects in the higher category of total flavonoid intake was 0.82 in
relation to subjects in the lower category intake. A trend was also found for risk of death from
CVD (RR: 0.85 and P=0.099) and CHD (RR: 0.74 and P=0.069). A dose-response analysis
showed that the lowest risk of all-cause mortality was lower in subjects consuming >200mg/d
of total flavonoids (13). The effects of cocoa flavonols was analysed in a meta-analysis of 35
studies, involving 40 treatment comparisons. This pooled analysis with moderate quality
evidence showed a modest, but significant lowering of both systolic and diastolic blood
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pressure of 1.8 mmHg on average (19). Furthermore, another subclass of flavonoids, quercetin,
has also been found to be effective in lowering blood pressure; however, a meta-analysis of 7
clinical trials only reached significance with dosages of >500mg/day (28). Another study
evaluated the dietary intake of total flavonoids and subclasses on incidence of hypertension. In
a prospective cohort of 40,574 healthy women, 9,350 cases of hypertension were observed
during a follow-up of approximately 14 years. A 10% lower rate of hypertension was found in
individuals within the higher quintile of flavonol intake when compared to the lower quintile
[hazard ratio (HR): 0.90, p=0.031]. Proanthocyanidin and anthocyanins also showed a similar
effect of lowering the incidence of hypertension by 9% between the highest and lowest quintile
of consumption (HR: 0.91, P= 0.0075 and HR: 0.91, P= 0.0051, respectively)(119). In this
matter, anthocyanins are emerging as a potential therapeutic option for CVD due to its effects
on ED mechanisms, mainly on oxidative stress and immune response.

1.5

Anthocyanins
Anthocyanins are the largest class of water-soluble plant pigments, which are

responsible for the blue, purple and red colour of many fruits and vegetables. Anthocyanins are
formed by the coupling of sugars to anthocyanidins, whilst anthocyanidins are their sugar-free
analogues. There are more than 300 known anthocyanins, but considering the different
possibilities for their glycosylated part, this can number more than 8,000 types. The most
common anthocyanins in foods are from six subclasses, namely cyanindin, (comprising 50%
of anthocyanins), pelargonidin (12%), peonidin (12%), delphinidin (12%), petunidin (7%) and
malvidin (7%). Degradation of anthocyanins in foods can occur by several food processing and
storage factors including pH, temperature, exposure to light and oxygen or interactions with
foods components, such as ascorbic acid, sugar and metal ions (120,121).
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In large population studies, the estimated average intake of anthocyanins is even more
challenging than assessing of total flavonoids due to a lack of valid and reliable data on the
food composition of dietary sources. Nonetheless, a multi-centre investigation in Europe
estimated the average daily intake of anthocyanins for men to be 19.83 mg and 64.88 mg in
Holland and Italy, respectively. Among women, the results showed an average daily intake of
18.73 mg in Spain and 44.08 mg in Italy (122). Besides the difficulties in obtaining accurate
information on the anthocyanin content of foods and challenges with the assessment of dietary
intake, seasonality and geographic variation also complicate such analysis. In Australia, a food
frequency questionnaire was validated to measure flavonoid intake in older adults, and an
Australian-specific anthocyanin food composition database for dietary studies is being
developed (123).
Cell culture, animal model, human clinical trials and epidemiological studies have
shown the potential effect of anthocyanins to improve vascular function, inflammatory
response and other CVD risk factors (26,121,124–137). The essential feature of these benefits
refers to the major role of anthocyanins modulating the immune response. A large number of
in vitro and animal studies (121,127,138–140) explain the mechanisms related to the antiinflammatory actions of anthocyanins. These include: (1) modulation of arachidonic acid
metabolism, in which lipid mediators that regulate inflammation (e.g. prostaglandins and
leukotrienes) have their key enzymes cyclooxygenases and lipoxygenases inhibited by
anthocyanins; (2) decreased activity of the NF-κB pathway, which is a transcription factor
responsible for triggering and regulating inflammatory processes, leading to the expression of
pro-inflammatory cytokines and enzymes; and (3) suppression of acute pro-inflammatory
genes that regulate inducible nitric oxide synthase (iNOS), which is responsible for preventing
excessive production of nitric oxide (NO).
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The beneficial effects of anthocyanins on ED may also be related to their ability to
mitigate the oxidative stress-related damage to the endothelium and their action in
endothelium-dependent vasodilation signalling pathways. Antioxidant mechanisms of
anthocyanins are exerted by direct and indirect pathways. Anthocyanins provide direct free
radical scavenging activity by electron donation (hydrogen), as well as by improving
endogenous antioxidant defences, such as restoring or enhancing antioxidant enzyme activity,
such as superoxide dismutase and glutathione peroxidase, as well as up-regulating gene
expression of glutathione peroxidase (22,138). This antioxidant activity appears to be superior
to that of other conventional antioxidants such as α-tocopherol, trolox and catechin
(138,141,142). The chemical structure of each anthocyanin subclasses also influences its
potential antioxidant effect, which is related to the number and position of hydroxyl groups,
conjugation groups, degree of glycosylation and the capacity of the aromatic group of donating
electrons. Thus, different anthocyanins may show different levels of scavenging activity
towards ROS and reactive nitrogen species (RNS), or other adverse metabolic products
(138,143).
The increase in bioavailability of NO, through increased expression of eNOS, has been
investigated in cell culture studies. Edirisinghe et al. (126), pre-treated human umbilical vein
endothelial cells with different concentrations of blackcurrant juice and for different time
periods, independent of vitamin C. The results showed an up-regulation of eNOS that was
activated via the Akt/PI3 kinase pathway, while the effect was not vitamin C-dependent. An
increased eNOS expression was also demonstrated in bovine artery endothelial cells treated
with cyanidin-3-glucoside. This increase, exerted via the Src-ERK1/2-Sp1 signalling pathway,
was in a dose and time-dependent manner. Significant results were observed after an incubation
time of only 8 hours, while after 24 hours of incubation NO output increased twofold (144).
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In animal models, studies using anthocyanins as a dietary intervention confirmed many
of the aforementioned effects observed in cell culture studies, including regulation of the
immune response and reduced oxidative stress, as well as mediation of lipid transport and
accumulation, lowering of blood pressure and improved vascular reactivity. In two acute
experimental mice models of peritonitis and paw oedema, anthocyanins provided from wild
mulberry inhibited carrageenan-induced inflammation by suppressing mRNA as well as
protein levels of COX-2 (145). In a model of hypercholesterolemia, mice fed with a high-fat
diet and treated with 2% açai pulp had improved oxidative stress-related biomarkers and better
lipid profiles, as well as reduced superoxide dismutase activity and increased paraoxonase
activity (protection of lipoproteins and membranes to oxidative damage) (146). Regarding
weight loss and adiposity, another study of rodents fed with a high-fat diet for 12 weeks along
with 40 and 200 mg/kg of cherry anthocyanins attenuated weight gain by 5.2% and 11.2%,
respectively. This was associated with a lower concentration of plasma leptin, glucose,
triacylglycerol, total cholesterol and LDL cholesterol, along with a decreased gene expression
of Il-6 and TNF in this tissue, and a reduction in adipose cell size (147). Cholesterol efflux
signalling can also be influenced by anthocyanins; however, this effect is attributed to its
downstream metabolites. For example, protocatechuic acid, a gut microbiota metabolite in
mice, exerts this cholesterol efflux from macrophages; however, anthocyanins in
physiologically reachable concentrations did not show this effect (148).
Parameters related to vascular function such as blood pressure and vascular reactivity
have also been investigated in animal models. In stroke-prone rats, treatment with a 3%
blueberry diet for 8 weeks resulted in a significant decrease in systolic blood pressure of 19%
and 30% in weeks 4 and 6, respectively, along with reduced markers of renal oxidative stress,
such as proteinuria and kidney nitrite (149). In vascular reactivity parameters, rats fed with
blueberries for 7 weeks showed diminished vasoconstrictor response to an L-phenylephrine
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challenge, while inhibition of NOS, but not COX caused a higher vasoconstriction in the
blueberry group. This was also evidenced as the endothelium-dependent vasorelaxation
induced by acetylcholine, mediated by the NO pathway, was greater in the anthocyanins group
compared to the placebo (150). Moreover, another study showed improvements in the aortic
endothelium-dependent vasorelaxation response, also induced by acetylcholine, in mice fed
with 2g/kg of cyanidin-3-glucoside for 8 weeks. This result was followed by an increase in
cGMP concentration and eNOS phosphorylation at Ser 1177 in the aorta (151).
A few studies have also advanced in nutrigenomic analysis of anthocyanin effects in
mice models. A mouse model of accelerated atherosclerosis development was fed with 0.02%
of the diet comprising bilberry anthocyanins extract. The attenuated atherosclerotic lesions in
the anthocyanins group was followed by a modulation in expression of 1,261 genes, which
were related mainly to different cellular processes such as oxidative stress, inflammation,
regulation of adhesion molecules, cell to cell adhesion, paracelullar permeability and
angiogenesis (152). The same research group previously found altered expression of 2,289
genes in liver tissue, in the same experimental model provided with the same diet.
Transcriptional analyses showed that these genes were involved in bile acid synthesis and
cholesterol uptake into the liver, and downregulation of pro-inflammatory cytokines (153).
The translation of findings from anthocyanin intervention studies is complex. This is
because the potential effects of these compounds depends on their complex absorption,
breakdown to phenolic metabolites and subsequent various actions in cells. Despite promising
findings to date, many of the mechanistic pathways of their effects are not fully elucidated in
humans. The method of delivery of anthocyanins also differs between studies and they may be
provided in whole foods, juices, extracts or as purified anthocyanins. While there is
homogeneity regarding some outcomes, many other parameters are not consistent between
studies. Table 1 summarizes several clinical trials using different forms of anthocyanins, and
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for several conditions related to ED. Studies evaluating parameters related to oxidative stress,
inflammation, lipid profile, glucose homeostasis, blood pressure, hemodynamic and vascular
outcomes were included. However, conditions such as inflammatory and infectious diseases,
cancers, as well as studies evaluating specific groups of individuals such as professional
athletes, smokers, children, and pregnant or breastfeeding women were not included.
Overall, chronic supplementation of anthocyanins showed a relevant role in oxidative
stress, lipid peroxidation, antioxidant status and vascular outcomes with the majority of studies
reporting improvements in related parameters. A moderate beneficial effect, with some
heterogeneity among studies, was evidenced for lipid profile, glucose homeostasis, vascular
inflammatory markers and hemodynamic factors. Although some studies showed
improvements in outcomes such as blood pressure, peripheral inflammatory markers and
anthropometry, these were the parameters with the highest inconsistency between studies using
anthocyanins in medium or long-term dietary interventions. On the other hand, postprandial
studies show the most promising results in the attenuation of deleterious postprandial effects
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Table 1-1. List of clinical trials with chronic and acute supplementation of anthocyanins
CHRONIC SUPPLEMENTATION OF ANTHOCYANINS
Study
Traustadó
ttir et al.
2009(154)

Lee et al.
2016 (155)
Davinelli
et al.
2015(156)
Li et al.
2015(157)

Habanova
et al.
2016(158)
McAnulty
et al.
2014(159)

Subjects/
condition
Healthy

Sampl
e size
12

Sex

Age

F/
M

6175

Body mass
index >23
kg/m2
Healthy,
overweight
and smokers
Diabetic

F/
M

1965

63

F/
M

4565

42

F/
M

>18
(39.8
±
13.8)

58

Healthy

F/
M

36

Healthy,
postmenopaus
al

F/
M

48.3
±
5.64
1850

25

Intervention/daily dose
– anthocyanins content
Tart cherry juice
(480mL) - 59.5 mg of
total anthocyanins

Duratio
n (days)
14

Double blind,
placebo controlled,
RCT
Double-blind,
placebo-controlled,
RCT
Double-blind,
placebo-controlled,
RCT

Extract of black soybean
- 31.45 mg of total
anthocyanins
Extract of maqui berry 468 mg of total
anthocyanins
Billberry and
blackcurrant purified
anthocyanins – 160mg
of total anthocyanins

56

Non-randomized,
pre-post
intervention study
Placebo-controlled,
RCT

65g of frozen bilberries
– 194mg of total
anthocyanins
Blueberry extract
(equivalent to 250 g
rehydrated berries) –
total anthocyanins value
not provided

Study design
Double blind,
placebo controlled,
crossover

28

168

42

42

Results (intervention vs control)
↓forearm ischemia-reperfusion F2isoprostane response
↓ urinary 8-hydroxy-2
9-deoxyguanosine; 8-hydroxyguanosine
↔ urinary isoprostanes
↓abdominal fat; TG; LDL-c; non-HDLc
↓ plasma OxLDL; urinary F2-isoprostanes
↔ anthropometry; blood pressure; lipid
profile
↓LDL-c; TG; apolipoprotein B-48;
apolipoprotein C-III; glucose; HOMA-IR
↑ HDL-c
↓F2-isoprostanes; 13hydroxyoctadecadienoic acid; carbonylated
proteins
↑ total radical-trapping antioxidant
parameter; FRAP
↓ TC; TG; LDL-c; glucose;
↑ HDL-c
↔ anthropometry; blood pressure
↓ AIx; aortic systolic pressure
↔ anthropometry; overall blood pressure
↓ diastolic blood pressure (sub-analyses)
↑ absolute NK cells
↔ ORAC; FRAP
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Kuntz et
al.
2014(160)

Study
Kardum
et al. 2014
(161)

Healthy

Subjects/
condition
Healthy

F

2327

Sex

Age

F

2549

30

Sampl
e size
29

Lynn et al.
2014(162)

Healthy

F/
M

3550

47

Wright et
al.
2013(163)
Broncel et
al.
2010(164)

BMI: 32.8 ±
4.6 kg/m2

M

53.1
± 7.6

16

Healthy
(n=22) and
metabolic
syndrome
(n=25)

F/
M

4265

47

Basu et al.
2011(165)

Metabolic
syndrome

F

52.0
±8.0

36

Double blind,
placebo controlled,
crossover, two
intervention groups
+ palcebo

Study design
Non-randomized,
pre-post
intervention study
Double-blind,
placebo-controlled,
RCT
Double-blind,
placebo-controlled,
RCT

Double-blind,
placebo-controlled,
RCT

Juice – 277.5mg of total
anthocyanins; smoothie
- 324.7mg of total
anthocyanins

14

Intervention/daily dose
– anthocyanins content
Chokeberry juice 25mg of total
anthocyanins

Duratio
n (days)
84

Tart cherry juice
concentrate - 273.5mg
total anthocyanins
Dried purple carrot118.5 mg of total
anthocyanins
Aronia extract - 3-Ocyanidin-galactoside
(64.5%), 3-O-cyanidinarabinoside
(28.9%), 3-O-cyanidinxyloside (4.2%), and 3O-cyanidinglucoside
(2.4%) – mg?
Cranberry juice - 12.4
mg of total anthocyanins
; 119mg of total
Proanthocyanidins

42

28

↑plasma superoxide dismutase; catalase
activity; TEAC
↔ plasma glutathione peroxidase and
erythrocyte superoxide dismutase
↓ plasma and urinary MDA
↔IL-2, -6, -8 and -10; CRP; sCD40;TNFα; MCP-1; CAMs
Results (intervention vs control)
↓ TBARS; PAB; TOS
↑ PON1; TAC
↔ anthropometry; blood pressure;
biochemical parameters
↔ arterial stiffness; CRP; blood pressure;
TC; HDL-c
↑ FRAP
↔ anthropometry; LDL-c; TC; blood
pressure; CRP

60

↓ systolic and diastolic blood pressure;
endothelin-1; TBARS; antioxidant enzymes
catalase
↓TC; LDL-c; TG;
↑ superoxide dismutase; glutathione
peroxidase; fibrinogen
↔ CRP

56

↔blood pressure; lipid profile; glucose;
CRP; IL-6
↓ serum MDA and 4-hydroxynonenal;
plasma OxLDL
↑ plasma antioxidant capacity

46

Basu et al.
2010(166)

Metabolic
syndrome

F/
M

50.0
± 3.0

66

Single-blind,
placebo-controlled,
RCT

Blueberry beverage –
742mg of total
anthocyanins

56

Dohadwal
a et al.
2011(167)

Coronary
artery disease

F/
M

62.0
±
10.0

44

Double blind,
placebo controlled,
crossover, RCT

Cranberry juice – 94mg
of total anthocyanins

28

Kent et al.
2017(168)

Mild to
moderate
dementia

Double-blind,
placebo-controlled,
RCT

Cherry juice – 138 mg
of total anthocyanins

Study
Thompson
et al.
2017(169)

Subjects/
condition

Sex

70+

49

Age

Sampl
e size

Healthy

Zhu et al.
2011/2013
(170,171)

Hypercholester
olemic

Hasselund
et al.
2012/2013
(172,173)

Healthy;
blood
pressure>140/
90 mm Hg; not
medicated

F/
M

38.0
±
12.0

F/
M

4065

M

3551

Study design

Intervention/daily dose
– anthocyanins content

Double blind,
placebo controlled,
crossover, RCT

Blackberry and billberry
extracts - 320mg of total
anthocyanins

16

150
31

84

Duratio
n (days)

28

Double blind,
placebo controlled,
crossover, RCT

Purified anthocyanins 320mg of total
anthocyanins

Double blind,
placebo controlled,
crossover, RCT

Purified anthocyanins –
640mg of total
anthocyanins

84
28

↓ diastolic and systolic blood pressure;
↓ plasma MDA; 4-hydroxynonenal;
OxLDL
↔ lipid profile; glucose; HbA1C; CRP;
CAMs; IL-6; myeloperoxidase
↔ blood pressure; FMD; carotid-radial
PWV
↓ carotid-femoral PWV
↔ lipid profile; glucose; insulin; CRP,
ICAM-1
↓ Systolic and diastolic blood pressure
↔ CRP; IL-6

Results (intervention vs control)
↓ monocyte-platelet aggregate formation;
platelet endothelial cell adhesion molecule1; procaspase activating compound-; Pselectin; ADP-induced whole blood platelet
aggregation
↔ blood pressure; fibrinogen; lipid profile,
CRP
↑ FMD; serum cGMP
↔ blood pressure; TG; TC; glucose; insulin
↓ VCAM-1; CRP; IL-1b; LDL-c
↑ HDL-c
↔ blood pressure
↑ HDL-c; von Willebrand factor,
↔ TC; TG; LDL-c; glucose; CRP; MCP-1;
P-selectin; CAMs; IL-6 (trend); TNF-α; IL4; L-arg/ADMA; FRAP
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ACUTE SUPPLEMENTATION OF ANTHOCYANINS
Study

Subjects/cond
ition

Sex

Age

Sampl
e size

Study design

Park et
al. 2016
(174)

Individuals
with insulin
resistence

F/
M

5667

21

Toaldo et
al. 2015
(175)

Healthy

F/
M

2055

30

Frank et
al.
2012(176)

Healthy

F/
M

2227

8

Randomized, openlabel, two-way
crossover

Edirisingh
e et al.
2011 (177)

Overweight;
25>BMI>33.5
k/m2

F/
M

50.9
±
15.0

24

Randomised,
single-blind,
placebocontrolled, crossover trial

Study

Subjects/cond
ition

Sex

Age

M

3065

23

Randomized,
controlled, doubleblind, crossover

Açai-based smoothie –
493mg of total anthocyanins

F/
M

62.0
± 8.0

15

Open label

Cranberry juice – 94mg of
total anthocyanins

Alqurashi
et al. 2016
(178)
Dohadwal
a et al.
2011 (167)

Healthy,
overweight
25>BMI>30k/
m2
Coronary
artery disease

Sampl
e size

Randomized
controlled, fourarm, dose-response,
crossover trial
Double-blind,
placebo-controlled,
cross-over, two
intervention groups

Intervention/daily dose –
anthocyanins content

Study design

High fat and carbohydrate
meal with freeze-dried whole
strawberry powder (0, 10, 20,
30 and 40g)
Organic red grape juice –
159.2 mg of total
anthocyanins / conventional
red grape juice – 42 mg of
total anthocyanins
Hibiscus sabdariffa L.
aqueous extract - 130.25mg
of total anthocyanins

high-carbohydrate, moderatefat meal + strawberry
beverage - 120.69mg of total
anthocyanins
Intervention/daily dose –
anthocyanins content

Sample
collection
(hours)
0, 0.5, 1,
1.5, 2, 3,
4, 5 and 6
0-1h

0, 0.5, 1,
1.5, 2,
2.5, 3, 4,
6, 8 and
10h
0, 0.5, 1,
1.5, 2, 3,
4, 5 and 6

Sample
collection
(hours)
0, 1, 2, 3,
4, 5, 6
and 7h
0, 2 and
4h

Results (intervention vs control)
↓ insulin; insulin;glucose; OxLDL
↔ IL-6
↓ TBARS; lipid hydroperoxides

↑ plasma FRAP AUC; plasma
ascorbic acid
↓ plasma uric acid
↓ urinary MDA
↑ urinary ascorbic acid
↓ CRP; IL-6; insulin
↔ IL-1β; PAI-1; TNF-α
Glucose;

Results (intervention vs control)
↑ FMD
↓ total peroxide oxidative status
AUC
↔ blood pressure; glucose
↔ blood pressure;
↑ FMD (%); FMD (mm)
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Keane et
al. 2016
(179)

Prehypertension
(SBP>130 mm
Hg, DBP >80
mm Hg, or
both)

M

31.0
± 9.0

16

Placebo-controlled,
single-blinded,
crossover,
randomized Latin
square design

Montmorency tart cherry
juice – 73.5 mg of total
anthocyanins

0, 1, 2, 3,
5 and 8h

Jin et al.
2011 (180)

Healthy

F/
M

44.5
±13.
3

20

Randomised,
double-blind,
placebocontrolled
cross-over acute

Blackcurrant juice – 50.5mg
of total anthocyanins

Kent et al.
2016 (181)

Young and
older adults

M/
F

1835 /
55+

13

Pilot cross-over
study

High-flavonoid cherry juice
(300mLx1 and 100mLx3) -

0 and 2h
(vascular
reactivity)
, 0-8
(plasma
and
urine), 824 (urine)
0, 2 and
6h

Rodriguez
-Mateoz et
al. 2013
(182)

Heathy

Randomized,
controlled, doubleblind, crossover

Five blueberry beverages –
129, 258, 310, 517 and
724mg of total anthocyanins

Zhu et al.
2011 (170)

Hypercholester
olemic

Randomized,
controlled, doubleblind, crossover

Purified anthocyanins 320mg of total anthocyanins

M

1840

21

F/
M

4065

12

0, 2, 4
and 6h

0, 1, 2
and 4h

↓ systolic blood pressure; DVP-RI;
PWV; peripheral blood pressure;
mean arterial pressure
↔ microvascular reactivity
[endothelium (trend) and nonendothelium dependent] ; heart rate;
DVP-SI(trend); AIx
↑ plasma ascorbic acid; uric acid;
insulin
↔ microvascular reactivity
↔ plasma FRAP; ORAC; TG;
ICAM-1; VCAM-1; glucose;

↓ systolic and diastolic blood
pressure; heart rate
↑ FMD
↓NADPH oxidase activity
↔ Aix; PWV; DVP-SI; DVP-RI;
↔ peripheral and central blood
pressures
↑ FMD; serum cGMP

Symbols: ↑ Higher than control treatment ↓ Lower than control treatment ↔ No significant effect. Abbreviations: RCT, random clinical trial; LDL-c, low-density lipoprotein
cholesterol; OxLDL, oxidized low-density lipoprotein; TBARS, thiobarbituric acid reactive substances; ORAC, oxygen radical absorbance capacity; FRAP, ferric ion reducing
antioxidant power; TEAC, trolox equivalent antioxidant capacity; MDA, malondialdehyde; TNF-α, Tumour necrosis factor alpha; MCP-1, monocyte chemoattractant protein1; CAMs, cell adhesion molecules; TAC, total antioxidative capacity; TOS, total oxidative status; PON1, paroxonase-1 activity; PAB, pro-oxidant-antioxidant balance;
AUC, area under the curve; CAT, antioxidant enzymes catalase; FMD, flow-mediated dilation; HbA1C , glycated haemoglobin; PWV, pulse wave velocity; ICAM-1, intercellular
adhesion molecule-1; VCAM-1, vascular adhesion molecule-1; DVP-RI, digital volume pulse reflection index; DVP-SI, digital volume pulse stiffness index; AIx, augmentation
index; L-arg/ADMA, L-arginine/asymmetric dimethyilarginine ratio; cGMP, cycluc guanosine monophosphate.
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on oxidative stress and antioxidant status, triacylglycerol and total cholesterol concentrations,
vascular endothelial function and inflammatory biomarkers. Post-prandial changes in blood
pressure and lipoproteins were least affected by anthocyanins (more details are provided in
Chapter 3: The postprandial effect of anthocyanins on cardiovascular disease risk factors: a
systematic literature review of high-fat meal challenge).
In addition to the findings reported in Table 1, other studies investigated the effect of
anthocyanins in a large numbers of subjects, both in large prospective cohorts and systematic
reviews with or without meta-analysis. Cassidy et al (183–185), conducted three different
analyses in the Nurses’ Health Study II evaluating the anthocyanin intake and incidence of
certain conditions and events related to ED. The flavonoid and anthocyanin intakes were
calculated using validated food-frequency questionnaires. In one cohort analysis of 93,600
healthy women aged between 25 and 42 years, an inverse association between intake of
anthocyanins (highest versus lowest quintiles) and risk of myocardial infarction was observed
(HR: 0.68; 95% CI, 0.49-0.96; P=0.03) after multivariate adjustment. The combined intake of
blueberries and strawberries, in individuals consuming more than three serving per week versus
a lower intake, tended to be associated with a decreased risk of myocardial infarction (HR:
0.66; 95% CI, 0.40-1.08; P=0.03). Anthocyanins were the only flavonoid class to show
positive benefits in relation to the incidence of these CVD events (184). Furthermore, while
following 43,880 healthy men with no prior diagnosis of CVD for 24 years, a total of 4046
myocardial infarction and 1572 stroke cases occurred, in which all of these events were
confirmed by medical records. After multivariate adjustment, a higher anthocyanin intake was
inverse associated with non-fatal myocardial infarction (HR: 0.81; 95% CI: 0.69-0.96; P= 0.03)
in normotensive individuals, whilst a borderline significant trend was observed in all
individuals (HR: 0.87; 95% CI: 0.75-1.00; P = 0.04; P= 0.098). Fatal myocardial infarction and
stroke was not associated with anthocyanin intake in that analysis (183). In another
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investigation, Cassidy et al.(185) examined the association between flavonoid intake and
incidence of hypertension by grouping results from three different cohorts. A total of 133,914
women from the Nurses' Health Study I and II, as well as 23,043 men from the Health
Professionals Follow-Up Study were followed-up for 14 years, resulting in 29,018 cases of
hypertension in women and 5629 cases of hypertension in men. A reduction of 8% in risk of
hypertension (RR: 0.92; 95% CI: 0.86, 0.98; P < 0.03) was found comparing individuals from
the highest quintile versus lowest quintile of anthocyanins intake. This effect was even higher
among individuals under 60 years of age (RR: 0.88; 95% CI: 0.84, 0.93; P < 0.001).
Regarding the pooled analyses of anthocyanin interventions in clinical trials, systematic
reviews and meta-analysis have been conducted for outcomes related to ED such as blood
pressure, CVD risk factors and vascular function, with inconsistent results. A meta-analysis
evaluating the effect of berries on CVD risk factors among healthy individuals or patients with
CVD (n = 1,251 subjects from 21 randomized clinical trials) reported that berry consumption
lowered LDL-c, systolic blood pressure, fasting glucose, body mass index, haemoglobin A1c
and TNF-α, whilst no significant effects were demonstrated for HDL-c, triglycerides, total
cholesterol and diastolic blood pressure. It is important to note that not all berries have
anthocyanins as their primary source of polyphenols; however, the majority of dietary
interventions from the included studies were rich in anthocyanins (186). Another systematic
review of randomized controlled trials evaluated the effect of purified anthocyanins and
anthocyanin-rich extracts on markers of CVD. A total of twelve clinical trials with both healthy
and individuals with CVD were included in this review, but the large heterogeneity prevented
the conduct of a meta-analysis. Considering LDL-c, HDL-c, total cholesterol, triglycerides and
blood pressure, an improvement was only evident for LDL-c among diseased individuals or
those with elevated concentrations of this biomarkers (131).
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Parameters such as vascular reactivity and stiffness have also been evaluated in a
systematic review and meta-analysis of 24 studies, including both acute and chronic dietary
interventions of anthocyanin-rich foods or extracts(26). Among the acute studies, FMD was
reported in 4 studies, while reactive hyperaemia index by peripheral arterial tonometry was
evaluated only in 2 studies. The pooled analysis showed a significant improvement for FMD,
mainly observed 1-8 hours after consumption of anthocyanin doses, which ranged from 7 to
724mg. There was no improvement in reactive hyperaemia index; however, when the
microvascular reactivity outcome was analysed collectively along with FMD, there was a
significant improvement after anthocyanin provision. Arterial stiffness, which was evaluated
through pulse wave velocity, was also improved by acute anthocyanins intake, whilst no
changes were observed for augmentation index. Once again, considering both outcomes for a
pooled analysis of vascular stiffness, there was a trend towards an improvement of this
parameter following anthocyanins intake. Among longer term studies ranging from one week
to six months, with anthocyanin daily doses of 12 to 320mg, an improvement in FMD was
found. The increase in reactive hyperaemia index did not reach significance; however, taken
together along with FMD for a vascular reactivity measure, the pooled analysis showed an
improvement in this parameter. In relation to arterial stiffness, the results from both pulse wave
velocity and augmentation index showed no improvements when analysed individually;
however, there was a trend toward an improvement in vascular stiffness when these two
parameters were analysed collectively (26).
Taken together, this body of pre-clinical, clinical and epidemiological evidence support
the potential beneficial effects of anthocyanins on vascular function and other CVD risk
factors, and warrant the conduction of clinical trials with innovative methodologies for a robust
investigation of such parameters.
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1.6

Problem statement

Several gaps in the literature remain regarding the association of flavonoids and their
potential health benefits. At the epidemiological level, only a few populations have been
investigated in appropriate large-scale studies. This type of evidence requires consideration of
specific differences in the flavonoid content of foods that exist between different geographical
areas and crops, as well as the variety of dietary patterns and cuisines between populations will
affect the amount and type of consumption of flavonoid-rich food items, while differing
lifestyle factors and life expectancies will also influence the contribution of flavonoids to the
incidence of hypertension and other chronic diseases. These methodological challenges limit
extrapolation of findings from epidemiological studies of flavonoid intake and incidence of
disease outcomes from one population to another. Still, previous analysis of dietary patterns,
conducted in the Australian population identified differences in the level of consumption of
individual food groups by age (187). Therefore, considering the limited evidence from
longitudinal studies that assess the association between the incidence of hypertension and
consumption of flavonoids in the Australian population, a life course approach is necessary.
At the clinical level, a number of studies have investigated the effect of specific
flavonoids across a wide range of conditions. Among the different groups of flavonoids,
anthocyanins are particularly promising in terms of their potential benefits in attenuating and
preventing pathological conditions, mainly through their potential anti-inflammatory, antioxidant and signalling effects. The effect of anthocyanins in the postprandial state have been
evaluated by several studies using the HFHE meal challenge. This method allows investigation
of whether these bioactive compounds are capable of attenuating the deleterious effects
following a HFHE meal; however, such findings have not been adequately collated and
synthesized regarding the scope of the impact of acute anthocyanin dietary intake on CVD risk
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factors. Within this range of studies, another gap that was identified is the lack of robust
investigation of the vascular function in the postprandial state, which along with the immune
response is an important predictor of CVD. This is particularly evident in older adults, as
several studies support a gradual loss of vascular health, and a new immune-metabolic
viewpoint for age-related diseases, termed ‘inflammaging’, characterized as a chronic lowgrade inflammation. Additionally, there are still several gaps to be addressed regarding the
effect of anthocyanins in this vascular-inflammatory axis in older adults, especially among
those with neurodegenerative conditions that share risk factors with CVD.

1.7

Hypothesis

Following the problem statement, this thesis has three main hypotheses, namely:
1) A higher dietary intake of flavonoids is associated with a lower incidence of
hypertension in Australian women;
2) An acute dietary intervention with food anthocyanins is capable of attenuating
potential postprandial deleterious effects of a high-fat high energy-meal on
vascular function, immune response and other CVD risk factors;
3) A chronic dietary intervention with food anthocyanins will improve
microvascular health, and reduce inflammation and blood pressure in older
adults with a diagnosis of MCI.

1.8

Research Objectives and Conceptual Framework
To test the study hypotheses, the following objectives were developed:
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1) To determine if there is an association between higher dietary intake of flavonoids and
subclasses and the incidence of hypertension in two cohorts of Australian women;
2) To collate and synthesize the current evidence of the postprandial effects of
anthocyanins on CVD risk factors in high-fat meal challenge studies;
3) To determine if consumption of food anthocyanins has postprandial effects on the
macro and microvascular function, inflammatory and oxidative stress biomarkers, and
lipid profile following a high-fat high-energy meal in overweight or obese older adults;
4) To determine if chronic consumption of food anthocyanins has beneficial effects on the
microvascular function, inflammatory biomarkers and 24 h ambulatory BP in older
adults with a diagnosis of MCI.

In order to test the above hypothesis and address the research objectives, four studies
were developed across three levels of evidence, including:
•

Epidemiological evidence: Secondary analysis of data from a nationally representative

cohort of Australian women.
•

Knowledge synthesis: Systematic Literature Review.

•

Experimental evidence: Two randomised placebo-controlled Clinical Trials (RCTs)

with an innovative design that allowed interpretation of both acute and chronic effects of
anthocyanin intake.

The Conceptual Framework for the thesis, demonstrating the four studies across the three levels
of evidence is shown in Figure 1-1.
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Figure 1-1. Thesis Conceptual Framework
GEE, generalized estimated equations; FFQ, food frequency questionnaire; CVD,
cardiovascular disease.

1.9 Significance of the Research
Flavonoids are emerging as potential dietary bioactive components that exert beneficial
effects on certain pathological conditions, as well as having a preventive role in several chronic
and degenerative diseases. This thesis aims to explore gaps in the literature in both cases.
Regarding the epidemiological aspect, this thesis addresses the association between daily
consumption of flavonoids and the incidence of hypertension. A population-based study was
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conducted to estimate the total intake of flavonoids and their subclasses in the Australian
female population by exploring data collected in a nationally representative cohort study. This
analysis found an association between flavonoids and the occurrence of hypertension, which is
a novel finding. This provides evidence that is useful for nutrition messaging and policies
targeting improved cardiovascular health in this population.
A robust review of pre-clinical literature showed that anthocyanins are capable of
improving vascular endothelial function, and have relevant anti-inflammatory and anti-oxidant
effects; however, clinical evidence of these effects in humans is still lacking in many aspects.
This thesis aims to advance this field, by conducting a systematic literature review to synthesize
and summarise the published literature relating to the acute effect of anthocyanins on
postprandial responses to a high energy, high fat stressor meal, as well as by undertaking two
randomised, placebo- controlled clinical trials to add to knowledge inquiry.
The two innovative clinical trials were conducted in older adults. The first investigated
the postprandial effects of anthocyanins following a HFHE meal challenge using a more robust
evaluation of vascular function than has been conducted in previous similar studies. Vascular
function was measured by exploring macro and microvascular parameters through a
combination of classical and novel techniques using the latest imaging technologies, including
FMD and LSCI. To our knowledge, this was the first study of its kind to conduct this protocol
using an anthocyanin dietary intervention. As well as the assessment of vascular function,
classical CVD biomarkers were included, such as lipid profile, blood pressure, and
inflammatory biomarkers. Another clinical trial was conducted to investigate the longer term
effects (8 weeks) of anthocyanin supplementation provided through the Australian-grown
Queen Garnet plum on inflammatory markers associated with CVD risk factors, along with
analysis of microvascular function and 24-hour ABP. The aim of this study was to investigate
such parameters in an older population with a diagnosis of mild cognitive impairment, which
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is a neurodegenerative condition that shares pathological mechanisms with CVD. Considering
the major role of the inflammatory response and vascular function in CVD and cognitive
decline, this data may be of clinical relevance for this high-risk group.
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Chapter 2: Association between flavonoid intake and risk of
hypertension in two cohorts of Australian women: a longitudinal
study

Large prospective studies and pooled analyses of clinical trials have shown health
benefits of flavonoids on CVD risk factors and incidence. However, only a few populations
were investigated by appropriate large-scale studies, including a comprehensive assessment of
flavonoid subclasses and food sources. This type of evidence requires a specific approach as
flavonoid content in foods can vary significantly among different geographic areas and crops,
as well as considering the cultural diversity in cuisine and dietary patterns within a country and
worldwide. Therefore, epidemiological studies associating flavonoid intake and incidence of
diseases can hardly be extrapolated from one population to another. In this matter, the present
population-based study estimated the association between intake of total flavonoids and its
subclasses and incidence of hypertension in two population-based cohorts of Australian
women, including reproductive-aged and middle-aged individuals. Flavonoid intake was
associated with a lower incidence of hypertension in both cohorts. Higher intakes of flavones,
isoflavones and flavanones, attributed mainly to orange, orange juice, apples and soy milk,
were associated with a reduced risk of hypertension among middle-aged women followed-up
over 15 years. Higher intakes of flavanols, attributed mainly to red wine and apples, were
associated with a reduced risk of hypertension among reproductive-aged women followed-up
for 12 years. These findings can be used in nutritional messages and policies aimed at
improving the cardiovascular health of women of different life stages
The majority of this chapter forms the substantive content of a published article
(Appendix C)
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2.1 Introduction
Cardiovascular disease (CVD) is a major cause of mortality globally and is the leading
cause of death for Australian men and women. In 2018, CVD was responsible for over 41,800
deaths in Australia (26% of all deaths)(188). Following a similar pattern to that observed
worldwide, the prevalence of hypertension among adults was 33.7% (36.0% among men and
31.4% among women in 2017-2018[1]. This prevalence increased with age, from less than 10%
in the 18-34 year age group to almost 50% in people aged over 85 years(188).
Hypertension is an independent risk factor for CVD and does not have a defined
aetiology. Several factors play a role in increased blood pressure including modifiable factors,
such as smoking, body weight, physical activity, alcohol, high sodium intake and other dietary
imbalances(189). Among the various pathophysiological mechanisms involved in
hypertension, the co-operative and synergistic action of inflammation and oxidative stress play
an important role(190–192).
Nutrition plays a major role in enhancing endogenous antioxidant defences and
regulating the inflammatory state(193). Epidemiological studies have identified many dietary
patterns that are associated with the prevention of diseases associated with inflammation(194).
Among the various protective dietary components are polyphenols, which are bioactive, plantbased compounds that naturally occur in fruits, vegetables, cereals and beverages(195). Of the
large number of polyphenolic compounds found in foods, the most common and widely
distributed class are flavonoids, present in virtually all plants. Flavonoids are classified into six
subclasses, namely flavanols (including proanthocyanidins), flavonols, flavanones, flavones,
isoflavones and anthocyanins(196). In the endothelium, dietary flavonoids can exert
physiological effects as both antioxidants and as signalling molecules(196,197).
Several large prospective studies and pooled analyses of clinical trials show health
benefits for total dietary flavonoid intake and some of its subclasses. A meta-analysis of five
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prospective cohort studies, comprising 200,256 individuals and 45,732 cases of hypertension,
showed a non-significant lower risk of hypertension for higher total flavonoid intake, while
dietary anthocyanin intake was associated with an 8% reduction in risk of hypertension when
comparing highest vs. lowest intake(198). The effects of cocoa flavonols were analysed in a
meta-analysis of 35 randomized clinical trials studies, showing significant lowering of both
systolic and diastolic blood pressure by 1.8 mm Hg(199). Furthermore, a meta-analysis of 7
trials involving 587 participants found that intake of quercetin, a flavanol subclass, resulted in
a significant reduction in blood pressure(200). However, differing dietary patterns and cuisines
between populations will affect the amount and type of consumption of flavonoid-rich food
items, while differing lifestyle factors and life expectancies will also influence the contribution
of flavonoids to the incidence of hypertension and other chronic diseases. Previous analysis of
dietary patterns in the ALSWH identified differences in the level of consumption of individual
food groups in the middle-aged and reproductive-aged cohorts (187). Therefore, considering
the limited evidence from longitudinal studies that assess the association between the incidence
of hypertension and consumption of flavonoids in the Australian population, a life course
approach is necessary.
This study aims to evaluate the association between intake of total flavonoids and its
subclasses and incidence of hypertension in two population-based cohorts of Australian women
that included reproductive-aged and middle-aged individuals.

2.2 Methods
Study population
The Australian Longitudinal Study on Women’s Health (ALSWH) includes a
representative sample of more than 40,000 women that were recruited in 1996. Women were
randomly sampled from the National Health Insurance scheme (Medicare) that includes all
Australian citizens and permanent residents(201). The reproductive-aged and middle-aged
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cohorts (including women born in 1973–78 and 1946–51, respectively) were used for the
purpose of this study, as these cohorts included validated assessment of dietary intake. Further
details of the recruitment methods, response rates, retention and attrition have been described
elsewhere (202).
These cohorts have been surveyed seven and eight times at approximately three-year
intervals, respectively, since 1996. The initial sample response rate from the middle-aged
cohort was n = 13,714 for Survey 1, with subsequent Surveys 2 to 8 yielding samples of n =
12,338 (90%), n = 11,221 (81.8%), n = 10,905 (79.5%), n = 100 10,638 (77.6%), n = 10,011
(73.0%), n = 9,151 (66.7%) and n = 8,622 (62.9%), respectively. In the reproductive-aged
cohort, the initial sample comprised n = 14,247, while response rates for Surveys 2 to 7 were
n = 9,688 (68%), n = 9,081 (63.7%), n = 9,145 (64.2%), n = 8,200 (27.6%), n = 8,126 (57%)
and n = 7,186 (50%), respectively. Dietary intake was assessed at Surveys 3 and 5 in the
reproductive-aged cohort, and at Surveys 3 and 7 in the middle-aged cohort. Survey 3 was
therefore used as baseline for both cohorts. The Human Research Ethics Committees of the
University of Newcastle and the University of Queensland approved the study methods. All
participants signed a consent form before joining the study.

Dietary intake
Dietary intake over the past 12 months was assessed through a validated FFQ, The
Dietary Questionnaire for Epidemiological Studies, version 2 (DQES v2)(203,204), which has
been validated against seven days of weighed food records with correlation coefficients ranging
from 0.28 for vitamin A to 0.78 for carbohydrates(204). Participants reported their usual daily
frequency of intake and portion size for 101 individual food items according to a 10-point scale
ranging from ‘Never’ to ‘Three or more times per day’. The Australian Food Composition
Database (NUTTAB95) was used to calculate energy, macro and micronutrient intakes(205).
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In order to determine flavonoid intake, each food item was assigned a total flavonoid
and subclasses content value using the ‘PhenolExplorer’ polyphenol food composition
database. The PhenolExplorer is a comprehensive and freely available database that contains
more than 35,000 content values for 500 different polyphenols in over 400 foods(206). Each
selected food item from the FFQ was manually cross‐referenced with this database. Foods
listed in the FFQ that were not in PhenolExplorer were assumed to contain no flavonoids. Of
the foods in the FFQ, 42 foods were assigned a flavonoid content. Flavonoid and subclass
intakes from each food were measured by multiplying the consumption (g/day) for each food
by its flavonoid content (per gram edible weight). Individual flavonoids from the six subclasses
were summed to provide a total value for each subclass, and data for total flavonoids were
calculated as the sum of these subclasses. A daily dietary intake of each flavonoid subclass and
total flavonoid intake was calculated for each individual. The food item ‘tea’, which is an
important source of flavonoids in this population, was not included in this version of the FFQ,
but a relevant question was present in another part of the survey. However, the rate of responses
and missing values differed from the FFQ data, thus the inclusion of “tea” and “herbal tea”
flavonoids was addressed in a sub-analysis.
Dietary intake was not assessed at every survey. Based on previous research showing
that diet quality is stable in these age cohorts(207,208), dietary intake data from Survey 3 were
applied to survey 4 in the reproductive-aged cohort and to Surveys 4 to 6 in the middle-aged
cohort. Survey 5 dietary data were applied to subsequent surveys in the reproductive-aged
cohort to account for any changes in intake.

Incidence of hypertension
The occurrence of hypertension was determined from self‐reported data on doctordiagnosed hypertension available in each survey from the following question: “In the past three
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years, have you been diagnosed or treated for: High blood pressure (hypertension)”. For
incidence estimation, hypertension was defined as new onset reported at Survey 4 onwards,
while participants that reported hypertension in the first three surveys were excluded from our
analysis. A previous study showed an agreement of 89% between self-reported hypertension
and antihypertensive medication use in the middle-aged cohort utilised in the present
study(209).

Covariates
Data on a wide range of demographic, socio-economic factors and hypertension risk
factors were collected in each survey for both cohorts. The following variables were included
as covariates: education (low – no formal qualifications or school or intermediate certificate or
equivalent; intermediate – high school or leaving certificate, trade/apprenticeships, or
certificate or diploma; or high – university degree); income management (impossible/difficult
all the time; difficult some of the time; or easy); body mass index (BMI)[underweight and
normal weight (BMI up to 25 kg/m2); overweight (BMI 25-30 kg/m2); or obese (BMI >30
kg/m2)]; smoking status (never been a smoker; former smoker; or current smoker); alcohol
consumption [rarely & non-drinker (<1 drink per week); low risk (up to 14 drinks per week);
or risky (15 to 28 drinks per week) & high risk (more than 28 drinks per week)]; doctordiagnosed diabetes type I & II combined (no or yes). Physical activity scores were derived
from validated questions on frequency and duration of walking, and on moderate- and
vigorous-intensity activity, and were categorised as: sedentary/low (<500 total metabolic
equivalent (MET) minutes/week); moderate (500 - <1000 MET minutes/week); or high (>1000
MET minutes/week)(210). In the middle-aged cohort, menopause status was determined using
questions regarding the occurrence of hysterectomy, oophorectomy, hormone replacement
therapy (HRT) and menstrual pattern, and categorised as ‘surgical menopause’, ‘not defined
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due to HRT or oral contraceptive pill, ‘pre-menopausal’, ‘peri-menopausal’ or ‘postmenopausal’. Four dietary intake variables derived from the FFQ, (fibre, cholesterol, vitamin
C and sodium) were also included as covariates.

Data analysis
Generalised Estimating Equation (GEE) analyses investigated associations of quintiles
of total flavonoid and subclass intake with incident hypertension, adjusting for demographic
and dietary variables, and hypertension risk factors. GEE was the chosen statistical approach
to enable accounting for repeated exposure and outcome measures in the same individual.
Survival analysis could not be performed due to lack of data on date of hypertension diagnosis.
An exchangeable correlation matrix, a binomial distribution of dependent variables and a log
link function were selected to conduct the GEE. Potential confounders were defined a priori
based on literature and on the available data. Four models were used to adjust for potential
confounders: (1) adjusted for energy intake and age; (2) additionally adjusted for hypertension
risk factors (diabetes, smoking, physical activity, alcohol intake and menopause status) and
demographics (education and income management); (3) additionally adjusted for dietary intake
variables related to flavonoid intake and hypertension risk (fibre, vitamin C, sodium and
cholesterol); and (4) additionally adjusted for BMI (potential mediator).
Sub-analyses were conducted by adding the total flavonoids, flavanols and flavonols
related to tea consumption for each individual. Another sub-analysis was conducted to
determine the influence on the results of additionally adjusting for gestational diabetes and
hypertension among women who reported a live birth during the study period. All analyses
were conducted using the software STATA/SE 15.1 (StataCorp LLC, TX, USA).
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2.3 Results
In the middle-aged cohort, 11,221 women completed Survey 3 and after exclusion for
hypertension reported prior to Survey 4 (n=3,334), missing data on dietary intake (n=407),
hypertension (n=339) and covariates (n=463), as well as implausible energy intake (<500kcal
or >5000 kcal/day) (n=48), 6,630 women were included for data analyses (Figure 2-1). In the
reproductive-aged cohort, 9,081 women completed Survey 3 and after exclusion for
hypertension reported prior to Survey 4 (n=693), missing data on dietary intake (n=140),
hypertension (n=1,367) and covariates (n=737), and implausible energy intake (n=45), 6,099
women were included for data analyses (Figure 2-2). No differences were found in baseline
characteristics between women in- and excluded for analyses in the middle-aged and
reproductive-aged cohort (Table 2-S1 and 2-S2).
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Figure 2.1. Flow diagram of the sample for analyses of the association between flavonoids
intake and incidenct hypertension in middle-aged women in the Australian Longitudinal Study
on Women’s Health, n=6,630

All baseline characteristics are presented according to quintiles of total flavonoid intake (Table
2-1 and 2-2 for middle-aged and reproductive-aged cohorts, respectively). There was a higher
level of education and physical activity, and a lower BMI, according to higher quintiles of total
flavonoid intake, in both cohorts. In the middle-aged cohort, there was a decreasing number of
current smokers across the quintiles of total flavonoids consumption, which was not observed
in the reproductive-aged cohort. Comparing the 5th quintile of intake between cohorts, there
was more than double the number of current smokers in the younger cohort compared to the
middle-aged cohort (20.8% vs 9.9%). Alcohol consumption had a similar non-linear pattern
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Figure 2-2. Flow diagram of the sample for analyses of the association between flavonoids
intake and incidenct hypertension in reproductive-aged women in the Australian Longitudinal
Study on Women’s Health, n=6,099

across quintiles in both cohorts for the ‘risky & high risk” alcohol intake category, however
individuals in the 5th quintile had higher values in both cohorts, which could be attributed to
the high flavonoid content of red wine. Concerning income management, the category “easy”
presented an increase across quintiles of flavonoid intake, while a decrease was observed in
the category “impossible/difficult all the time”, showing that higher income is associated with
higher flavonoid intake.
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Table 2-1. Baseline characteristics of middle-aged women in the Australian Longitudinal
Study on Women’s Health according to quintiles of total flavonoids intake, n=6,630

Variables

Categories

Mean
age
(years) (SD)
low
Educationb (%) intermediate
high
impossible/difficu
lt all the time
Income
difficult some of
management
the time
(%)
not too bad
easy
normal weight
c
BMI (%)
overweight
obese
never smoker
Smoking status former smoker
(%)
current smoker

Total flavonoid intake
Quintile Quintile Quintile
1
2
3
n =1289 n =1304 n =1315
52.3
52.4
52.4
(1.44)
(1.42)
(1.44)
74.31
66.08
62.48
15.55
19.93
22.06
10.14
13.99
15.46
12.80
11.03
8.05

Quintile Quintile
4
5
n =1367 n =1353
52.5
52.5
(1.45)
(1.46)
54.93
53.72
24.09
23.70
20.98
22.58
7.16
6.67

26.67

26.97

23.33

26.20

22.41

43.11
17.42
46.26
32.68
21.06
52.46
25.10
22.44

44.49
17.52
49.58
30.21
20.20
58.29
25.30
16.40

48.10
20.52
51.18
32.28
16.55
65.82
21.88
12.30

44.14
22.49
51.47
32.60
15.92
65.63
24.09
10.28

47.39
23.52
54.92
31.14
13.94
61.76
28.31
9.92

pvaluea
0.0027
<
0.0001

<
0.0001

<
0.0001

<
0.0001

sedentary or low
57.09
51.81
45.84
44.23
39.78
<
moderate
21.16
18.91
23.69
23.67
25.41
0.0001
high
21.75
29.29
30.47
32.10
34.82
rarely & non- 46.46
39.94
37.88
30.83
23.78
Alcohol
drinker
<
consumption
0.0001
low risk
47.64
53.01
58.32
64.70
65.53
(%)
risky & high risk
5.91
7.04
3.80
4.47
10.69
surgical
29.23
29.19
25.77
27.13
22.67
menopause
not defined due to 18.60
19.46
19.98
18.96
18.99
Menopause
HRT/OCP
0.039
status (%)
pre-menopausal
9.55
9.36
10.49
8.85
10.44
peri-menopausal
19.39
17.33
17.99
19.55
22.67
post-menopausal
23.23
24.65
25.77
25.53
25.24
97.24
97.50
97.02
96.38
98.03
Diabetes type I no
0.167
& II (%)
yes
2.76
2.50
2.98
3.62
1.97
BMI, body mass index; HRT, hormone replacement therapy; OCP, oral contraceptive pill. aP-value of
Physical
activityd (%)

chi-square test. bEducation: low, none or school certificate; intermediate, high school certificate,
trade/apprenticeship, certificate/diploma; high: university or higher university degree . cBMI: normal
weight, 16-25 kg/m2; overweight, 25-30 kg/m2, obese, >30 kg/m2. dPhysical activity: sedentary & low,
<500 metabolic equivalents (MET) per week; moderate, 500-1000 MET per week; high, >1000 MET
per week.
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Table 2-2. Baseline characteristics of reproductive-aged women in the Australian Longitudinal
Study on Women’s Health according to quintiles of total flavonoids intake, n=6,099

Variables

Categories

Total flavonoid intake
Quintile Quintile Quintile
1
2
3
n =1177 n =1203 n =1245
27.6
27.6
27.4
(1.45)
(1.46)
(1.47)
13.42
9.72
7.03
51.60
47.11
43.06
34.98
43.18
49.90
12.07
10.99
9.92

Quintile Quintile
4
5
n =1236 n =1239
27.6
27.6
(1.43)
(1.44)
5.24
6.02
37.69
34.81
57.07
59.17
7.81
9.47

Mean
age
(years) (SD)
low
Educationb (%) intermediate
high
impossible/difficu
lt all the time
Income
difficult some of 33.64
30.62
24.86
27.79
management
the time
(%)
not too bad
37.77
39.94
39.79
41.54
easy
16.51
18.45
25.43
22.85
normal weight
58.93
63.98
65.61
67.36
c
BMI (%)
overweight
22.60
22.47
20.42
21.66
obese
18.47
13.54
13.97
10.98
never smoker
57.38
63.98
62.04 62.12
Smoking status
former smoker
16.82
15.41
17.15
17.51
(%)
current smoker
25.80
20.61
20.81
20.38
sedentary or low
51.39
44.16
39.11
33.04
Physical
moderate
22.08
24.83
25.53
24.33
activityd (%)
high
26.52
31.01
35.36
42.63
rarely & non- 46.54
38.96
32.18
24.83
Alcohol
drinker
consumption
low risk
50.77
58.98
65.41
72.50
(%)
risky & high risk
2.68
2.06
2.41
2.67
98.86
98.92
98.65
98.81
Diabetes type I no
& II (%)
yes
1.14
1.08
1.35
1.19
a
b
BMI, body mass index. P-value of chi-square test. Education: low, none or

25.44
39.74
25.35
68.74
20.51
10.75
60.36
18.84
20.81
30.37
23.87
45.76
20.71

pvaluea
0.0177
<
0.0001

<
0.0001

<
0.0001
<
0.0001
<
0.0001

<
0.0001
73.27
6.02
99.01
0.956
0.99
school certificate;

intermediate, high school certificate, trade/apprenticeship, certificate/diploma; high: university or
higher university degree. cBMI: normal weight, 16-25 kg/m2; overweight, 25-30 kg/m2, obese, >30
kg/m2. dPhysical activity: sedentary & low, <500 metabolic equivalents (MET) per week; moderate,
500-1000 MET per week; high, >1000 MET per week.

Baseline nutrient and food group intake, according to quintiles of total flavonoid intake,
are presented in the Supplementary material (Table 2-S3 and 2-S4 for middle-aged and
reproductive-aged cohorts, respectively). There was an increasing consumption of the majority
of dietary variables (energy, PUFA, protein, carbohydrates, vitamin C, fibre, calcium, iron, low
fat dairy, vegetables, legumes, fruits and fruit juice) across quintiles in both cohorts, while
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‘high fat dairy’ was the only variable which decreased across quintiles. The consumption of
tea increased with the increasing consumption of total flavonoids in the middle-aged cohort,
but not in the reproductive-aged cohort.
The baseline proportional intake of flavonoid subclasses that contributed to total
flavonoids for both cohorts are presented in the Supplementary material (Figure 2-S1). The
addition of tea substantially increased total flavonoid intake (89.8 to 244.7 mg and 71.5 to
167.2 mg in the middle-aged and reproductive-aged cohorts, respectively) as well as the
relative contribution of flavonols to total flavonoid intake (47 to 79%, and 32 to 70%, in the
middle-aged and reproductive-aged cohorts, respectively). Baseline food sources of flavonoid
subclass intakes are presented in the Supplementary material (Figure 2-S2 and 2-S3 for middleaged and reproductive-aged cohorts, respectively). The top two contributors to flavonols,
flavanols and isoflavones, along with the three top contributors to sources of anthocyanins,
flavones and flavanones, were identical in both cohorts. Red wine and apples were the main
source of flavanols, while strawberries and red wines were the main source of anthocyanins.
Orange and orange juice were the main sources of flavanones, while orange juice and
watermelon were the major source of flavones. Red wine, onion and spinach were the main
sources of flavonols, while soymilk was the major source of isoflavones.
In the middle-aged cohort, there were 1,645 cases (24.9%) of hypertension during a
maximum of 15 years follow-up. Higher intakes of flavones [adjusted relative risk (ARR) for
intake quintile 5 vs 1: 0.82, 95% CI: 0.70-0.97], isoflavones (0.86, 0.75-0.99) and flavanones
(0.83, 0.69-1.00) were associated with a lower risk of hypertension (Table 2-3). Intakes of total
flavonoids, anthocyanins, flavanols and flavonols were not associated with incidence of
hypertension. In the reproductive-aged cohort, there were 336 cases (5.5%) of hypertension
during a maximum of 12 years follow-up. In this cohort, the relative risks for total flavonoids,
flavanols and flavonols were lower when comparing quintile 4 versus quintile 1. A higher
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intake of flavanols (ARR for intake quintile 4 vs 1: 0.70, 95% CI: 0.49-0.99) was associated
with a 30% lower risk of hypertension (Table 2-4). In both cohorts when including tea in the
analysis, intake of total flavonoids and flavanols, were not associated with incidence of
hypertension (Table 2-S5 and 2-S6). A sub-analysis was conducted in the reproductive-aged
cohort among women that gave birth to children. In addition to the fully adjusted model from
previous analyses, a model additionally adjusted for gestational diabetes and gestational
hypertension did not change the results (Table 2-S7).

Table 2-3. Relative risks for associations of total flavonoids and subclasses intake with incident
hypertension in middle-aged women in the Australian Longitudinal Study on Women’s Health,
n=6,630

Mean
intake
(mg) (SD)
N
(%)
cases
Model 1
Model 2
Model 3
Model 4

Total Flavonoids
Quintile 1 Quintile 2
n =1289
n =1304

Quintile 3
n =1315

Quintile 4
n =1367

Quintile 5
n =1353

27.9 (10.0)

52.4 (5.8)

74.0 (7.1)

102.9 (10.4)

169.6 (48.5)

312 (24.2)

351 (26.9)

328 (24.9)

342 (25.0)

301 (22.2)

1.00
1.00
1.00
1.00

1.02 (0.89 – 1.16)
1.07 (0.93 – 1.22)
1.07 (0.93- 1.22)
1.08 (0.95 – 1.24)

0.90 (0.78 – 1.03)
0.99 (0.86 – 1.13)
0.98 (0.86 – 1.13)
1.02 (0.88 – 1.17)

0.88 (0.77 – 1.01)
0.99 (0.86 – 1.14)
0.99 (0.85 – 1.14)
1.03 (0.89 – 1.19)

0.76 (0.66 – 0.87)
0.86 (0.74 – 0.99)
0.84 (0.71 – 1.00)
0.90 (0.76 -1.06)

9.7 (4.4)

23.9 (3.8)

36.0 (2.7)

47.6 (4.3)

86.6 (34.8)

303 (23.5)

341 (26.1)

319 (24.2)

359 (26.2)

312 (23.1)

1.00
1.00
1.00
1.00
Flavonols

0.97 (0.85 – 1.11)
1.02 (0.89 – 1.16)
1.04 (0.91 – 1.19)
1.03 (0.90 – 1.18)

0.94 (0.82 – 1.08)
0.97 (0.85 – 1.11)
0.99 (0.86 – 1.13)
1.01 (0.88 – 1.15)

0.97 (0.85 – 1.11)
1.05 (0.92 – 1.20)
1.10 (0.96 – 1.26)
1.10 (0.96 – 1.26)

0.81 (0.70 – 0.93)
0.88 (0.77 – 1.02)
0.94 (0.81 – 1.09)
0.97 (0.83 – 1.12)

3.4 (1.5)

5.5 (2.6)

6.3 (3.9)

6.4 (3.9)

15.0 (8.3)

318 (24.7)

304 (23.3)

348 (26.5)

341 (24.9)

323 (23.9)

1.00
1.00
1.00

0.90 (0.78 – 1.03)
0.94 (0.82 – 1.08)
0.96 (0.83 – 1.10)

0.95 (0.83 – 1.08)
1.00 (0.88 – 1.15)
1.03 (0.90 – 1.17)

0.96 (0.84 – 1.09)
1.00 (0.88 – 1.14)
1.02 (0.90 – 1.17)

0.86 (0.76 – 0.99)
0.93 (0.81 – 1.07)
0.98 (0.85 – 1.13)

Flavanols
Mean
intake
(mg) (SD)
N
(%)
cases
Model 1
Model 2
Model 3
Model 4
Mean
intake
(mg) (SD)
N
(%)
cases
Model 1
Model 2
Model 3
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Model 4
Mean
intake
(mg) (SD)
N
(%)
cases
Model 1
Model 2
Model 3
Model 4
Mean
intake
(mg) (SD)
N
(%)
cases
Model 1
Model 2
Model 3
Model 4
Mean
intake
(mg) (SD)
N
(%)
cases
Model 1
Model 2
Model 3
Model 4

0.97 (0.84 – 1.11)
1.00
Anthocyanins

1.04 (0.91 – 1.19)

1.04 (0.91 – 1.18)

1.02 (0.89 – 1.18)

0.61 (0.3)

1.6 (0.3)

2.9 (0.5)

5.3 (0.99)

12.4 (5.8)

308 (23.9)

341 (26.1)

354 (26.9)

311 (22.7)

320 (23.6)

1.00
1.00
1.00
1.00
Flavones

0.99 (0.86 – 1.13)
1.03 (0.90 – 1.18)
1.04 (0.91 – 1.19)
1.02 (0.90 – 1.17)

1.02 (0.90 – 1.17)
1.08 (0.95 – 1.24)
1.10 (0.96 – 1.26)
1.08 (0.94 – 1.23)

0.85 (0.74 -0.98)
0.95 (0.82 – 1.09)
0.97 (0.84 – 1.11)
0.94 (0.81 – 1.08)

0.92 (0.80 – 1.05)
0.99 (0.86 – 1.14)
1.03 (0.89 – 1.19)
0.99 (0.86 – 1.15)

1.54 (0.7)

3.9 (0.7)

6.8 (0.9)

10.7 (1.4)

21.0 (8.5)

347 (26.9)

305 (23.4)

335 (25.5)

357 (26.1)

290 (21.4)

1.00
1.00
1.00
1.00
Isoflavones

0.83 (0.73 – 0.95)
0.88 (0.77 – 1.00)
0.87 (0.76 – 1.00)
0.88 (0.77 – 1.00)

0.86 (0.76 – 0.98)
0.94 (0.82 -1.07)
0.93 (0.81 – 1.07)
0.94 (0.82 – 1.08)

0.88 (0.77 – 1.00)
0.98 (0.86 – 1.11)
0.97 (0.84 – 1.12)
0.96 (0.84 – 1.11

0.72 (0.63 – 0.83)
0.81 (0.70 – 0.93)
0.82 (0.69 – 0.97)
0.81 (0.69 – 0.96)

0.22 (2.5)

0.31 (3.4)

0.30 (2.8)

0.61 (4.0)

13.8 (16.6)

361 (28.0)

340 (26.1)

318 (24.2)

325 (23.8)

290 (21.4)

1.00
1.00
1.00
1.00
Flavanones

0.92 (0.81 -1.05)
0.92 (0.81 – 1.04)
0.92 (0.81 – 1.05)
0.91 (0.80 – 1.04)

0.85 (0.74 – 0.97)
0.86 (0.76 -0.98)
0.87 (0.76 – 0.99)
0.87 (0.76 - 0.99)

0.84 (0.74 – 0.97)
0.89 (0.78 – 1.01)
0.90 (0.80 – 1.04)
0.95 (0.84 – 1.09)

0.70 (0.61 – 0.80)
0.77 (0.68 – 0.89)
0.81 (0.71 -0.94)
0.87 (0.76 – 1.00)

35.4 (11.3)

64.7 (27.9)

322 (23.5)

308 (22.8)

0.82 (0.72 – 0.94)
0.92 (0.80 – 1.05)
0.88 (0.75 – 1.03)
0.90 (0.77 – 1.04)

0.77 (0.67 – 0.88)
0.87 (0.76 – 1.00)
0.79 (0.65 – 0.96)
0.83 (0.69 – 1.00)

Mean
6.1 (9.2)
13.9 (10.2)
22.6 (9.8)
intake
(mg) (SD)
N
(%)
343 (26.6)
322 (24.7)
339 (25.8)
cases
0.85 (0.74 – 0.97) 0.88 (0.77 – 0.99)
Model 1
1.00
0.90 (0.79 – 1.03) 0.96 (0.84 – 1.10)
Model 2
1.00
0.90 (0.79 – 1.03) 0.94 (0.82 – 1.08)
Model 3
1.00
0.91 (0.80 – 1.04) 0.95 (0.83 -1.09)
Model 4
1.00
Model 1: adjusted for total energy intake and age; Model 2:

model 1 + additionally adjusted for

hypertension risk factors (smoking status, diabetes, physical activity, alcohol intake, menopause status)
and demographics variables (education, income management); Model 3: model 2 + additionally
adjusted for dietary intake variables (fibre, cholesterol, vitamin C, sodium); Model 4: model 3 +
additionally adjusted for body mass index.
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Table 2-4. Relative risks for associations of total flavonoids and subclasses intake with incident
hypertension in reproductive-aged women in the Australian Longitudinal Study on Women’s Health,
n=6,099

Mean
intake
(mg) (SD)
N
(%)
cases
Model 1
Model 2
Model 3
Model 4

Total Flavonoids
Quintile 1 Quintile 2
n =1177
n =1203

Quintile 3
n =1245

Quintile 4
n =1236

Quintile 5
n =1239

32.6 (27.9)

49.2 (29.3)

63.2 (30.6)

83.8 (34.2)

126.0 (54.4)

74 (6.3)

79 (6.1)

70 (5.3)

51 (4.1)

62 (4.6)

1.00
1.00
1.00
1.00

0.97 (0.71 – 1.32)
1.02 (0.75 – 1.39)
0.99 (0.72 – 1.36)
1.05 (076. 1.43)

0.85 (0.62 – 1.17)
0.92 (0.66 – 1.27)
0.87 (0.62 – 1.23)
0.93 (0.66 – 1.30)

0.60 (0.42 – 0.86)
0.66 (0.46 – 0.95)
0.61 (0.42 – 0.91)
0.68 (0.46 – 1.01)

0.74 (0.53 – 1.05)
0.79 (0.55 – 1.12)
0.68 (0.44 – 1.06)
0.77 (0.50 – 1.20)

7.6 (11.8)

12.5 (14.2)

17.1 (13.8)

23.9 (15.0)

48.3 (31.8)

82 (7.0)

77 (6.4)

69 (5.5)

53 (3.9)

55 (4.1)

1.00
1.00
1.00
1.00
Flavonols

0.89 (0.66 – 1.21)
0.93 (0.69 – 1.27)
0.94 (0.69 – 1.28)
0.98 (0.72 – 133)

0.76 (0.56 – 1.04)
0.81 (0.59 – 1.12)
0.82 (0.59 – 1.14)
0.90 (0.65 – 1.24)

0.58 (0.41 – 0.81)
0.63 (0.44 – 0.89)
0.64 (0.45 – 0.92)
0.70 (0.49 – 0.99)

0.61 (0.43 – 0.85)
0.61 (0.43 – 0.88)
0.64 (0.44 – 0.93)
0.72 (0.49 – 1.04)

3.4 (1.5)

5.5 (2.6)

6.3 (3.9)

6.4 (3.9)

15.0 (8.3)

71 (5.5)

82 (6.3)

57 (4.3)

50 (3.7)

55 (4.1)

1.06 (0.78 – 1.45)
1.00
1.10 (0.81 – 1.51)
1.00
1.10 (0.80 – 1.50)
1.00
1.12 (0.82 – 1.54)
1.00
Anthocyanins

0.75 (0.54 – 1.06)
0.81 (0.57 – 1.14)
0.80 (0.56 – 1.15)
0.88 (0.61 – 1.25)

0.65 (0.45 – 0.92)
0.69 (0.48 – 0.99)
0.69 (0.48 – 1.00)
0.79 (0.54 – 1.14)

0.72 (0.51 – 1.01)
0.74 (0.52 – 1.06)
0.74 (0.51 – 1.08)
0.86 (0.59 – 1.26)

1.8 (2.9)

2.9 (2.8)

4.1 (2.9)

5.8 (3.4)

10.5 (7.5)

70 (5.4)

69 (5.3)

68 (5.2)

68 (5.0)

61 (4.5)

1.00
1.00
1.00
1.00
Flavones

0.92 (0.66 – 1.28)
0.97 (0.70 – 1.34)
0.98 (0.70 – 1.36)
0.97 (0.70 – 1.35)

0.89 (0.64 – 1.24)
0.95 (0.68 – 1.32)
0.96 (0.69 – 1.33)
0.93 (0.67 – 1.30)

0.92 (0.66 – 1.27)
0.98 (0.70 – 1.37)
0.99 (0.71 – 1.40)
0.99 (0.71 – 1.39)

0.86 (0.61 – 1.20)
0.89 (0.63 – 1.26)
0.93 (0.65 -1.33)
0.88 (0.62 – 1.26)

1.5 (0.7)

3.9 (0.7)

6.8 (0.9)

10.7 (1.4)

21.0 (8.5)

75 (6.4)

58 (4.8)

78 (6.3)

57 (4.6)

68 (5.5)

1.00

0.76 (0.55 – 1.07)

0.99 (0.73 – 1.37)

0.69 (0.49 – 0.97)

0.83 (0.59 – 1.17)

Flavanols
Mean
intake
(mg) (SD)
N
(%)
cases
Model 1
Model 2
Model 3
Model 4
Mean
intake
(mg) (SD)
N
(%)
cases
Model 1
Model 2
Model 3
Model 4
Mean
intake
(mg) (SD)
N
(%)
cases
Model 1
Model 2
Model 3
Model 4
Mean
intake
(mg) (SD)
N
(%)
cases
Model 1
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Model 2
Model 3
Model 4
Mean
intake
(mg) (SD)
N
(%)
cases
Model 1
Model 2
Model 3
Model 4

0.80 (0.57 – 1.11)
1.00
0.80 (0.57 – 1.12)
1.00
0.79 (0.57 – 1.12)
1.00
Isoflavones

1.04 (0.77 – 1.43)
1.03 (0.75 – 1.43)
1.06 (0.77 – 1.46)

0.75 (0.53 – 1.05)
0.73 (0.50 – 1.05)
0.73 (0.51 – 1.05)

0.89 (0.64 – 1.26)
0.84 (0.54 – 1.32)
0.84 (0.54 – 1.30)

0.3 (3.1)

0.3 (2.9)

0.5 (3.9)

1.0 (4.8)

9.5 (14.1)

71 (6.0)

62 (5.1)

82 (6.6)

68 (5.5)

53 (4.3)

1.00
1.00
1.00
1.00
Flavanones

0.86 (0.61 – 1.20)
0.90 (0.64 – 1.25)
0.90 (0.64 – 1.25)
0.92 (0.66 – 1.28)

1.16 (0.84 – 1.58)
1.20 (0.88 – 1.64)
1.22 (0.89 – 1.66)
1.30 (0.95 -1.77)

0.91 (0.65 – 1.26)
0.99 (0.71 – 1.37)
1.01 (0.72 – 1.41)
1.12 (0.80 – 1.57)

0.68 (0.48 – 0.96)
0.76 (0.53 – 1.08)
0.83 (0.57 – 1.20)
1.03 (0.71 – 1.49)

33.7 (18.4)

57.1 (31.2)

71 (5.7)

68 (5.5)

0.98 (0.70 – 1.35)
1.06 (0.76 – 1.48)
1.09 (0.76 – 1.56)
1.13 (0.79 – 1.63)

0.95 (0.68 – 1.33)
1.03 (0.73 – 1.45)
1.03 (0.64 – 1.66)
1.08 (0.67 – 1.73)

Mean
11.2 (15.9) 17.1 (15.0)
24.8 (16.5)
intake
(mg) (SD)
N
(%)
69 (5.9)
70 (5.8)
51 (4.1)
cases
1.01 (0.73 – 1.40) 0.81 (0.58 – 1.15)
Model 1
1.00
1.06 (0.76 – 1.46) 0.86 (0.61 – 1.21)
Model 2
1.00
1.07 (0.77 – 1.49) 0.87 (0.61 – 1.24)
Model 3
1.00
1.13 (0.82 – 1.57) 0.90 (0.63 – 1.28)
Model 4
1.00
Model 1: adjusted for total energy intake and age; Model 2:

model 1 + additionally adjusted for

hypertension risk factors (smoking status, diabetes, physical activity, alcohol intake) and demographics
variables (education, income management); Model 3: model 2 + additionally adjusted for dietary intake
variables (fibre, cholesterol, vitamin C, sodium); Model 4: model 3 + additionally adjusted for body
mass index.

2.4 Discussion
Findings from this population-based prospective study of Australian women showed an
association between a higher dietary intake of flavonoid subclasses and lower incidence of
hypertension. In the middle-aged cohort, a higher intake of flavone, flavanone and isoflavone
subclasses of flavonoids were associated with a lower incidence of hypertension. In the
reproductive-aged cohort, higher intakes of flavanols were associated with lower incidence of
hypertension. Inconsistencies in the present findings between cohorts may be explained by
generational differences in food intake, as previously demonstrated by differences in the level
of consumption of individual food items in the ALSWH middle-aged and reproductive-aged
cohorts(187). Our analyses have also shown differences in the contribution of foods to
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flavonoid intake, both in the diversity and in the percentage of food items for each subclass,
which may further contribute to explaining the differences in associations between the cohorts.
Additionally, the generational differences on hypertension risk factors(211) may also partly
explain the inconsistencies found for associations between subclasses of flavonoids and
incidence of hypertension in the two different age-range cohorts in our study. Similar analyses
have been conducted in other populations. Cassidy et al.(212) examined the association
between flavonoid intake and incidence of hypertension in a combined grouping of three
different cohorts that included 133,914 women from the Nurses' Health Study I and II, and
23,043 men from the Health Professionals Follow-Up Study. Across 14 years of follow-up,
there were 29,018 cases of hypertension in women and 5629 cases of hypertension in men. A
reduction of 8% in the risk of hypertension (RR: 0.92; 95% CI: 0.86-0.98) was found,
comparing individuals from the highest quintile versus lowest quintile of anthocyanin intake.
This association was stronger among individuals younger than 60 years (RR: 0.88; 95% CI:
0.84-0.93). Other subclasses were not associated with hypertension; however, a pooled analysis
for individual compounds suggested a 5% (95% CI: 0.91-0.99) lower risk for the highest
compared with the lowest quintiles of intake of the flavone apigenin. In participants ≤60 y, a
6% (95% CI: 0.88-0.97) lower risk was observed for the flavanol catechin(212). Another study
conducted in women found that the highest quintile of flavonol intake was associated with a
10% lower rate of hypertension compared to the lowest quintile (HR: 0.90; 95% CI: 0.84-0.97)
after a follow-up of 14 years(213). Proanthocyanidin (polymerised flavanols) and anthocyanin
subclasses also showed a similarly lowered risk of 9% in incidence of hypertension between
highest and lowest quintiles of consumption (HR: 0.91; 95% CI: 0.84-0.97; and HR: 0.91, 95%
CI: 0.85-0.97, respectively)(213).
In the present study, there were slight differences between the two age cohorts with regard
to contribution of subclasses to total flavonoid intake, but few relevant differences compared
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to the aforementioned studies conducted in other countries. In both the middle-aged and
reproductive-aged cohorts, the four subclasses that were main sources of flavonoids were the
same (in descending order: flavanols, flavanones, flavonols and anthocyanins) as those
reported in USA cohorts(212,214). In a cohort of French women, anthocyanins were the
subclass that provided the second highest amount of flavonoids(213). There were, however,
pronounced differences between our study and other cohort studies in total amount of flavonoid
intake. A limitation is that the FFQ in the ALSWH did not include tea, but this could be
ascertained from questions in another part of the survey. The daily total flavonoid intake,
including tea flavonoids, in the middle-aged and reproductive-aged cohorts was 245 and 167
mg/day, respectively. Comparing to cohort studies from other countries, our results were
similar to the value of 190 mg/day reported in NHANES 1999–2002(214), but lower than the
358 to 415 mg/day reported in the analysis of the three Health Professionals cohort studies by
Cassidy et al.(212) and the amount of 575 ±302 mg/day reported in a French cohort(213).
Comparisons between such studies need to be interpreted with caution due to the use of
different databases for flavonoid calculation, as well as considering that such databases are
constantly being updated to reflect changes in the food supply. However, a previous study
conducted in a cohort of women aged over 75 years (n=1063) observed that the application of
the United States Department of Agriculture (USDA) and phenol-explorer source data yielded
a high correlation of intake estimates for total-flavonoids, flavanols, flavanones and
anthocyanidins, while a poorer correlation for flavonols and flavones was found(215). Both
studies conducted in USA(212,214) used the United States Department of Agriculture (USDA)
database, while the study conducted in France(213) used the European Phenol-Explorer
database.
In both the middle-aged and reproductive-aged cohorts, total flavonoid intake increased
with higher education, income and physical activity and lower BMI, with the same pattern
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found for education(213,214), income(214), physical activity(212,214) and BMI(212,213)
among other studies. A higher intake of total flavonoids found in our middle-aged, compared
to reproductive-aged, cohort (245 vs 167 mg/day, respectively) is consistent with an increased
flavonoid density of diets with age that is reported in other cohorts(213,214).
Three subclasses of flavonoids, flavones, isoflavones and flavanones, were associated
with a lower risk incident hypertension in the middle-aged cohort. The primary contributor for
flavones and flavanones was orange juice (66% and 45% respectively), while for isoflavones
was soy milk (93%). Flavones have been shown to exert an anti-hypertensive effect, mainly
through their vasorelaxation properties(216). Flavone derivatives possess an endotheliumdependent vasorelaxant effect, associated with an increased production of NO and prostacyclin
PGI2 in a concentration-dependent manner(216). For example, luteolin, a flavone found in high
concentrations in food items evaluated in the present study (including watermelon, celery and
pumpkin) has been shown to exert a direct effect on vasorelaxation by improving acetylcholineinduced NO generation(217).
The BP lowering potential of isoflavones is linked to their signalling properties in the
endothelium. The soy isoflavones, genistein, daidzein and glycitein, activate endothelial nitric
oxide synthase and increase the capacity of serum to stimulate prostacyclin release in human
endothelial cells(218). However, their effects on blood pressure remain equivocal, mainly due
to inter-individual differences in equol (a gut microbiota-derived isoflavone metabolite)
production as well as different dietary sources of isoflavones(218,219).
The main flavanones, naringin, hesperidin, and eriodictoyl, present a wide range of
beneficial properties, such antioxidant, anti-inflammatory, hypolipidemic, and anti-atherogenic
activities(217). The main source of flavanones worldwide are citrus fruits(217), as was found
in both cohorts in the present study. A few studies support our findings of the association
between flavanone intake and reduced incident hypertension. Experimental studies indicate
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that the antihypertensive activity of flavones are mediated by endothelium-dependent and
endothelium-independent mechanisms. Not only can flavones increase NO generation, but can
also reduce [Ca2+]i and the consequent contraction of endothelial muscle cells(220).
The inclusion of tea flavonoids in our analyses resulted in the association of flavanols
with lower incidence of hypertension not remaining longer significant in the reproductive-aged
cohort. Some factors may explain this finding. The missing values and response rate of the
FFQ did not match the questions about tea within the survey. Thus, the sub-analysis had a
lower sample size and less statistical power. The percentage of total flavonoids and flavanols
from tea is also much higher in the present study compared to other similar studies in the
USA(212,214) and France(213), in which the annual per capita consumption of tea is 0.23 and
0.20 kg, compared to 0.75 kg in the Australian population. Lastly, the consumption of black
tea alone was not associated with a lower incidence of hypertension in the present study (ARR
for intake quintile 4 vs 1: 0.96, 95% CI: 0.74-1.59).
Limitations of this study include the use of self-reported data for hypertension. This may
have caused misclassification of cases; however, a previous study(209) showed a high
correlation (89%) between self-reported doctor-diagnosed hypertension and use of
antihypertensive medication. Moreover, flavonoid content in foods is likely to be influenced
by seasonality and geographic areas, and there may be discrepancies between food composition
databases and flavonoid content in foods between different countries. Potential measurement
error and selection bias based on the factors of seasonality and geographic areas were
attenuated by the fact that the FFQ reflected 12 months of dietary intake and that recruitment
of participants was proportional in all Australian states. In general, FFQs may lack detail about
some flavonoid-rich food sources(221). The FFQ included in ALSWH was developed over two
decades ago(204), and it may not have included relevant high-flavonoid food items that have
increased in popularity over this period, such as blackberries, cherries, blueberries and
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raspberries(222). This could have led to an underestimation of anthocyanin intake, as the mean
intake in the present study was 4.7 mg/day in the middle-aged and 5.0 mg/day in the
reproductive-aged cohort, compared to 24.2 mg/day reported in 2019 in the overall Australian
population from a nationally representative sample that used two 24-hr recalls as the method
of dietary assessment(222). The mean anthocyanin intakes in other cohort studies that have
found a reduction in incident hypertension were 12.5 mg/day(212) and 71.0 mg/day(213),
while another cohort from NHANES 1999–2002(214) reported a dietary intake of only 3.03
mg/day. Strengths of this study include the representative sample of Australian women across
two age cohorts, the prospective design, and repeated measures.
Residual confounding is a known problem in all observational studies; however,
adjustments were made for key confounding factors, in-line with previous studies. Potential
confounders were extensively explored in our models, with access to a wide range of
demographic, hypertension risk factor and dietary intake variables. The large sample size
allowed for a stepwise regression with bidirectional elimination in order to create the models
for such adjustments, therefore avoiding major multicollinearity and overfitting issues of the
model. Results were not adjusted for multiple testing. A common limitation is the inability to
adjust for all dietary intake variables that are highly related (collinearity). The main predictor
variable in this study, flavonoids, represents bioactive compounds that are present in virtually
all plants; therefore, adjusting for all dietary components such as fibre, potassium and inorganic
nitrates, that are also present in plants and/or other high-flavonoid food items is not viable in
the modelling. We included fibre in our model because of its high significance in the model,
and the well-established contribution of fibre in overall diet quality that is associated with blood
pressure, as well as its high linearity with potassium and inorganic nitrates. Lastly, there was a
relevant number of missing survey data on both cohorts; however, there is only a small
probability that such loss over time was selective, as it is unlikely that a person would be unable
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or unwilling to complete the next survey as a result of being diagnosed with hypertension.
Hypertension is a ‘silent’ condition that per se has no major cognitive or physical implications,
and has a non-invasive and non-onerous treatment(189). Potential attrition bias could be due
to hypertension being a risk factor for major adverse cardiovascular events (MACE), which
can lead to debilitating complications(223); however, this would only have been a cause for
selective drop-out if a MACE occurred without the diagnosis of hypertension, or after the
diagnosis of hypertension and before the following survey (period of approximately 3 years).
Still, there was a higher response rate for surveys conducted in the middle-aged cohort (62.9%)
compared to the reproductive-aged cohort (50.0%), despite a 5-fold higher number of cases of
hypertension in the former. Concerning the exclusion of women due to missing data, there was
no significant change in any variable included in the models in both cohorts. Recruitment of
participants was proportional to population size in all Australian states, thereby enabling
generalizability of the study findings to Australian women.

2.5 Conclusion
Flavonoid intake was associated with a lower incidence of hypertension in two
population-based cohorts of Australian women who were either of reproductive-age or middleaged. Higher intakes of flavones, isoflavones and flavanones, attributed mainly to orange,
orange juice, apples and soy milk, were associated with a reduced risk of hypertension among
middle-aged women followed-up over 15 years. Higher intakes of flavanols, attributed mainly
to red wine and apples, were associated with a reduced risk of hypertension among
reproductive-aged women followed-up for 12 years. These findings can be used in nutritional
messages and policies aimed at improving the cardiovascular health of women of different life
stages.
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2.6 Supplementary Material

Table 2-S1. Baseline characteristics of the study population comparing the sample with exclusions
(n=6,630) with the sample with no exclusions (n=7,887) for missing data of middle-aged women in the
Australian Longitudinal Study on Women’s Health
Variables
Mean age (years)
Total energy (kcal)
Total flavonoid
intake
Total flavonoid
intake (including tea)
Fibre
Cholesterol
Vitamin C
Sodium
Educationb (%)

Income management
(%)

BMIc (%)

Smoking status (%)

Categories
-

n=6,630
58.4 ±1.4
1583.3 ±539.8
89.8 ±54.1

n=7,887
58.4 ±1.4
1579.0 ±549.0
88.1 ±54.5

P-valuea
0.99
0.64
0.06

-

244.7 ±143.1

243.3 ±144.1

0.54

low
intermediate
high
impossible/difficult all the
time
difficult some of the time
not too bad
easy
normal weight
overweight
obese
never smoker
former smoker
current smoker

20.3 ±8.1
240.3 ±107.5
117.1 ±64.0
2105.0 ±782.1
61.2
21.4
17.4
9.7

20.0 ±8.0
241.3 ±110.1
116.5 ±65.5
2098.3 ±790.3
63.2
20.7
16.1
10.6

0.06
0.58
0.58
0.61
0.97

21.9
45.5
22.9
45.9
33.8
20.4
60.8
29.0
10.2

22.2
45.4
21.9
45.3
33.9
20.8
60.3
28.8
10.8

0.99

0.98

0.97

sedentary or low
35.11
36.2
0.98
moderate
23.7
23.5
high
41.1
40.3
rarely & non-drinker
32.8
33.8
Alcohol consumption
low risk
61.0
60.1
(%)
risky & high risk
6.2
6.1
surgical menopause
30.0
30.5
1.0
not defined due to
7.1
7.0
HRT/OCP
Menopause
status
(%)
pre-menopausal
0.1
0.1
peri-menopausal
2.0
2.0
post-menopausal
60.7
60.3
no
94.8
94.8
1.0
Diabetes type I & II
(%)
yes
5.2
5.2
Values are mean and SD (±) or percentages (%). BMI, body mass index; HRT, hormone replacement
Physical activityd (%)

therapy; OCP, oral contraceptive pill. aP-value of independent t-test or chi-square test. bEducation: low,
none

or

school

certificate;

intermediate,

high

school

certificate,

trade/apprenticeship,
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certificate/diploma; high: university or higher university degree. cBMI: normal weight, 16-25 kg/m2;
overweight, 25-30 kg/m2, obese, >30 kg/m2. dPhysical activity: sedentary & low, <500 metabolic
equivalents (MET) per week; moderate, 500-1000 MET per week; high, >1000 MET per week.
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Table 2-S2. Baseline characteristics of the study population comparing the sample with exclusions
(n=6,099) versus the sample with no exclusions (n=8,388) for missing data of reproductive-aged women
in the Australian Longitudinal Study on Women’s Health

Variables
Total energy (kcal)
Total flavonoid
intake
Total flavonoid
intake (including tea)
Fibre
Cholesterol
Vitamin C
Sodium
Mean age (years)
(SD)

Categories
-

n=6,099
1638.7 ±586.5
71.5 ±49.0

n=8,388
1638.9 ±604.7
70.3 ±48.8

P-valuea

-

167.2 ±123.5

165.5 ±123.4

0.41

-

19.4 ±7.3
266.9 ±115.0
105.9 ±59.0
2256.8 ±889.2
33.7 ±1.4

19.3 ±7.4
269.3 ±122.1
104.9 ±59.0
2267.4 ±925.3
33.7 ±1.5

0.42
0.23
0.31
0.49
0.21

-

0.14

low
5.9
7.0
0.84
intermediate
37.6
40.0
high
56.7
53.1
impossible/difficult all the
10.1
11.2
0.98
time
Income management
difficult some of the time
26.5
28.2
(%)
not too bad
41.2
39.7
easy
22.2
20.9
normal weight
56.0
55.8
0.99
BMIc (%)
overweight
25.5
25.5
obese
18.5
18.7
never smoker
65.2
62.2
0.85
Smoking status (%)
former smoker
23.3
24.6
current smoker
11.5
13.4
sedentary or low
49.4
49.6
0.99
d
Physical activity (%)
moderate
22.1
22.5
high
28.4
27.8
rarely & non-drinker
35.6
36.3
0.99
Alcohol consumption
low risk
60.3
59.6
(%)
risky & high risk
4.1
4.2
no
97.8
97.6
0.99
Diabetes type I & II
(%)
yes
2.2
2.4
Values are mean and SD (±) or percentages (%). BMI, body mass index. aP-value of independent tEducationb (%)

test or chi-square test. bEducation: low, none or school certificate; intermediate, high school
certificate, trade/apprenticeship, certificate/diploma; high: university or higher university degree.
c

BMI: normal weight, 16-25 kg/m2; overweight, 25-30 kg/m2, obese, >30 kg/m2. dPhysical activity:

sedentary & low, <500 metabolic equivalents (MET) per week; moderate, 500-1000 MET per week;
high, >1000 MET per week.
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Table 2-S3. Baseline nutrient and food group intake according to quintiles of total flavonoids intake
in middle-aged women in the Australian Longitudinal Study on Women’s Health, n=6,630
Intake per
day
Total
flavonoids
(mg)

Quintile 1
n =1289

Total flavonoid intake
Quintile 2 Quintile 3 Quintile 4
n =1304
n =1315
n =1367

27.9 ±10.0

52.4 ±5.8

74.0 ±7.1

1381.5
±479.0

1476.2
±484.0

20.2 ±7.2

Quintile 5
n =1353

p-value1

102.9
±10.4

169.6
±48.5

< 0.0001

1561.9
±497.1

1655.7
±526.1

1784.2
±590.4

< 0.0001

35.5 ±4.0

47.4 ±4.6

62.1 ±6.3

95.1 ±27.2

<0.0001

58.3 ±24.2

60.4 ±24.1

60.9 ±24.8

63.3 ±25.8

66.9 ±27.1

< 0.0001

38.0

36.8

35.1

34.4

33.7

24.0 ±10.9

24.7 ±11.1

24.4 ±11.2

24.9 ±11.6

25.9 ±11.9

< 0.0001

8.8 ±4.5

9.0 ±4.3

9.5 ±4.8

10.2 ±4.8

< 0.0001

MUFA (g)

20.5 ±8.8

21.3 ±8.9

21.4 ±9.0

22.4 ±9.6

Protein (g)
Energy from
diet (%)
Carbohydrates
(g)
Energy from
diet (%)
Vitamin C
(mg)
Cholesterol
(mg)
Fibre (g)

71.4 ±28.1

76.4 ±28.1

79.4 ±26.5

84.7 ±29.9

11.0 ±5.5
23.6
±10.22
89.8 ±34.0

20.7

20.7

20.3

20.5

20.1

144.2
±50.2

158.1
±52.9

175.4
±54.5

187.8
±58.4

206.7
±70.4

41.7

42.8

44.9

45.4

46.3

110.48
±40.9
235.4
±97.5
20.0 ±6.6
858.8
±287.5
11.5 ±4.3
82.1
±145.5
231.5
±178.0

135.8
±50.6
244.6
±108.0
22.4 ±7.2
913.3
±306.7
12.4 ±4.8
77.8
±152.6
250.9
±188.8
107.2
±46.7
28.9 ±19.7
249.8
±112.9

Energy (kcal)
Flavonoids per
1000 kcal
Total fat (g)
Energy from
diet (%)
Saturated fat
(g)
PUFA (g)

Calcium (mg)
Iron (mg)
High fat dairy
(g)
Low fat dairy
(g)
Vegetables (g)
Legumes (g)
Fruits (g)
Fruit juice (g)
Tea (g)
Values presented

< 0.0001
< 0.0001

< 0.0001

173.9
< 0.0001
±84.7
225.4
237.1
256.0
< 0.0001
±107.0
±103.2
±117.1
15.1 ±5.8
17.2 ±6.1
25.3 ±9.3
< 0.0001
751.8
807.3
931.5
< 0.0001
±282.2
±284.7
±318.9
9.5 ±4.2
10.5 ±4.2
13.6 ±5.9
< 0.0001
123.3
98.0
66.0
< 0.0001
±180.0
±163.9
±135.5
168.7
207.3
260.3
< 0.0001
±181.1
±183.2
±185.2
118.3
83.4 ±45.0 90.6 ±44.9 98.3 ±42.9
< 0.0001
±53.2
26.8 ±19.6 26.8 ±17.6 27.8 ±19.5
30.3 ±20.3
< 0.0001
102.7
139.8
197.1
312.4
< 0.0001
±72.8
±84.6
±99.0
±152.2
135.4
20.4 ±32.4 43.3 ±57.8 68.0 ±75.3 89.8 ±95.2
< 0.0001
±157.1
108.7
268.3
288.8
293.2
295.8
< 0.0001
±148.2
±201.2
±195.3
±192.5
±197.3
in mean and standard deviation (±). 1p-value based on one-way ANOVA. PUFA,
67.9 ±26.7

87.7 ±34.6

polyunsaturated fatty acids; MUFA, monounsaturated fatty acids; CHO, carbohydrates; High fat dairy:
85

full cream milk, hard cheese, firm cheese, soft cheese, cream cheese, flavoured milk; Low fat dairy:
ricotta, cottage cheese, low fat cheese, reduced fat milk, skim milk, soy milk, Vegetables: beetroot,
broccoli, cabbage, capsicum, carrots, cauliflower, celery, garlic, lettuce, mushrooms, onion, pumpkin,
spinach, tomatoes, zucchini; Legumes: baked beans, bean sprouts, green beans, other beans, chickpeas;
Fruit: apples, pineapples, apricots, bananas, mango, watermelon, rockmelon, honeydew, oranges,
peaches, pears, strawberries.
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Table 2-S4. Baseline nutrient and food group intake according to quintiles of total flavonoids intake
in reproductive-aged women in the Australian Longitudinal Study on Women’s Health, n=6,099
Intake per
day
Total
flavonoids
(mg)
Energy
(kcal)
Flavonoids
per 1000
kcal

Quintile 1
n =1177

Quintile 2
n =1203

Quintile 3
n =1245

Quintile 4
n =1236

Quintile 5
n =1239

p-value1

20.2 ±6.6

39.1 ±5.2

58.6 ±6.2

84.7 ±9.7

147.6
±43.0

< 0.0001

1436.7
±526.3

1549.6
±552.4

1647.6
±576.4

1681.3
±595.8

1897.4
±684.3

<0.0001

14.1 ±4.6

25.2 ±3.3

35.6 ±3.8

50.4 ± 5.8

77.8 ±22.7

<0.0001

Tota fat (g)

61.8 ±27.3

64.0 ±28.5

66.9 ±29.2

66.5 ±29.5

73.1 ±32.2

<0.0001

Energy from
diet (%)
Saturated
fat (g)
PUFA (g)

38.7

37.2

36.5

35.6

34.7

26.6 ±12.6

27.1 ±13.2

27.9 ±13.0

27.2 ±13.5

29.3 ±14.7

<0.0001

8.3 ±4.3

8.8 ±4.4

9.4 ±5.0

9.7 ±4.7

11.0 ±5.4

<0.0001

MUFA (g)

21.6 ±9.8

22.4 ±10.3

23.6 ± 10.9

23.5 ±10.8

25.9 ±11.8

<0.0001

Protein (g)
Energy from
diet (%)
Carbohydra
tes (g)
Energy from
diet (%)
Vitamin c
(mg)
Cholesterol
(mg)
Fibre
Calcium
(mg)
Iron (mg)

71.8 ±27.0

77.6 ±29.1

81.9 ±30.9

83.1 ±31.9

91.6 ±36.6

<0.0001

20.0

19.4

19.9

19.8

19.3

150.0 ±54.5

167.3 ±56.9

180.9 ±59.5

189.0 ±63.6

219.6 ±49.6

41.8

43.2

43.0

45.0

46.3.

64.2 ±22.9

93.3 ±31.0

118.2±40.0

142.8 ±56.0

197.4 ±91.3

231.2
±101.3
14.3 ±5.3
764.1
±273.5
9.3 ±3.8

239.7
±107.8
16.7 ±5.7
824.2
±268.2
10.6 ±4.4

249.0
±111.8
18.4 ±6.2
848.0
±276.6
11.4 ±4.7

248.0
±116.2
20.2 ±6.9
877.9
±289.4
11.9 ±4.9

269.8
±133.1
23.8 ±8.6
912.6
±328.7
13.5 ±5.5

High fat
dairy (g)

150.0
±196.1

125.2
±176.8

108.6
±165.3

91.2
±149.3

92.2
±158.1

<0.0001

Low fat
dairy (g)
Vegetables
(g)

165.1
±177.2

189.0
±172.5

202.6
±174.3

222.9
±172.0

221.7
±173.2

<0.0001

72.9 ±42.4

87.8 ±46.1

91.9 ±45.3

98.7 ±46.8

109.4 ±54.8

<0.0001

Legumes (g)

23.6 ±20.7

25.7 ±21.1

26.5 ±21.3

27.7 ±22.0

30.6 ±25.8

<0.0001

Fruits (g)

73.5 ±48.1

110.1
±65.7

145.0
±86.9

Fruit juice
(g)

20.7 ±24.3

60.7 ±54.9

99.1 ±78.2

Tea (g)

118.2
±160.9

144.4
±164.3

135.4
±160.7

196.0
±112.1
129.3
±115.0
135.9
±155.9

267.1
±153.5
222.6
±210.8
143.0
±160.3

<0.0001

<0.0001
<0.0001
<0.0001
<0.0001
<0.0001

<0.0001
<0.0001
<0.0001

87

Values presented in mean and standard deviation (±). 1p-value based on one-way ANOVA. PUFA,
polyunsaturated fatty acids; MUFA, monounsaturated fatty acids; CHO, carbohydrates; High fat dairy:
full cream milk, hard cheese, firm cheese, soft cheese, cream cheese, flavoured milk; Low fat dairy:
ricotta, cottage cheese, low fat cheese, reduced fat milk, skim milk, soy milk, Vegetables: beetroot,
broccoli, cabbage, capsicum, carrots, cauliflower, celery, garlic, lettuce, mushrooms, onion, pumpkin,
spinach, tomatoes, zucchini; Legumes: baked beans, bean sprouts, green beans, other beans, chickpeas;
Fruit: apples, pineapples, apricots, bananas, mango, watermelon, rockmelon, honeydew, oranges,
peaches, pears, strawberries.
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Table 2-S5. Relative risks for associations of total flavonoids and flavanols intake (including tea)
with incident hypertension in middle-aged women in the Australian Longitudinal Study on Women’s
Health, n=6,630

Intake
(mg),
mean±SD
N (%)
cases
Model 1
Model 2
Model 3
Model 4

Quintile 1
n =1289

Total Flavonoids
Quintile 2
Quintile 3
n =1304
n =1315

Quintile 4
n =1367

Quintile 5
n =1353

44.8 ±21.6

132.1 ±27.0

241.6 ±28.4

354.3 ±24.6

434.8 ±46.1

315 (24.4)

312 (24.2)

343 (26.1)

335 (24.5)

329 (24.3)

1.00
1.00
1.00
1.00

0.87 (0.76 – 1.00)
0.93 (0.81 – 1.06)
0.94 (0.87 – 1.14)
0.95 (0.83 – 1.09)

0.93 (0.81 – 1.06)
0.99 (0.86 – 1.12)
1.00 (0.89 – 1.16)
1.02 (0.90 – 1.17)

0.98 (0.86 – 1.12)
1.01 (0.88 – 1.15)
1.02 (0.89 – 1.16)
1.05 (0.92 – 1.19)

0.89 (0.78 – 1.02)
0.96 (0.84 – 1.10)
0.98 (0.85 – 1.13)
1.02 (0.89 – 1.18)

288.2 ±38.1

342.0 ±29.8

325 (23.8)

343 (25.4)

0.96 (0.84 – 1.10)
0.98 (0.86 – 1.12)
0.99 (0.86 – 1.13)
1.03 (0.90 – 1.17)

0.96 (0.84 – 1.09)
1.03 (0.90 – 1.18)
1.08 (0.94 – 1.23)
1.11 (0.97 – 1.27)

Flavanols
Intake
13.7 ±8.4
77.0 ±25.7
177.8 ±30.5
(mg),
mean±SD
N (%)
314 (24.3)
309 (23.7)
343 (26.1)
cases
0.90 (0.79 – 1.03)
0.97 (0.85 -1.10)
Model 1
1.00
0.95 (0.83 – 1.09) 1.02 (0.89 – 1.16)
Model 2
1.00
0.98 (0.85 – 1.12) 1.04 (0.91 – 1.19)
Model 3
1.00
0.99 (0.86 – 1.13)
1.06 (0.92 -1.20)
Model 4
1.00
Model 1: adjusted for total energy intake and age; Model 2:

model 1 + additionally adjusted for

hypertension risk factors (smoking status, diabetes, physical activity, alcohol intake, menopause status)
and demographics variables (education, income management); Model 3: model 2 + additionally
adjusted for dietary intake variables (fibre, cholesterol, vitamin C, sodium); Model 4: model 3 +
additionally adjusted for body mass index.
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Table 2-S6. Relative risks for associations of total flavonoids and flavanols intake (including tea)
with incident hypertension in reproductive-aged women in the Australian Longitudinal Study on
Women’s Health, n=5,340

Intake
(mg),
mean±SD
N (%)
cases
Model 1
Model 2
Model 3
Model 4

Quintile 1
n =1030

Total Flavonoids
Quintile 2
Quintile 3
n =1049
n =1090

Quintile 4
n =1088

Quintile 5
n =1083

34.6 ±13.5

77.8 ±13.3

131.6 ±15.7

212.0 ±32.9

370.3 ±72.7

68 (6.6)

80 (7.6)

58 (5.3)

50 (4.6)

59 (5.4)

1.00
1.00
1.00
1.00

1.12 (0.82 – 1.54)
1.19 (0.87 – 1.64)
1.18 (0.85 – 1.63)
1.26 (0.91 – 1.74)

0.80 (0.57 – 1.13)
0.85 (0.61 -1.21)
0.85 (0.60 -1.22)
0.94 (0.66 – 1.34)

0.69 (0.48 – 0.99)
0.75 (0.52 – 1.08)
0.75 (0.51 – 1.09)
0.89 (0.61 – 1.30)

0.80 (0.57 – 1.12)
0.85 (0.60 – 1.21)
0.86 (0.60 – 1.23)
1.04 (0.72 – 1.48)

146.4 ±38.4

300.1 ±67.0

52 (5.7)

62 (5.7)

0.63 (0.45 – 0.88)
0.66 (0.47 -0.94)
0.68 (0.48 – 0.97)
0.79 (0.56 – 1.12)

0.73 (0.53 – 1.01)
0.78 (0.56 – 1.08)
0.81 (0.58 – 1.13)
0.95 (0.68 – 1.33)

Flavanols
Intake
8.0 ±4.3
30.1 ±9.1
75.9 ±18.5
(mg),
mean±SD
N (%)
79 (7.7)
66 (6.3)
56 (5.1)
cases
0.80 (0.58 – 1.10) 0.69 (0.49 – 0.96)
Model 1
1.00
0.84 (0.61 – 1.16) 0.73 (0.52 – 1.02)
Model 2
1.00
0.85 (0.62 – 1.18) 0.75 (0.53 – 1.05)
Model 3
1.00
0.88 (0.64 – 1.22) 0.82 (0.58 – 1.15)
Model 4
1.00
Model 1: adjusted for total energy intake and age; Model 2:

model 1 + additionally adjusted for

hypertension risk factors (smoking status, diabetes, physical activity, alcohol intake) and demographics
variables (education, income management); Model 3: model 2 + additionally adjusted for dietary intake
variables (fibre, cholesterol, vitamin C, sodium); Model 4: model 3 + additionally adjusted for body
mass index.
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Table 2-S7. Relative risks for associations of total flavonoids and subclasses intake with incident
hypertension in reproductive-aged women that gave birth to children in the Australian Longitudinal
Study on Women’s Health, n=3,345

Intake
(mg),
mean±SD
N (%)
cases
Model 1
Model 2

Quintile 1
n =655

Total Flavonoids
Quintile 2
Quintile 3
n =664
n =671

Quintile 4
n =678

Quintile 5
n =677

28.5 ±21.9

45.5 ±24.4

62.1 ±25.1

84.1 ±29.6

132.4 ±51.1

31

41

35

19

26

1.00
1.00

1.40 (0.87 – 2.24)
1.43 (0.89 – 2.28)

1.20 (0.72 – 2.00)
1.23 (0.74 – 2.04)

0.65 (0.35 – 1.22)
0.66 (0.35 -1.24)

0.97 (0.49 – 1.91)
0.99 (0.50 – 1.94)

Flavanols
Intake
(mg),
mean±SD
N (%)
cases
Model 1
Model 2

6.4 ±8.0

11.1 ±11.1

16.4 ±11.3

24.2 ±13.0

50.8 ±29.3

30

38

35

25

24

1.00
1.00

1.24 (0.77 -1.99)
1.25 (0.78 – 2.01)

1.19 (0.73 – 1.97)
1.23 (0.75 – 2.04)

0.91 (0.52 – 1.60)
0.94 (0.54 – 1.64)

0.87 (0.49 – 1.57)
0.90 (0.50 – 1.61)

Flavonols
Intake
(mg),
mean±SD
N (%)
cases
Model 1
Model 2

3.7 ±2.3

5.4 ±2.6

7.2 ±3.4

8.4 ±4.4

12.6 ±7.1

33

45

22

25

20

1.00
1.00

1.40 (0.89 – 2.18)
1.42 (0.91 – 2.21)

0.81 (0.47 -1.40)
0.84 (0.49 – 1.46)

0.89 (0.52 – 1.52)
0.90 (0.52 – 1.54)

0.75 (0.41 – 1.35)
0.76 (0.42 – 1.37)

Anthocyanins
Intake
(mg),
mean±SD
N (%)
cases
Model 1
Model 2

1.5 ±2.3

2.7 ±2.4

3.9 ±2.6

5.8 ±2.8

10.8 ±6.3

37

35

31

31

18

1.00
1.00

0.87 (0.55 – 1.37)
0.87 (0.55 – 1.37)

0.77 (0.78 – 1.23)
0.78 (0.49 – 1.25)

0.82 (0.51 – 1.34)
0.84 (0.52 – 1.38)

0.50 (0.28 – 0.90)
0.52 (0.29 – 0.92)

Flavones
Intake
(mg),
mean±SD
N (%)
cases
Model 1
Model 2

1.2 ±1.8

1.9 ±2.0

2.8 ±1.9

4.2 ±2.1

7.6 ±4.4

32

30

38

25

27

1.00
1.00

1.03 (0.63 – 1.69)
1.03 (0.63 – 1.69)

1.27 (0.78 – 2.07)
1.29 (0.79 – 2.09)

0.82 (0.46 – 1.46)
0.85 (0.48 – 1.50)

0.91 (0.45 – 1.87)
0.93 (0.45 – 1.89)

Isoflavones
Intake
(mg),
mean±SD
N (%)
cases
Model 1
Model 2

0.27 ±2.8

0.20 ±2.3

0.29 ±2.6

0.61 ±3.3

9.9 ±14.5

39

29

39

24

21

1.00
1.00

0.73 (0.46 – 1.17)
0.73 (0.45 – 1.17)

1.12 (0.72 – 1.74)
1.12 (0.73 – 1.74)

0.75 (0.44 – 1.25)
0.75 (0.45 – 1.25)

0.87 (0.50 – 1.51)
0.88 (0.50 – 1.52)
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Flavanones
Intake
(mg),
mean±SD
N (%)
cases
Model 1
Model 2

9.2 ±13.7

16.0 ±13.1

24.0 ±14.0

33.9 ±15.6

61.1 ±30.8

32

34

28

32

26

1.00
1.00

1.25 (0.77 – 2.02)
1.27 (0.79 – 2.06)

0.98 (0.58 – 1.66)
1.01 (0.60 – 1.70)

1.17 (0.67 – 2.04)
1.19 (0.68 – 2.08)

1.08 (0.51 – 2.31)
1.10 (0.52 – 2.36)

Total flavonoids (including tea)
Intake
(mg),
mean±SD
N (%)
cases
Model 1
Model 2

41.2 ±25.0

80.2 ±28.0

130.4 ±31.5

209.4 ±46.4

367.2 ±79.0

36

36

26

23

24

1.00
1.00

1.10 (0.69 – 1.76)
1.10 (0.69 – 1.75)

0.84 (0.50 – 1.40)
0.85 (0.51 – 1.42)

0.82 (0.47 – 1.41)
0.84 (0.48 – 1.44)

0.79 (0.46 – 1.36)
0.79 (0.46 – 1.35)

Flavanols (including tea)
Intake
10.3 ±9.8
30.5 ±13.4
76.2 ±23.8
146.7 ±42.1
297.2 ±68.4
(mg),
mean±SD
N (%)
37
34
21
24
29
cases
1.24 (0.77 – 1.99) 1.19 (0.73 – 1.97) 0.91 (0.52 – 1.60)
0.87 (0.49 – 1.57)
1.00
Model 1
1.25
(0.78
–
2.01)
1.23
(0.75
–
2.04)
0.94
(054
–
1.64)
0.90 (0.50 – 1.61)
1.00
Model 2
Model 1: adjusted for total energy intake, age, hypertension risk factors (smoking status, diabetes,
physical activity, alcohol intake, demographics variables (education, income management), dietary
intake variables (fibre, cholesterol, vitamin C, sodium) and body mass index; Model 2: Model 1 +
additionally adjusted for gestational diabetes and gestational hypertension.
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Figure 2-S1. Flavonoids subclasses intake among total flavonoids in reproductive-aged (n=6,099)
and middle-aged (n=6,630) women in the Australian Longitudinal Study on Women’s Health.
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A, middle-aged cohort; B, reproductive-aged cohort; C, middle-aged cohort including tea flavonoids;
D, reproductive-aged cohort including tea flavonoids.
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Figure 2-S2. Food source of flavonoids subclasses intake in middle-aged women in the Australian
Longitudinal Study on Women’s Health, n=6,630
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Figure 2-S3. Food source of flavonoids subclasses intake in reproductive-aged women in the
Australian Longitudinal Study on Women’s Health, n=6,099

Flavones
5%
3%

Isoflavones
3%

6%

11%

8%

78%
86%
Orange juice

Watermelon*

Pumpkin

Others

Celery
Tofu

Soy Milk

Others

Flavanols

Flavanones
1%

2%

6% 3%

17%
34%

32%

50%
7%
48%

Orange

Orange juice

Apple

Others

Strawberries

Apple

Chocolate

Red wine

Banana

Others

96

Flavonols

Anthocyanins
1%

18%

19%

26%
3%

10%
56%

3%

15%

14%
29%

6%

Strawbery

Tinned or frozen fruits

Onion

Brocolli

Spinach

Apple

Red wine

Strawberries

Red wine

Apple

Fruit jam

Others

97

CHAPTER 3: The postprandial effect of anthocyanins on
cardiovascular disease risk factors: a systematic literature review
of high-fat meal challenge studies

The effect of anthocyanins in the postprandial state have been evaluated by several
clinical trials using a HFHE meal challenge. This method allows to assess if these bioactive
compounds are capable of attenuating the deleterious effects following a HFHE meal; however,
such findings were not yet collated and synthetized with the scope of the impact of
anthocyanins on CVD risk factors. Therefore, systematic research literature was conducted in
this purpose. A total of 13 eligible studies were included and beneficial effects of anthocyanins
were reported with most promising results indicating the attenuation of deleterious postprandial
effects on oxidative stress and antioxidant status, triacylglycerol and total cholesterol
concentrations, vascular endothelial function and inflammatory biomarkers. Post-prandial
changes in blood pressure and lipoproteins were least affected by anthocyanins.
The majority of this chapter forms the substantive content of a published article
(Appendix A)

3.1 Introduction

Cardiovascular diseases (CVD) are still the number one cause of death globally,
representing 31% of deaths in 2016. Most CVDs can be prevented by addressing and managing
behavioural risk factors such as diet (224). Several CVD risk factors are associated to the
atherosclerotic process and other vascular dysfunctions closely linked to nutrition (225).
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There is an emerging evidence that metabolic imbalances at the postprandial state,
particularly after a high-energy meal rich in fat, are important contributing factors to
development of CVD (105,106). Overall, the underlying mechanism involves a sharp increase
in triacylglycerol along with an aberrant production of pro-oxidant molecules leading to an
oxidative stress state, which may impair vascular and endothelial functions, as well as mediate
the onset of an inflammatory response, which further contributes to the generation of more free
radicals, thus creating a deleterious vicious cycle (105–107). Dietary fats comprise
heterogeneous molecules with diverse structures, which affect diverse cell processes such as
transcription regulation, cellular and organelle membrane structure and function, ion channel
activity and electrophysiology. Responses vary depending on both the fatty acid composition
of the food source, as well interactions with accompanying nutrients, the food matrix, and how
it has been processed(108). Modification of the type of dietary fat in a food or overall meal has
been shown to result in postprandial effects on appetite (109), lipaemia and markers for
inflammation and endothelial activity (110).
The high-fat meal (HFM) challenge is one way to investigate these imbalances
promoted in a daily basis in Western diets (105). Thus, this type of studies allows dietetic
therapeutic opportunities to attenuate the harmful effects of aberrant production of pro-oxidant
molecules. Nutrition plays a major role in enhancing endogenous antioxidant defences and
regulating the inflammatory state (9) and dietary components consumed alongside a high fat
meal may be beneficial in blunting a harmful postprandial response (226).
Anthocyanins, a subclass of flavonoids, are emerging as a potential therapeutic option
for CVD risk factors(21). Anthocyanins are the largest class of water-soluble plant pigments,
that are responsible for the blue, purple and red colour of many fruits and vegetables, such as
blueberries, blackberries, red grapes, plums and eggplants (22). The positive results of
anthocyanins on CVD risk factors are related to its antioxidant and immunomodulatory effects,
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thereby attenuating the cooperative and synergistic deleterious effects of oxidative stress and
inflammation in this condition (21,23). In humans, anthocyanins intake has been associated
with a lower risk of cardiovascular events (24,25), as well as studies using anthocyanins as a
diet intervention have shown improvements in vascular function (26) and in biomarkers related
to oxidative stress (27–30), antioxidant status (28,30–32), lipid profile (33–35) and
inflammatory response (36,37) in both long-term and acute designs.
To date, there has been no review of the effect of such compounds in studies using a
HFM challenge. In order to address this question, a systematic literature review was undertaken
using the procedures outlined in the PRISMA statement (227) aiming to evaluate if
concomitant consumption of anthocyanins with a HFM attenuates the deleterious postprandial
response of parameters known to be CVD risk factors, including blood pressure, vascular
endothelial function, lipid profile and biomarkers related to oxidative stress, antioxidant status
and immune response.

3.2 Methods

Search strategy
A systematic literature review was undertaken using the procedures outlined in the
PRISMA statement (227). Five electronic databases were searched up to the period of 1st
February 2020; Medline, Scopus, CINAHL, Web of Science and PubMed. Two researchers
were responsible for studies selection, data extraction, quality assessment and synthesis. The
search strategy was carried out in accordance with the database orientations using Boolean
operators (OR and AND), parenthesis, quotation marks and asterisk. Quotation marks were
used to search for exact terms or expressions; parenthesis were used to indicate a group of
search terms or combine two groups of search terms enabling all possible combinations of

100

sentences; asterisks were used to search all words derived of the precedent inflected part. The
groups of search terms used were: "endothelium function" or "endothelium dysfunction" or
"laser speckle" or "laser doppler" or "flow-mediated dilatation" or FMD or LSCI or "arterial
stiffness" or "pulse wave velocity" or PWV or "lipid profile" or LDL or VLDL or ox-LDL or
"oxidative stress" or "lipid peroxidation" or "blood pressure" or cytokines or inflammation or
immune or inflammatory or chemokine or adhesion or malondialdehyde or isoprostanes or
nitrite or nitrate or ENO* "nitric oxide") AND ("postprandial" or "postprandial" or "post
prandial" or "meal challenge" or "challenge meal" or "test meal") AND anthocyanins. The
study selection, quality assessment, data extraction and synthesis were conducted by two
researchers independently and then reviewed by all authors. The review was registered with
PROSPERO (CRD42019126265).

Selection criteria
Selection criteria were formed using the Population Intervention Comparison Outcome
Study design (PICOS) format (227). The criteria used to screen the titles and abstracts of
literature returned through database searching (Table 3-1).

Table 3-1. PICOS (participants, interventions, comparisons, outcomes, and study
design) criteria to define the research question
Parameter
Participants
Interventions
Comparators

Inclusion criteria
Young adults (18-59 years of age)
Dietary intervention with anthocyanins in whole food or purified
extract
A comparison group receiving a control intervention
CVD risk factors including blood pressure, lipid profile, vascular and

Outcomes

endothelial function, biomarkers related to inflammation, oxidative
stress and antioxidant status
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Study design

Randomised or cross-over clinical trials with high fat meal challenge
for all groups.

Only articles published in English were included. Exclusion criteria: mean age of
participants <18 or >59 years; no nutritional information of the HFM, placebo or dietary
intervention; other conditions besides the HFM challenge. Reference lists of included articles
were screened for further studies that may have been missed in initial database search.

Data extraction
Two independent reviewers extracted data and cross checked results to ensure
consistency. The following data were extracted from each study and reported in a summary
table; year of publication, author(s), participant demographics, sample size, anthocyanin source
and dose, control used, test meal and study outcomes (Table 3-2). Authors were contacted if
further information was required.

Risk of bias assessment
Studies included in this review were assessed for potential bias using the revised
Cochrane risk-of-bias tool for randomised trials (228). Two researchers independently
reviewed each study, performing evaluation across five risk-of-bias domains, with each domain
rated either low risk, high risk or some concern of bias. The prescribed algorithm was used to
determine domain ratings and overall risk-of-bias judgement for each study (228).

3.3 Results

Study selection
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A total of 9135 articles returned through database searching. 1464 duplicates were
removed and 7671 articles were excluded during title and abstract screening (Figure 3-1). The
full-text of the remaining 29 articles were accessed and evaluated according the study selection
criteria. Sixteen articles were excluded as they did not meet all criteria and the remaining 13
studies were eligible for the review.

Figure 3-1: Flow diagram of the search and selection strategy.

Characteristics of studies included in review
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The characteristics of the 13 studies reviewed are summarised in Table 3-2. All studies
included had a cross-over design with a wash-out period ranging from 4 to 28 days, of which
four were double-blinded (229–232), seven were single-blinded (37,233–238) and two did not
present blind strategies (239,240). The mean age of subjects involved in included studies
ranged from 20.2 to 50.9 years and five studies were conducted only in male subjects
(229,232,233,237,240), while all other recruited men and women. The majority of studies were
conducted on healthy individuals, except for one study on subjects with an atherosclerosisprone phenotype (233), one on subjects with obesity and insulin resistance phenotype (235)
and another one with participants with at least one CVD risk factor (239). In relation to the
dose of anthocyanins used in the intervention, six studies used a dose <100mg
(37,230,231,233,236,239) and four studies used doses >100mg (229,232,237,238), while two
studies used three different doses (235,240) and one study used two different doses (234) within
both ranges. Overall, the dose ranged from 11.2 to 1530mg of anthocyanins. The fat content
within meal challenges were <40g in four studies (37,230,234,235) and >40g in nine studies
(229,231–233,236–240). Concerning fat content as % of energy, the meal challenges in six
studies provided >50% of energy from fats(229,230,232,233,239,240), while seven studies
provided <50% energy from fats(37,231,234–238). The main type of fats within the challenge
meals were derived from animal products with high content of saturated fats such as cream,
sausages, cheese, fried potatoes, bacon, eggs and butter. There were no relevant source of
omega-3 fatty acids included in any of the challenge meals. All studies used a macronutrient
matched placebo in the control arm. In eleven studies(126,129,186,229–234,241), either a
beverage, yoghurt or smoothie was used, while two studies(238,240) provided meals without
incorporating the freeze-dried source of anthocyanins. One study used water as an additional
control treatment(239), while another also matched the content of vitamin C in the
placebo(232)
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Table 3-2. High-fat meal challenge studies analysing cardiovascular risk factors
Reference
Alqurashi et
al. 2015,
UK(229)

Cerletti et al.
2014,
Italy(239)

Edirisinghe et
al. 2010,
USA(37)

Miglio et al.
2012,
Italy(230)

Population sample
size
Healthy male adults
(n=23), mean age 46yr
± 1.9, BMI 27.6kg/m2
± 0.4

Diet intervention(s)

Control arm(s)

Test meal

Outcomes

Açai smoothie: 150g
frozen açai pulp, 50g
banana, 155.1Kcal,
8.5g fat, 2.4g PTN,
17.2g CHO, 7.2g
fibre, 493mg
anthocyanins

Colour and
macronutrient
matched smoothie

Meal+beverage:
869.7 Kcal
(60.6% from fat),
58.5g fat, 74.4g
CHO, 11.4g PTN

Blood pressure: ↔
FMD: ↑ 1.4%, p=0.001 at 2h and ↑ 0.8%,
p<0.001 at 4h.
Plasma total oxidant capacity (peroxide
concentrations): ↓ area under the curve over
7h, p=0.02

Adults (n=18: 9
females, 9 males),
36.9 ± 10.5yr, BMI
26.8 ±4.0. At least one
CVD risk factor
(overweight,
hypertension,
smoking, high serum
cholesterol or TG
levels
Healthy adults (n=24,
14 females, 10males)
BMI 29.2 ±2.3,
50.9yrs ± 15

Red orange juice:
53.1mg anthocyanins

a) Blonde orange
juice; b) water

890 Kcal (52.6%
from fat), 52g fat,
25g PTN, 81g
CHO

Augmentation index (vascular stiffness): ↓
2.18 ± 19.26 to -6.11 ± 11.90, p=0.0030
Reactive hyperaemia index (vascular
reactivity): ↔
Blood pressure: ↔ (diastolic blood pressure
within group:↓ p=0.0045)
TAG: ↔ (↓ within the intervention group,
p=0.0131)

Milk based beverage +
strawberry powder,
39.04mg
anthocyanins

Macronutrient
matched placebo
beverage

962.3 Kcal
(28.1% from fat),
30g fat, 36g PTN,
135g CHO

hsCRP: ↓ 3.1 (SEM 0.1) vs 2.7 (SEM 0.5)
mg/L, P=0.02 at 6h
IL-6: ↓ 3.4 (SEM 0.5) vs 4.5 (SEM 0.5)
pg/ml, P<0.05 at 6h.
TNF-α: ↔
IL-1β: ↔

Healhy adults (n=14),
45yr ± 9, BMI
26.8kg/m2 ± 2.2

a) Fruit juice (86%
mix apple, grape,
blueberry,
pomegranate juices),
6.5mg anthocyanins
b) Fruit juice (63%

Energy and sugar
matched placebo,
66g CHO

1344 Kcal (54.2%
from fat), 81g fat,
104g CHO, 52g
PTN, 3.1g fibre

Urinary FRAP: ↑ 35%, p<0.01
Plasma TRAP: ↑ p<0.05 at 1h, ↑ 8%,
p<0.001 at 2h, ↑ p<0.01 at 4h.
Plasma FRAP: ↔
Plasma uric acid: ↓ p<0.05 at 8h

105

Plasma Thiols: ↓ p<0.05 at 0.5, 1, 4 and 8h,
↓ p<0.01
Ascorbic acid: ↔

mix of pineapple,
blackcurrant and plum
juices), 16mg
anthocyanins
Ono-Moore et
al. 2016,
USA(234)

Healthy adults (n=23,
18 females, 5 males),
30yr ± 3yr, BMI
21.9kg/m2 ± 0.4

Yoghurt + freeze dried
blueberry powder: a)
87.9mg
anthocyanins; b)
154.5mg
anthocyanins

Macronutrient
matched control
yoghurt: 191
Kcal, 0.6g fat,
45.1g CHO, 1.2g
PTN, 10g fibre

653 Kcal (40.0%
from fat), 29g fat,
73.6g CHO, 24g
PTN

TAG: ↔
LDL-c: ↔
HDL-c: ↔
IL-8: ↔
IL-1β: ↔
TNF-α: ↔

Park et al.
2016,
USA(235)

Adults with obesity
and insulin resistance
phenotype (n=21, 16
females, 5 males),
39.8yr ± 13.8, BMI
40.2 ± 7.2
Healthy adults (n=30,
13 females, 17 males),
BMI 31 kg/m2 ± 0.5,
28yr ± 2.0

Freeze dried whole
strawberry powder: a)
42.2mg
anthocyanins; b)
87.9mg; c) 154.5mg

Milk based colour
and macronutrient
matched beverage

967 Kcal (23.6%
from fat), 25.4g
fat, 146.2g CHO,
36.9g PTN, 12.3g
fibre

TAG: ↔
ORAC: ↔
IL-6: ↔
OxLDL-c: ↓ –3.0 ± 0.8 U/L, p<0.05

Freeze dried
strawberry powder:
163.41mg
anthocyanins (added
to meal)

Strawberry
flavoured powder
(added to meal)

1004Kcal (44.8%
from fat), 50g fat,
105g CHO, 32g
PTN, 7g fibre

Blood pressure: ↔
TAG: ↔
OxLDL-c: ↔
MDA: ↔
Augmentation index: ↔
Aortic stiffness (PWV): ↔

Healthy adult males
(n=9), 20.2yr (18.727.3), BMI 24.6 kg/m2
(20.7-29.4)

Berry concentrate: a)
added on beverage,
90mg anthocyanins;
b) added on burger
and on beverage,
174.3mg
anthocyanins

Plain burger and
water

527 Kcal (58.9%
from fat), 48.7g
PTN, 34.33g fat,
4.6g CHO

TAG: ↔
MDA: ↓ p<0.05 at all time points for
intervention “b” and ↓ p<0.05 at 5 and 6h for
intervention “a”
PTNcarbonyls: ↓ p<0.05 at 2, 3, 4, 5 and 6h
for intervention “b” and ↓ p<0.05 at 4 and 6h
for intervention “a”
Plasma FRAP: ↔
Ascorbic acid: ↔

Richter et al.
2017,
USA(238)

Urquiaga et
al. 2016,
Chile(240)
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TAG: ↔
OxLDL-c: ↔
IL-6: ↓ p=0.048 (intervention consumed
before the meal) over 10h; ↔ (intervention
consumed within and after the meal, trend
p<0.1) over 10h
ORAC: ↑ p<0.05
Total antioxidant status: ↑ 4.5%, p=0.05.
TAG: ↔
TC: ↔
LDL-c: ↔
HDL-c: ↔

Huang 2016,
USA(236)

Healthy adults (n= 14,
9 males and 5
females), 25yrs ± 4,
BMI 26kg/m2 ± 2

Freeze dried
strawberry added to a
beverage, 49.02mg
anthocyanins

Macronutrients
matched
beverage: 41Kcal,
0.8g PTN, 0.1g
fat, 9.1g CHO

841 Kcal (43.9%
from fat), 41g fat,
96g CHO

Kay & Holub
2002,
Canada(237)

Healhy males(n=8),
mean age 46.9 ±1.9),
BMI 23.8kg/m2 ± 0.8

Freeze dried wildblueberry supplement:
1160mg
anthocyanins

Control
supplement
matched in CHO
and energy

853 Kcal (49.3%
from fat), 46.7 g
fat, 75.2g CHO,
32.4g PTN, 4.5g
fibre

Peluso et al.
2011,
Italy(231)

Healthy adults, (n=14,
12 males and 2
females), 45.1yrs ±
8.6, BMI 26.8 kg/m2 ±
2.2

Blackcurrant, plum
and pineapple
beverage: 16mg
anthocyanins

Placebo beverage
devoid of
antioxidant
activity

Meal+beverage:
1344 Kcal (30.0%
from fat), 184g
CHO, 44.8g fat,
49g PTN

TAG: ↔
TC: ↔ [prevented a significant increase
(p<0.001) observed only at the control group
over 8h]
IL-17: ↓ p<0.05 at 4 and p<0.01 at 8h
IL-6: ↓ 0.5h (p<0.01), 1h (P<0.05) and 2h
(p<0.001)
TNF-a: ↓ at multiple time points (p<0.01 at
1h, p<0.05 at 2 and 6h, p<0.001 at 4 and 8h)

Blackcurrant based
beverage (15%
blackcurrant puree,
9% raspberry puree,
7% cherry puree, 39%
red grape juice +
banana puree):
11.2mg anthocyanins
(7.5mg delphinidin-3glucoside, 7.5mg
cyanidin-3-glucoside,

Macronutrient
matched
beverage:
1029Kcal, 63.8g
fat, 6.0g PTN,
107.6g CHO,
1.8g fibre

Blackcurrant
based beverage
(added cream and
sugar): 1029 Kcal
(55.8% from fat),
63.8g fat, 6.0g
PTN, 107.6g
CHO, 1.8g fibre

TAG: ↔ (↓ trend, p=0.059)
LDL-c: ↔
HDL-c: ↔
TC: ↔
OxLDL-c: ↔
IL-1β: ↔
TNF-α: ↔
ORAC: ↑ p<0.040 at 90min and p<0.02 at
120 min
Ascorbic acid: ↑ 14 mmol/l, p<0.004

Huebbe et al.
Adult with
2011,
atherosclerosis prone
Germany(233) phenotype (n=11),
37.4 yrs ±1.9, BMI
32.1 ±1.2
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0.8mg malvidin-3glucoside)

Polley et al.
2019,
USA(232)

Healthy adults (22 yrs
± 3.0), BMI 25.5 ±3.4

Montmorency tart
cherry concentrate:
1513.8mg
anthocyanins

Macronutrient
matched beverage
+11mg of vitamin
C: 166.5Kcal,
CHO 39.4g; PTN
2.24g

Biscuit, sausage
patty and butter:
920 Kcal (58.7%
from fat), 60.0g
fat, 22.2g PTN,
72g CHO,

ORAC: ↔
FRAP: ↔
TG: ↔

Abbreviations and symbols: CHO, carbohydrate; PTN, protein; FMD, flow-mediated dilatation; Kcal, kilocalories; TAG, triacylglycerol; TC, total cholesterol;
HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; OxLDL-c, oxidized low-density lipoprotein cholesterol; hsCRP, high
sensitivity C-reactive protein; FRAP, ferric reducing ability of plasma; TRAP, total radical-trapping antioxidant parameter; ORAC: oxygen radical absorbance
capacity; ↔, no significant changes; ↑, significant increase; ↓, significant decrease
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Risk of bias
The overall risk of bias was judged as “low risk” for ten studies (37,229,230,232,234–
236,238–240), while three studies (231,233,237) were judged as having “some concern” due
to ranking as such in one or more risk domains (Table 3-3). Among the studies that were
identified as having “some concern” regarding risk of bias, two studies (233,237) had missing
information on domain 1 (risk of bias arising from the randomization process) and one study
(231) had missing information on domain 3 (risk of bias due to missing outcome data) (228).
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Polley et al., 2019

Huebbe et al., 2016

Peluso et al. 2011

Kay & Holub, 2002

Huang et al., 2016

Urquiaga et al, 2017

Richter et al., 2017

Park et al., 2016

Ono-Moore et al., 2016

Miglio et al., 2014

Edirisinghe et al., 2011

Cerletti et al., 2016

Alqurashi et al, 2016

Table 3-3. Overall risk of bias of included studies

Domain 1: Risk of bias arising
from the randomisation process
Domain 2: Risk of bias due to
deviations from the intended
interventions (effect of assignment
to intervention)
Domain 3: Risk of bias due to
missing outcome data
Domain 4: Risk of bias in
measurement of the outcome
Domain 5: Risk of bias in selection
of the reported result
Overall risk of bias
Symbols:

low risk;

some concern
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Outcomes
The outcomes analysed in the included studies were blood pressure, lipid profile,
vascular and endothelial function, as well as biomarkers related to inflammation, oxidative
stress and antioxidant status (Table 3-2). The postprandial response of such outcomes were
analysed after the intake of the high-fat meal challenge, which means that a significant decrease
may actually mean an attenuation of an increase pattern. Three studies measured blood pressure
(229,238,239) before and after the HFMC, none of which found significant changes in systolic
blood pressure. One study found a reduction in diastolic blood pressure in the anthocyanins
intervention group (p=0.0045), while an absence of effect was observed in the other two arms
administering water or a matched anthocyanins-free placebo (239). Vascular and endothelial
function were evaluated by three studies (229,238,239). Alqurashi et al. (229) assessed
endothelial function in the brachial artery by flow-mediated dilatation (FMD) with a
postprandial increase of 1.4% versus 0.4% at 2h (p=0.001) and an increase of 0.8% versus a
decrease of -0.3% at 6h (p<0.001), comparing the intervention with the placebo group,
respectively. Cerletti et al. (239) assessed vascular stiffness through the augmentation index
(AI) and vascular reactivity through the reactive hyperaemia index (RHI). The latter did not
present significant changes, but there was a significant decrease (2.18 ± 19.26 to -6.11 ± 11.90,
p=0.0030) in the AI 3h after the meal only in the anthocyanins intervention arm (239). Richter
et al. (238) investigated AI and augmentation pressure through pulse wave analysis and the
aortic stiffness assessed by carotid-femoral pulse wave velocity (PWV). None of the
parameters were significantly different between intervention and control arms (238).
Regarding the lipid profile, ten studies evaluated triacylglycerol (TAG) (231–240), of which
one study found a higher decrease (p=0.0131) in the intervention group (239) and other study
found a trend(p=0.059) of a decrease 60 minutes after ingestion of the HFMC (233). Total
cholesterol (TC) was evaluated by five studies (231,233,234,237,239) and two studies found
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significant changes. Cerltetti et al. (239) found a reduction (p=0.0339) only in the anthocyanin
intervention arm (239), while Peluso et al. (231) found that the anthocyanins prevented an
increase in the intervention group, therefore a significant increase was only observed in the
control group over 8h (p<0.001) (231). The studies that measured HDL-c (233,234,237) and
LDL-c (233,234,237) did not find any significant changes.
Among inflammatory markers, six studies evaluated IL-6 (37,231,233–236)
concentrations, of which three (37,231,236) reported significant changes. In one study (37) the
anthocyanin intervention was able to attenuate an increase in IL-6 response six hours after the
HFMC compared to the placebo group [3.4 (SEM 0.5) versus 4.5 (SEM 0.5) pg/ml, P<0.05].
Similarly, Peluso et al. (231) found a significant attenuation in postprandial IL-6 concentration
at 0.5 (p<0.01), 1 (P<0.05) and 2h (p<0.001) time points (231). Another study (236) found a
trend to attenuate such response in two groups (consuming the anthocyanins intervention
within or after the HFMC) and a significant decrease in the group consuming the anthocyanins
intervention before the meal (p=0.048). The cytokine TNF-α was evaluated by four studies
(37,231,233,234) and with one study (231) finding a significant result preventing a postprandial
rise of TNF-α concentrations at multiple time points (p<0.01 at 1h, p<0.05 at 2 and 6h, p<0.001
at 4 and 8h).
There were no significant changes in IL-1β concentrations between treatments cross
the three studies evaluated this cytokine (37,233,234). Only one study (37) evaluated hsCRP
concentrations before and after the HFMC presenting a significant lower concentration
compared to placebo [3.1 (SEM 0.1) versus 2.7 (SEM 0.5) mg/L, P=0.02]. Still, there was one
study that measured IL-8 concentration finding not significant results (234) and one study that
evaluate Il-17 which found a significant postprandial reduction at 4(p<0.05) and 8h(p<0.001)
time points (231).
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A large variety of oxidative stress and antioxidant status biomarkers were measured by
nine studies (229,230,232,233,235–238,240) included in this review. Four studies
(233,235,236,238) evaluated OxLDL-c concentrations; however, only one study (235) found a
significant reduction (–3.0 ± 0.8 U/L, p<0.05) in the intervention arm compared to placebo.
Plasma malondialdehyde (MDA) concentration was measured in two studies (238,240) in
which one found that the anthocyanins interventions arms were able to prevent postprandial
MDA accumulation (p<0.05 at multiple time points), and the mean value of the area under the
curve of was reduced compared to placebo (240). This same study also found a reduction
(p<0.05 at multiple time points for both anthocyanins interventions) in plasma protein
carbonyls and an increase in the DPPH (2,2-diphenyl-1-picrylhydrazyl) plasma antioxidant
capacity (240). The ferric reducing ability of plasma (FRAP) assay was used to examine
antioxidant capacity in was evaluated by three studies (230,232,240), but no significant effects
of anthocyanin intervention were detected. However, Miglio et al. (230) found a 35% increase
in the urinary excretion of antioxidants as indicated by raised urinary FRAP (P<0.01). This
same study found an increase (p<0.05 at 1h, p<0.001 at 2h and p<0.01 at 4h) in plasma total
radical-trapping antioxidant parameter (TRAP), as well as a significant attenuation in the
increase of endogenous antioxidants thiols and uric acid (UA) (p<0.05 at 8h). Plasma ascorbic
acid (vitamin C) was measured in four studies (230,233,237,240), of which one study (233)
found an increase in the anthocyanin intervention arm (+14 mmol/l, p<0.004) compared to the
placebo. The oxygen radical absorbance capacity (ORAC) of plasma/serum was evaluated,
before and after the HFMC, in five studies (232,233,235,237,240), of which two found
significant changes. In one study (233), the intervention was able to prevent the postprandial
decrease in the ORAC of plasma at 90 and 120 min following the HFM challenge (p<0.040
and p<0.02, respectively), while another study (237) found a significant increase in serum
ORAC 1h after the HFMC in intervention group when compared to the control (p<0.05).
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Furthermore, this same study found a significant increase in the total antioxidant status (TAS)
assay (+4.5%, p=0.05). Lastly, one study (229) measured the total oxidant capacity in plasma
by assessing the total peroxide concentrations, and found a significantly lower incremental area
under the curve in the intervention group(p = 0.02).

3.4 Discussion
The results of studies included in this systematic literature review indicate that the
postprandial state, after exposure to a high fat meal, may provide a useful context to investigate
acute metabolic changes, from well-known lipid responses to complex phenolic compound
signalling pathways that contribute to the development of CVD. A wide range of risk factors
such as blood pressure, lipid profile, vascular and endothelial function, as well as biomarkers
related to inflammation, oxidative stress and antioxidant status were included as outcomes in
the acute studies in the review.
Despite the lack of positive results in blood pressure, of which only study found a
significant decrease in diastolic blood pressure (239), vascular and endothelial parameters
showed more positive results. It is more likely that such parameters will respond in a higher
magnitude than blood pressure in acute studies, due to the excess postprandial production of
pro-oxidant molecules following the HFMC. This may in turn inactivate endothelial dependent
factors, in particular nitric oxide, leading to impaired vasodilation and the onset of an
inflammatory response, which further leads to the generation of more free radicals (226,242).
In this matter, açai consumption was associated with improvements in endothelial vascular
function, measured by FMD, in healthy overweight man, which was also followed by an
increase in total oxidant capacity in plasma, assessed as a measure of total peroxide
concentrations (229). The significant improvement in FMD found in this study(229) was 1%
higher than in controls, a magnitude of effect that has been shown in a meta-analysis to be
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associated with an overall 8 % reduction in CVD risk (RR= 0.92; 95%CI: 0.88; 0.95) for each
percentage increase (92) . Flow-mediated dilatation is a non-invasive measurement of
endothelium function that has been associated with CVD risk prediction(92,243). Another
study found a decrease in arterial stiffness, measured by AI, after consumption of blood orange
juice anthocyanins in individual with at least one CVD risk factor (overweight, hypertension,
smoking, high serum cholesterol or triacylglycerol levels) (239).
A recent systematic review evaluated the postprandial inflammatory response to HFM
challenge, in which IL-6 was stated as the inflammatory marker with the stronger response to
this stress (244). IL-6 has a pleiotropic nature showing both anti and pro-inflammatory roles
and regulating a plethora of immune and metabolic responses, however a high concentration
of this cytokine has been associated with CVD and mortality (77,245). Still, IL-6 has a high
expression on vascular endothelium and the pharmacological inhibition of IL-6 improves
endothelial function (78). The inhibitory effect on postprandial IL-6 concentrations found
within the studies added in this review demonstrates a potential therapeutic effect of
anthocyanins for CVD (37,231,236). One possible mechanism that anthocyanins may exert this
effect is through decreasing the activity of the NF-κB pathway, which is a transcription factor
responsible for triggering and regulating inflammatory processes, leading to the expression of
pro-inflammatory cytokines and enzymes (21,121). Concerning the clinical significance of the
magnitude of effects reported in the studies that observed benefits associated with anthocyanin
intake, the significant changes of between 0.34 and 0.90 pg/mL represent changes from
baseline of >2 SD(37,236) and >3 SD(231). These results are clinically meaningful considering
the predictive roles of IL-6 concentration in CVD risk. Hazard ratios of 1.80 are reported
according to each 1-SD increase in IL-6 for risk of first-ever cerebrovascular events in
individuals with vascular risk factors without any pre-existing cardiovascular disease(79).
Further, a positive predictive value of 100% is reported for coronary artery disease when IL-6
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concentrations exceed 1.0 pg/mL in patients who have an intermediate cardiovascular risk
profile and chest pain(246). In a meta-analysis of 17 prospective studies investigating clinical
coronary outcomes (i.e., myocardial infarction or coronary death), an odds ratio of 1.61 (95%
CI 1.42–1.83) was found per 2 SD increase in baseline IL-6 (247). Another meta-analysis of
17 studies comprising 288,738 healthy individuals reported a significantly higher IL-6
concentration in CVD cases compared to non-CVD controls (standardized mean difference
[95% CI]) of 0.14 [0.09, 0.20]/mean difference of 0.36 [0.28, 0.44] pg/mL) [52]. These
significant changes in IL-6 concentration were found only in studies which the mean BMI of
participants were >25kg/m2. Overweight and obesity are an independent risk factor for CVD,
as well as are associated with a low-grade continuous inflammation with high implications in
the atherosclerotic process. The possibility of regulating this persistent not resolved
inflammatory state can be crucial in attenuating the progress of the atherosclerosis disease,
especially in the early stages. This is the same scenario, in which the only study (37) that
evaluated CRP found a significant reduction of 0.4 (SD 0.1) mg/L in a study population with a
mean BMI >29kg/m2. This effect reduced the hsCRP concentration in the intervention arm to
values <3.0 mg/L, which is considered a clinical threshold for many cardiovascular conditions,
including a reduced hospitalisation rate for heart failure in subjects with stable coronary heart
disease[53]. CRP is also associated with CVD and mortality (67,68), and has been implicated
in endothelial dysfunction in in vitro and in vivo studies (65,66). On the other hand, the
cytokines IL-1β and TNF-α not appear to transiently and/or robustly change in the postprandial
period after a HFMC, thus a decrease in concentration of these molecules is not likely to occur
with acute diet interventions (244). In the present review, the three studies that evaluate IL-1β
were conducted in healthy normal weight (234), healthy overweight (37) and overweight/obese
adults with atherosclerosis prone phenotype (233), however none of them found significant
changes. TNF-α also plays a pleiotropic and major role in CVD, but high concentrations have
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been associated with deleterious effects mainly through vascular dysfunction and atherogenesis
by many mechanisms such as regulation of the vascular permeability, disruption of the
endothelial barrier, degradation of glycocalyx, increased production of ROS and decreasing
NO bioavailability and increase its removal (250,251). In line with the review by Emerson et
al. (2017) (244), the studies included in our review found inconsistent changes of TNF-α
concentrations after the HFMC, i.e. two studies found a decrease (233,234), one an increase
(231) and other study reported no changes (37). The study that had a postprandial increase in
TNF-α concentration was the only one that found a significant lowering effect with the diet
intervention with anthocyanins (231). Another relevant finding in this same study was the
inhibitory effect of on postprandial increase of IL-17, a cytokine with highly pro-inflammatory
properties that are also associated with CVD, especially with cardiovascular events such as
stroke and myocardial infarction (252). There is accumulating evidence that IL-17 it is involved
in the pathogenesis of cardiovascular diseases by amplifying the inflammation induced by other
cytokines in synergistic interactions (253). This cytokine is also positively correlated with
OxLDL-c, a molecule with a crucial role in the oxidative stress mediated atherosclerosis
development.
OxLDL-c is a key factor in the initiation and progression of atherosclerosis and
contributes to endothelial dysfunction and plaque destabilization through various mechanisms
(254). Among the four studies that measured postprandial concentration of Ox-LDL-c, the only
study that found a significant reduction was conducted in participants with an obese and insulin
resistant phenotype [35]. Several other oxidative stress and antioxidant status biomarkers were
investigated within the added studies in this review, showing the most promising results in
relation to the effects of anthocyanin intervention on parameters following the HFM challenge.
MDA is an end product of lipid peroxidation, the radical-initiated oxidative decomposition of
poly-unsaturated fatty acids (255). Urquiaga et al. (240) found a reduction in postprandial
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concentration of MDA at multiple time points following two different anthocyanin
interventions (i.e. added to food or beverage) using a berry concentrate. This same study also
found a reduction in plasma protein carbonyls and an increase in the DPPH (2,2-diphenyl-1picrylhydrazyl) plasma antioxidant capacity (240). Protein carbonylation is one of the most
harmful irreversible oxidative protein modifications, and is considered a major hallmark of
oxidative stress‐related disorders (256). The DPPH assay is a method that is widely used to test
the ability of compounds to act as free radical scavengers or hydrogen donors, and therefore
can be used to evaluate antioxidant activity. Another anti-oxidant assay, the FRAP, (based on
single electron transfer reaction to evaluate the antioxidant effect of nonenzymatic defense in
biological fluids) was measured in three studies that reported no significant effect of the
anthocyanin intervention in plasma (230,232,240). However, one of these studies found a 35%
increase in the urinary excretion of antioxidants (P<0.01), which was followed by an increase
TRAP and an attenuation in the increase of endogenous antioxidants thiols and UA. TRAP
differs from FRAP as an assay that measures the ability of antioxidants to buffer a reaction
probe against peroxidation, and it’s determined by measuring the length of time that oxygen
uptake is inhibited (257). Results from both FRAP and TRAP methods have to be carefully
interpreted considering that FRAP has low specificity in measuring the antioxidant activity of
many important antioxidants such as ascorbic acid, glutathione and albumin, and that TRAP
does not necessarily provide a reliable or sensitive measure of the ability of plasma to interfere
with lipid peroxidation[66]. UA levels are related to oxidative status, especially antioxidant
capacity and it is well known that high plasma UA levels are strongly associated CVD (258).
Taken together, the positive results of these three different oxidative stress biomarkers show a
relevant anti-oxidant signalling effect of anthocyanins in these studies conducted in healthy
adults (230,240). Another relevant biomarker of antioxidant status is vitamin C, which is a
readily water-soluble and not storable in tissues. Therefore, vitamin C is a good biomarker for
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short-term studies (259). One study added in this review found an increase in plasma vitamin
C (233); however, even though the placebo was matched in macronutrients and energy, only
the diet intervention had a relevant content of vitamin C (122.3 vs 0.3mg). Thus, it is unlikely
that the plasma concentration of vitamin C was increased due to the anthocyanins. The ORAC
of plasma/serum, which was evaluated in five studies in this review, appears to be a
controversial method in regard to its application for in vivo studies, especially after the
withdraw of the ORAC food database by the USDA in 2010. There is still debate regarding the
absorbance and breakdown of polyphenols, such as flavonoids and subclasses, into smaller
phenolics compounds with signalling, anti-inflammatory and anti-oxidant properties (242).
Nevertheless, two studies found an increase in plasma ORAC following 60 (233), 90 and 120
(237) minutes after the HFMC, and one study also found a significant increase in TAS (237),
another non-specific assay that assess the overall antioxidant status of a sample.
The post-prandial response in the lipid profile, when compared to fasting lipids, can
represent a different and even independent risk factor for CVD (34,106). The transient lipid
and lipoprotein accumulation that occurs in the circulation after a high-fat meal represents the
individual capacity to metabolize an acute fat input (260) and has been associated as an
important risk factor in atherosclerosis development (107). The most relevant postprandial lipid
marker it is triacylglycerol. It is the lipid with the greatest post-prandial difference from fasting
lipid markers (34), and has been associated as an independent risk factor for cardiovascular
events (35). The results found in our review support these statements, as significant changes
were only found in triacylglycerol (233,239) concentrations and total cholesterol (231,239),
which has a composition of 20% triacylglycerol in its formula.
The choice of placebo in this type of acute study design is important in order to identify
whether it is indeed the anthocyanin effect that is observed in the results, or whether there are
other nutrients or food constituents that may be affecting the study outcomes. All studies
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included in this review included a placebo that was matched in macronutrient and fibre content,
however other nutrients such as vitamin C and other flavonoids that may also play a role in
postprandial oxidative stress and inflammation are not commonly considered. It is complex,
and often impossible, to provide a perfectly matched placebo in food studies of this type,
therefore results from studies that use different placebos should be carefully scrutinized.
The most notable challenge and limitation of this study was to address a wide range of
CVDs biomarkers assessed in this type of acute clinical trial. Overall, the comparison among
studies had a relevant clinical importance of these metabolic, immune and physiological factors
that has a synergistic impact on CVDs, however there was a variety of parameters addressed
with different methods within each of such factors. This made the possibility of meta-analysis
or other pooled analyses unfeasible, however it not impeded results to be compared narratively.
Another source of heterogeneity in these studies may have resulted from variability in the HMF
challenges regarding their macronutrient and energy content, particularly the types of fat, as
well as the format in which the meals were delivered. Accumulating evidence suggests that the
health effects of dietary fats vary(108). Substitution of saturated fatty acids from butterfat with
omega-6 PUFA resulted in a decreased postprandial lipaemia, as well as reduced
concentrations of IL-6, TNF-α, soluble TNF-α receptors, and soluble vascular cell adhesion
molecule-1 in overweight men(110). However, all studies included in this review used animal
products as the main source of fat, and there were two main types of meals: 1) beverages that
were enriched with cream and/or milk; or 2) mixed meals including animal products with a
high content of saturated fat such as sausages, cheese, butter, eggs and bacon. A standardized
meal for these type of studies would be preferred but may be difficult to implement because of
cultural diversity in cuisine and dietary patterns. Despite that all included studies were
conducted in young and middle-aged adults (mean age ranging from 20.2 to 46.9y), there were
slightly differences in mean BMI with two studies having participants with BMI<25kg/m2
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(234,240) six with BMI from 25-30kg/m2 (37,229–231,236,239) and three with BMI>30kg/m2
(233,235,238) .Only three studies were not conducted in healthy adults, of which participants
were not considered healthy due to lipidaemia (233), insulin-resistance phenotype (235) or with
at least one CVD risk factor (239). However, studies conducted in participants with major
chronic diseases with implication on CVDs, such as diabetes and hypertension, were not
included in this review. Another feature in the design of this type of study is that tests are
conducted over multiple time following the HFM challenge, thereby raising a concern that the
number of false positive findings may be inflated. For this reason, the interpretation of results
found in only one or a few time points, and that are not sustained, has to be interpreted with
caution. Still, parameters that have been used in the studies to investigate oxidative stress and
antioxidant status represent a wide range of analytical methods, and there is no formal
mechanism to establish consensus regarding the optimal biomarkers for such nutritional studies
(259,261).

3.5 Conclusion

Despite some positive findings, there was heterogeneity for changes in some CVD risk
factors between studies. The most promising results were for the attenuation of deleterious
postprandial effects on oxidative stress and antioxidant status, triacylglycerol and total
cholesterol concentrations, as well as for vascular endothelial function and inflammatory
biomarkers. The post-prandial changes in blood pressure and lipoproteins were the parameters
least affected by anthocyanin treatment. Further studies are required in order to advance in the
knowledge of how post-prandial changes are associated with CVD incidence and progress, and
to investigate how these imbalances can be attenuated by bioactive compounds such
anthocyanins.
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CHAPTER 4: Anthocyanins attenuate vascular and inflammatory
responses to a high fat high energy meal challenge in overweight
older adults: a cross-over, randomized, double-blind clinical trial.

The findings from the previous study ‘The postprandial effect of anthocyanins on
cardiovascular disease risk factors: a systematic literature review of high-fat meal challenge’
guided the original design and conduct of this clinical trial. Within this range of studies, another
gap that was identified is the possibility of a more robust investigation of the vascular function
in the postprandial state, which along with the immune response are important predictors of
CVD. Therefore, we created a protocol to explore macro and microvascular parameters by
combining classical and novel techniques with the latest imaging technologies, such as the
flow-mediated dilatation (FMD) and the Laser Speckle Contrast Imaging (LSCI). To our
knowledge, this was the first study to conduct this type of protocol in studies with nutritional
interventions. Additionally, the present clinical trial also aim to determine if consumption of
food anthocyanins has postprandial effects on inflammatory and oxidative stress biomarkers,
and lipid profile following a high-fat high-energy meal in older adults with overweight or
obesity
The results supported that fruit-based anthocyanins attenuated the potential
postprandial detrimental effects of a HFHE challenge on parameters of vascular and
microvascular function, and inflammatory biomarkers in overweight older adults.
The majority of this chapter forms the substantive content of a published article
(Appendix B).
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4.1 Introduction
Metabolic imbalances in the postprandial state, particularly following a high fat high
energy (HFHE) meal, are associated with long term development of CVD(106,107). The
underlying mechanisms involve a sharp increase in circulating triacylglycerol concentrations,
along with a pro-inflammatory response and an aberrant production of pro-oxidant molecules,
which together may impair vascular endothelial function(105,262,263). Endothelial
dysfunction is associated with an impaired bioavailability of nitric oxide (NO) and an upregulation of various other molecules involved in the adverse vascular function(6,264).
This is particularly evident in older adults, as several studies support a new immunemetabolic viewpoint for age-related diseases, termed “inflammaging” which is characterized
by a chronic, low-grade inflammatory response in the absence of a pathogen(7). Additionally,
excessive adiposity at all ages is associated with an up-regulation of a pro-inflammatory state,
as the accumulation of adipose tissue mass promotes the secretion and release of inflammatory
mediators, including high sensitive C-reactive protein (hs-CRP), interleukin-6 (IL-6),
interleukin 1 beta (IL-1β) and tumour necrosis factor alpha (TNF-α)(63,64). This process also
leads to chronic low-grade inflammation that is driven by a nutrient excess and/or overnutrition
and has the same mechanisms as those underpinning “inflammaging”(7). A HFHE challenge
is a method to investigate such imbalances that regularly occur in response to typical ‘Western’
dietary patterns(264,265). A review of 57 studies investigating the postprandial state has shown
that a HFHE meal induces acute postprandial inflammation; however, heterogeneity was
observed for cytokines and soluble adhesion molecules, while leukocyte surface markers,
mRNA and proteins were elevated in almost all studies(266). Strategies that aim to attenuate
these potential detrimental postprandial effects will be of clinical relevance.
Dietary factors play a major role in regulating the inflammatory state and mobilizing
the endogenous antioxidant defences(9). Protective dietary components that are consumed
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together with a HFHE meal may be beneficial in attenuating the potentially harmful
postprandial responses(226). Anthocyanins, a subclass of flavonoids, are emerging as one such
potential agent for ameliorating adverse CVD risk factors(21,222,267). Anthocyanins have
been shown to elicit immunomodulatory(21,23) and antioxidant effects(23,268), thereby
blunting the cooperative and synergistic deleterious effects of oxidative stress and
inflammation(190) and may, therefore, provide protection against CVD risk factors. A number
of in vitro and in vivo studies have shown that anthocyanins upregulate endothelial nitric oxide
synthase (eNOS) mRNA and NO synthesis(126,144,269,270) via several signalling pathways,
and prevent peroxynitrite-mediated ED(125,271). Anthocyanins can also prevent the
expression of adhesion molecules and the adhesion of monocytes to endothelial cells
challenged by pro-inflammatory agents, and have the ability to elicit cell adaptive responses
involving the transcription factor Nrf2(272). However, there is still limited data regarding the
effect of anthocyanins on vascular function(273). To our knowledge, no study to date has
investigated such effects on the microvasculature and predictive values for CVD are not yet
defined, as they are for vascular function measured by flow mediated dilatation(11), which is
considered to be a well-recognized early biomarker of atherosclerosis and a key contributor to
the onset and progression of CVD(243,274,275). Measurement of the systemic
microcirculatory function may help to identify ED pathological processes, and better elucidate
the mechanisms underlying structural changes among these two vascular beds(96,102,276).
The aim of this study was to investigate the postprandial effects of food anthocyanins
on vascular and microvascular functions, inflammatory biomarkers and oxidative stress
following a HFHE meal challenge in overweight older adults. A secondary aim was to evaluate
the acute effects of the 4 day run-in period of food anthocyanins on such markers. Outcomes
combined both vascular and microvascular function analyses, along with the evaluation of
classic CVD risk factors and associated biomarkers(277,278), including blood pressure, serum
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concentration of triacylglycerols (TG) and total cholesterol (TC), inflammatory markers
including hs-CRP, IL-6, IL-1β, TNF-α, and serum derivatives of reactive oxidative metabolites
(DROM).

4.2Methods
This study was conducted according to the guidelines of the Declaration of Helsinki,
and approved by the University of Wollongong Human Research Ethics Committee, New
South Wales, Australia (HREC 2019/043). It was also registered with the Australian New
Zealand Clinical Trials Registry (ACTRN12620000437965). Written informed consent was
obtained from all subjects.

Study Subjects
Sixteen subjects (13 female and 3 male) were recruited from Wollongong, NSW,
Australia through advertisements within the local community, and through the University of
Wollongong and Illawarra Health and Medical Research Institute social media networks
between June and August 2019. Inclusion criteria included males and females aged 55+ years
with a body mass index (BMI) ≥25kg/m2. Exclusion criteria were: current treatment or
diagnosis of hypertension or diabetes; chronic liver or renal diseases; history of cardiovascular
events; current administration of either anti-inflammatory medication, aspirin or warfarin;
smoking; diagnosis or self-reported gastrointestinal disorders; allergy to stone fruits or food
colorants, unwillingness to consume a full English style breakfast that included meat products
(e.g. vegetarians) at the research facility.

Study Design and Treatments
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The study was a crossover, randomized, controlled, double-blind design with a 4 day
run-in period. The study design and procedures are outlined in Figure 4-1. Briefly, four days
prior to the test days, participants were asked to consume either 250 mL of Queen Garnet plum
juice (intervention) or apricot juice (control) per day. Participants underwent consultation with
a dietitian that included education on avoiding foods that are rich in anthocyanins during the 4
day run-in period prior to testing. On the night prior to the testing day, a standardised low
flavonoid frozen meal was consumed for dinner by all participants. Participants fasted (12h)
prior to the testing day.
On the testing day, participants were required to consume a HFHE meal in conjunction
with a 250mL dose of either the intervention or the control juice. Blood samples and blood
pressure measures were collected at baseline (fasted state), and 2h and 4h following the
consumption of the HFHE meal. Vascular function and microvascular blood flow was
evaluated at baseline and 2h after the meal. Urine was collected for 24h following the HFHE
meal.
After a wash-out period of 14 days, participants were allocated to the opposite treatment arm,
starting with the 4 day run-in period. Randomization was conducted by a researcher
independent to the data collection using a computer generated randomization sequence and,
in order to minimize order effects, an across subjects counter-balancing process was used.
Several blinding strategies were undertaken, including advertising the study to participants as
a “fruit juice study” without providing information on which fruit was being investigated, as
well as colouring of the control juice to match the intervention juice colour. The usual dietary
intake of participants was collected before the beginning of the study using a 3-day food
record, consisting of 2 weekdays and 1 weekend day, and analysed using Foodworks 10
(Xyris Software, Australia), which includes the Australian Food Composition Database
2019(279). (Table 4-1)
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Table 4-1. Dietary intake of participants
Energy (kcal)

1724 (375.6)

Protein (g)

80.7 (26.0)

Fat – total (g)

71.4 (18.9)

Saturated fat (g)

29.2 (5.0)

Carbohydrates (g)
Dietary fibre (g)
Sodium (mg)

171.2 (42.3)
20.7 (7.4)
1870.5 (563.8)

Vitamin C (mg)

30.4 (22.9)

Vitamin E (mg)

3.7 (2.6)

Vitamin A* (µg)

362.6 (170.7)

Anthocyanins (mg)

19.1 (31.8)

Values are mean and SD. *Total Vitamin A equivalents.
Values were obtained from the Australian Food Composition
Database 201926.

Figure 4-1. Study design and procedures repeated on each treatment arm

Test meals, and intervention and control juices
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The test meal consisted of 1 hash brown (62g) 2 beef chipolatas (90g), 1 croissant
(168g) served with unsalted butter (5g) and apricot jam (10g) and 2 scrambled eggs (2 x52g
eggs, 30mL pure cream, 10g unsalted butter, 0.5g salt) (Table 4-2). One serving of Queen
Garnet plum juice (intervention) was provided as 220g of plum puree with 30mL of water
added. The anthocyanin content was analysed by the Queensland Department of Agriculture
and Fisheries (DAF, Australia) by Performance Liquid Chromatography (HPLC) (91.3 mg of
anthocyanins per 100g of Queen Garnet plum juice) and a pH differential method (94
mg/100g), following the standard AOAC 2005.02 protocol for total monomeric anthocyanin
pigment(280). The 200 mg of anthocyanins provided per serve can be considered a high dose
based on a systematic literature review of similar studies. In that review, only 2 of the included
13 studies used a higher dose, and a number of studies achieved significant vascular effects at
doses lower than 100mg(273). Apricot juice was chosen as the control juice due to its similar
consistency, nutritional content and total flavonoid concentration, but an overall lack of
anthocyanins(281). Food dyes (red and blue) were added to the apricot juice to resemble the
colour of the Queen Garnet plum juice.

Table 4-2. Nutrition information of the test meal and fruit juices
Test meal1

Plum juice
(250 mL)

Apricot juice
(250 mL)

Energy (kcal)

856.9

98

96

Protein (g)

25.9

0.6

0.7

Fat – total (g)

65.3

< 0.1

< 0.1

Saturated fat (g)

32.9

< 0.1

< 0.1

Carbohydrates (g)

41.4

22.2

22.2

Dietary fibre (g)

1.7

4.4

4.0
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Sodium (mg)

1

941

6

2

Vitamin C (mg)

0

0.3

1.2

Anthocyanins (mg)

02

200.83

02

Anthocyanins (mg)

02

206.84

02

Whole meal including one hash brown (62g), two scrambled eggs (104g) with pure cream

(30g), butter (10g) and salt (0.5g), two beef chipolatas (90g), one croissant (168g) with butter
and apricot jam; 2Phenol-explorer 3.0(282); 3High Performance Liquid Chromatography; 4pH
differential method. Values were obtained from the Australian Food Composition
Database 201926.

Blood pressure
BP was measured at baseline (fasted state), and 2h and 4h following the consumption
of the HFHE meal using an using a Welch Allyn Connex 6700 Vital Signs Monitors (Welch
Allyn, NSW, Australia). Participants were rested in supine position for 5 minutes, in a quiet
room with a correctly fitting arm cuff. BP was measured on both arms, and a repeat measure
taken on the arm with the higher reading, with the average of the two readings recorded(283).

Flow mediated dilation (FMD) and microvascular perfusion
Participants were rested in a quiet, temperature-controlled room (23 °C ±1), in a supine
position for 20 minutes. In brief, the first procedure was the microvascular PORH test
conducted on the left arm, followed by the FMD conducted on the right arm, and lastly
iontophoresis of acetylcholine, combined with LSCI, conducted in the left forearm (with 30
minutes between tests in the left forearm).
Vascular function was measured using FMD following standard guidelines(284), by a
trained researcher. The same blinded researcher administered the test for each participant at
two time points (baseline and 2hrs post-meal consumption, Figure 4-1) on both treatment arms,
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and was responsible for the analysis of the resulting images to prevent inter-rater error. FMD
of the brachial artery was measured using an uSmart3300 Ultrasound system (Terason,
Massachusetts, USA) in combination with a semi-automated computerized analysis system
(FMD Studio, QUIPO, Pisa, Italy). The brachial artery was imaged longitudinally at 2-10cm
proximal to the antecubital fossa. Video recording collected beat to beat measures of the
diameter and velocity for 1 minute, and the average was used as the baseline. Then the blood
pressure cuff placed around the forearm was inflated to 60mmHg above resting systolic blood
pressure. Blood flow was restricted for 5 minutes, then the cuff was rapidly released, resulting
in reactive hyperaemia. Video was recorded for the 5 minutes period following the cuff release.
The FMD response was calculated as the relative diastolic diameter change from baseline
compared to the peak diastolic diameter following hyperaemia and expressed as a percentage.
This flow-mediated dilatation protocol is routinely performed in our laboratory using the
methods outlined by Francois et al. (2016)(285); with intra-subject coefficients of variation of
7.1% for %FMD.
Microvascular cutaneous vascular reactivity was measured using an LSCI system with
a laser wavelength of 785 nm (Pericam PSI System, Perimed AB, Järfälla, Sweden). The image
acquisition rate was 21 images/s, and the distance between the laser head and the skin surface
was fixed at 25 ±0.5 cm. The skin of the volar side of the left arm was gently cleaned with 70%
isopropyl alcohol swabs. Three equidistant skin areas (region of interest) of approximately 80
mm2 were selected in the central volar part for the left arm(286), avoiding any skin mark or
bulge areas(95). Participants were instructed to avoid any movement, and not to speak or
breathe deeply during the record(95). During the PORH test, the baseline perfusion was
measured in the volar side of the left forearm for 2 minutes, followed by an arterial occlusion
maintained for 3 minutes using a blood pressure cuff around the upper arm inflated to a pressure
of 50-60 mmHg above systolic pressure reading(96,276). After the blood pressure cuff was
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released, the PORH response was recorded for 3 minutes. The following parameters were
extracted: baseline flow (BF), biological zero (BZ) and peak value (PV)(95). The PV was
obtained with a 5 second “time of interest” starting from the highest value after deflation of the
cuff(286). RF was calculated as BF – BZ. The maximum PORH perfusion (PORHmax) was
calculated as PV – RF (Supplementary material, Figure S1 and Table S1). This PORH
protocol is routinely performed in our laboratory; with intra-subject coefficients of variation of
7.7% for PV and 11.4% for PORHmax.
Additionally, a pharmacological reactivity test was conducted using iontophoresis of
acetylcholine (2%, dissolved in deionized water) using a micropharmacology system (PF 751
PeriIont USB Power Supply; Perimed) with a single electrical current of 0.1mA for 30s(101).
Microvascular blood flow was recorded for 2 minutes prior to the current and 8 minutes after
the pharmacological stimulus. The maximum perfusion following the iontophoresis of
acetylcholine (IONTmax) was calculated by using subtracting the RF from the PV using the
same procedures used in the PORH test (Supplementary material, Table S1).

Blood and urine samples
Plasma and serum samples were stored at -80 °C, prior to analysis. IL-1β, IL-6 and
TNF-α, were analysed in a Luminex 200 using a Human High sensitivity T cell magnetic bead
panel kits (Merck Millipore, Billerica, MA, USA). hs-CRP, TC and TG were analysed on a
BK400 automated chemistry analyser using a commercial immunoturbidometric assay
(Biobase, Shandong, China). Derivatives of reactive oxidative metabolites were analysed in a
Cobas Mira Plus (Roche, Washington, USA) using a commercially available colorimetric kit
(Diacron, Grosseto, Italy).
Urine samples were collected between 0-4h, 4-12h and 12-24h and stored at -80 °C,
prior to analysis. Aliquots of 3 mL from each timepoint were pooled and 1 mL of the pooled
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sample was analysed using ultra-performance liquid chromatography–tandem mass
spectrometry (UPLC-MS/MS) to determine differences in excretion of total anthocyanins
(expressed as cyanidin-3-O-glucoside equivalents equivalents), and phenolic acid metabolites
related to anthocyanins (protocatechuic acid, hippuric acid and ferulic acid). Briefly, 1 ml urine
was extracted by solid phase extraction using Discovery® DSC-18 (6 mL, 1 g) cartridges(287).
The eluate was evaporated under nitrogen, reconstituted in 1 % formic acid in water and
analysed by UPLC-MS/MS (Waters Acquity H-Class UPLC instrument coupled to a Waters
Xevo TQ tandem mass spectrometer), operating in multiple reaction monitoring and positive
electrospray ionization modes. The presence of each compound is expressed in ng/mL or
µg/mL

Statistical Analyses
Data are presented as mean and standard deviation or median and interquartile range.
Natural log transformation was used when non-normal data better fit the normal distribution
(triacylglycerol, total cholesteterol, hs-CRP, PV and PORHmax). Two-way repeated measures
ANOVAs were used to investigate the outcomes. Significant interaction effects were analysed
by post-hoc comparisons with Bonferroni correction. Dependent t- and Wilcoxon signed-tank
tests evaluated the difference in baseline measures to investigate the effects of the 4 day run-in
period, as well as to investigate the differences in other time points among the treatments.
Pearson and Spearman coefficients were calculated to evaluate potential baseline correlations
between vascular parameters and inflammatory biomarkers. All LSCI parameters were
transformed from arbitrary perfusion units (PU) to cutaneous vascular conductance (cvc) by
dividing the obtained values by the mean arterial pressure to yield cvc in PU/mmHg. SPSS
(version 25, IBM, Chicago, IL, USA 2019) was used for all statistical analyses. Significance
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was accepted at alpha p<0.05, and non-significant p values between p=0.05-0.099 were
considered a trend in the data.
The primary endpoint of change in FMD from baseline to 2 h was used for the power
calculation. Based on a previous study that found a significant effect of anthocyanins on postprandial changes in FMD(229), and aiming for a significant improvement of 1% in FMD, 13
participants were required to achieve a study power of 80% with an α of 0.05.

4.3 Results
All sixteen recruited subjects completed the study (n=16). The mean age and BMI for
the study group were 65.9 years (SD 6.0) and 30.6 kg/m2 (SD 3.9), respectively. Mean baseline
body anthropometry and clinical measures (weight, height; total cholesterol, triacylglycerol,
systolic and diastolic blood pressure) are presented in Table 4-3. No harms or unintended
effects were observed through the study. The sample size of some vascular parameters was
reduced due to experimental error (participant movement during the tests), resulting in n=15
for PORH and FMD, and n=13 for iontophoresis with acetylcholine. No significant correlations
were observed between baseline vascular parameters and inflammatory biomarkers (P>0.05)
(Supplementary material, Table S2).

Table 4-3. Baseline demographics
n

16

Female

13

Male

3

Age (years)

65.9 (SD 6.0)

Body weight (kg)

81.5 (SD 10.5)

Height (cm)

163 (SD 8.7)

BMI (kg/m2)

30.6 (SD 3.9)

Total cholesterol (mmol/L)

6.28 (IQR 1.33)
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Triacylglycerol (mmol/L)

0.94 (IQR 0.84)

SPB (mm Hg)

120.2 (SD 12.3)

DPB (mm Hg)
69.3 (SD 7.4)
Values are means and standard deviation or median and
interquartile range. SD, standard deviation; IQR,
interquartile range; DBP, diastolic blood pressure;
SBP, systolic blood pressure.

Blood pressure, triacylgycerol and cholesterol
There were significant post-prandial changes on diastolic blood pressure,
triacylglycerol and total cholesterol across the time points (P<0.05 for time effect), but no
significant interaction or simple effect of treatment between the intervention and the control
arms (P>0.05) (Table 4-4).
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Table 4-4. Blood pressure, triacylglycerol, total cholesterol and triacylglycerol before and after a high fat high energy meal challenge in
control and intervention groups.
Measures

Group

Baseline

2h

4h

Control

118.9 (SD 11.1)

116.3 (SD 12.6)

123.2 (SD 12.8)

SPB (mm hg)
Anthocyanins 118.8 (SD 12.9)
Control

70.1 (SD 6.9)

117.7 (SD 10.6)

123.4 (SD 12.4)

67.4 (SD 7.3)

70.5 (SD 7.6)

DBP (mm hg)
Anthocyanins

68.0 (SD 6.7)

Control
0.95 (IQR 0.79)
Triacylglycerol
(mmol/L)
Anthocyanins 0.89 (IQR 0.89)

66.6 (SD 5.5)

70.8 (SD 6.6)

1.30 (IQR 0.96)

2.12 (IQR 1.45)

1.29 (IQR 1.35)

2.22 (IQR 2.35)

Timea

Treatmenta

Time x treatmenta

0.001*

0.692

F(2,30)=0.278,
P=0.759, ηp2=0.018

0.002*

0.148

F(2,30)=1.684,
P=0.203, ηp2=1.01

>0.001*

0.357

F(2,30)=0.083,
P=0.921, ηp2=0.006 b

Total
Control
6.16 (IQR 1.39) 6.02 (IQR 1.65) 6.09 (IQR 1.26)
F(2,30)=0.648,
cholesterol
>0.001*
0.756
P=0.530,
ηp2=0.041 b
Anthocyanins 6.28 (IQR 1.27) 6.40 (IQR 1.16) 6.27 (IQR 1.14)
(mmol/L)
Values are mean and standard deviation or median and interquartile range (n=16). SD, standard deviation; IQR, interquartile range; ηp2, partial
eta-squared, DBP, diastolic blood pressure; SBP, systolic blood pressure. a P-values for two-factors repeated measures ANOVA; b results from
log natural transformed dat
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Vascular function
Postprandial changes (i.e. the difference between baseline and 2h after the HFHE meal)
in mean FMD were +0.16% in the anthocyanins group and -0.47% in the control group (Table
4-5). There was a significant treatment effect (P=0.028); however, there was no main effect of
time (P=0.474) or interaction between treatment and time (P=0.219) (Table 4-5). Dependent
t-tests showed no significant difference between baseline in FMD results (P=0.212, +4.09%
SD 1.12 intervention vs 3.58% SD 1.14 control arm) indicating no effect of the 4 day run-in
period, and a significant difference (P=0.019) of 1.14% in post-prandial FMD among
treatments (+4.25% SD 1.34 intervention vs 3.11% SD 1.00 control arm), (Figure 4-2a). There
was no significant interaction between time and treatment nor a significant treatment effect for
the peak shear rate; however, a trend towards a time effect was observed (P=0.091) (Table 45)
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Table 4-5. Vascular and microvascular reactivity parameters before and after a high fat high energy meal challenge in control and intervention
groups.
Parameter
FMD (%)

Baseline

2h

Control

3.58 (SD 1.14)

3.11 (SD 1.00)

Anthocyanins

4.09 (SD 1.12)

4.25 (SD 1.34)

Control

954.7 (SD 344.1)

881.9 (SD 219.6)

Peak shear
rate (sec -1)

Group

Anthocyanins

955.5 (SD 324.7)

811.5 (SD 300.5)

Control

1.20 (IQR 0.37)

1.08 (IQR 0.28)

PV (cvc)

Anthocyanins

1.21 (IQR 0.28)

1.16 (IQR 0.23)

Control

0.85 (IQR 0.28)

0.73 (IQR 0.23)

PORHmax
(cvc)

Anthocyanins

0.88 (IQR 0.27)

0.83 (IQR 0.21 )

IONTmax

Control

0.45(SD 0.20)

0.45 (SD 0.25)

(cvc)

Anthocyanins

0.43 (SD 0.22)

0.41 (SD 0.22)

Timea

Treatmenta

Time x treatmenta

0.474

0.028

F(1,14)=1.653, P=0.219,
ηp2=0.106

0.091

0.583

F(1,14)=1.293, P=0.275,
ηp2=0.085

<0.001

0.125

F(1,14)=0.121 P=0.465,
ηp2=0.036 b

<0.001

0.062

F(1,14)=2.247 P=0.155,
ηp2=0.130 b

0.748

0.620

F(1,12)=0.020, P=0.889,
ηp2=0.002

Values are mean and standard deviation or median and interquartile range. FMD, flow-mediated dilatation; SD, standard deviation; IQR,
interquartile range; cvc, cutaneous vascular conductance in PU/mmHg; ηp2, partial eta-squared; PV, peak value; PORHmax, post-occlusive
reactive hyperaemia maximum perfusion; IONTmax, maximum perfusion following iontophoresis of acetylcholine. a P-values for two-factors
repeated measure
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Figure 4-2. Flow mediated dilatation and microvascular reactivity parameters before and after
a high fat high energy meal challenge in control and intervention groups (n=15 for panels A, B
and C, and n=13 for panel D). Values are mean and error bars are standard deviation (A and
D) or median and error bars are 1st and 3rd quartile (B and C). FMD, flow mediated dilatation;
PORHmax, post occlusive reactive hyperaemia maximum perfusion; cvc, cutaneous vascular
conductance in PU/mmHg *P<0.05 (dependent t-test at A and Wilcoxon signed-tank test at C);
†P=0.088(Wilcoxon signed-tank test).
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No significant interactions between time and treatment were evident for any parameter
of the PORH test (Table 4-5). A significant time effect for PV and PORHmax (p<0.001 for
both parameters) was found, indicating a post-prandial effect of the HFHE meal challenge
independent of treatment. The treatment effect for PV was not significant (P=0.125) and
dependent t-tests showed no significant difference resulting from the 4 day run-in period on
fasting measures (P=0.334, Wilcoxon signed-tank test). There was a trend for a higher postprandial PV in the anthocyanins group (p=0.088, Wilcoxon signed-tank test) (Figure 4-2b).
The parameter PORHmax presented a trend towards a treatment effect (P=0.062) and no
significant difference carried by the 4 day run-in period in fasting measures (P=0.594,
Wilcoxon signed-tank test) (Figure 4-2). A significantly higher postprandial PORHmax of
0.10 PU/mmHg (P=0.049, Wilcoxon signed-tank test) was evident in the anthocyanins group
compared to the control group (Figure 4-2c). The microvascular reactivity test induced by the
iontophoresis of acetylcholine showed no significant effects for IONTmax (Table 4-5). There
was no significant difference between the fasting (P=0.582, dependent t-test) and post-prandial
(P=0.684, dependent t-test) IONTmax between the treatments (Figure 4-2d). The data used to
calculate the microvascular parameters are presented in the supplementary material (Table S3).

Inflammatory markers and serum derivatives of reactive oxidative metabolites
A significant interaction effect was found for serum hs-CRP (P=0.036) (Table 4-6).
Corrected pairwise comparisons showed no significant differences between the baseline
(fasted), 2h and 4h postprandial values for both treatments (P>0.05) (Figure 4-3). However,
there was a significantly lower hs-CRP concentration 4h postprandially in the anthocyanins
group when compared to the control arm (P=0.026, Wilcoxon signed-tank test), as well as
trends in the baseline and in the 2h postprandial time point (P=0.098 and P=0.083, respectively,
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Wilcoxon signed-tank test) (P=0.095 at baseline P=0.099 at 2h, and P=0.008 at 4h, Wilcoxon
signed-tank tests) (Figure 4-3).
There were no significant effects for serum concentration of IL-6, TNF- α and IL-1β
(Table 4-6). A trend in the treatment effect was evident for IL-6 concentrations (P=0.075).
There was a significantly lower concentration of IL-6 at the 4h post-prandial time point in the
anthocyanins group when compared to the control group (P=0.009, Wilcoxon signed-tank test)
(Figure 3). There was no significant difference evident following the 4 day run-in period in
fasting concentrations for any of the inflammatory biomarkers between groups (P>0.05,
dependent t tests) (Figure 4-3).
There was a significant effect of time (P=0.002) in serum concentrations of DROM,
however, no significant treatment or interaction effect was evident (P>0.05) (Table 4-6).

Urinary excretion of total anthocyanins and phenolic acids
The 24h concentration of total anthocyanins in the urine was higher in the intervention
arm 1.86 ng/mL (IQR 3.23) than the control arm 0.015 ng/mL (IQR 0.12) following the HFHE
meal challenge (P<0.001 ) (Table S4, Supplementary material). Concerning anthocyanins
metabolites, there were significantly higher concentration of hippuric acid in the urine for
participants within intervention arm versus the control (P=0.027), while no significant
differences were observed for protocatechuic acid and ferulic acid.
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Table 4-6. Serum concentration of inflammatory biomarkers and derivatives of reactive oxidative metabolites before and after a high fat
high energy meal challenge in control and intervention groups.
Parameter

Group

Baseline

2h

4h

hs-CRP
(mg/L)

Control

2.30 (IQR 1.95)

2.40 (IQR 2.05)

2.30 (IQR 1.95)

IL-6
(pg/mL)
TNF-α
(pg/mL)
IL-1β
(pg/mL)
DROM
(cu)

Anthocyanins

1.70 (IQR 1.00)

1.70 (IQR 0.95)

1.80 (IQR 0.90)

Control

5.95 (IQR 4.20)

5.40 (IQR 3.70)

5.98 (IQR 4.73)

Anthocyanins

6.00 (IQR 8.83)

Control

13.65 (IQR 10.65)

5.85 (IQR 6.45)

Time x treatmenta

0.299

0.094

F(2,30)=3.763,
P=0.036, ηp2=0.212b

0.436c

0.075

F(2,30)=0.635,
P=0.537, ηp2=0.041

0.277

0.987

F(2,30)=0.868,
P=0.430, ηp2=0.055

0.896

0.868

F(2,30)=1.436,
P=0.254, ηp2=0.087

0.002

0.298

F(2,30)=0.752,
P=0.480, ηp2=0.048

12.45 (IQR 9.25) 12.53 (IQR 9.89)

13.65 (IQR 8.88)

14.30 (IQR 7.95) 13.10 (IQR 7.33)

Control

1.60 (IQR 1.39)

1.55 (IQR 1.65)

1.55 (IQR 1.26)

Anthocyanins

1.20 (IQR 1.15)

1.40 (IQR 1.10)

1.45 (IQR 1.28)

Control

487.3 (SD 77.6)

497.1 (SD 81.1)

502.6 (SD 68.3)

473.1 (SD 75.5)

Treatmenta

5.55 (IQR 5.48)

Anthocyanins

Anthocyanins

Timea

496.4 (SD 77.0)

496.5 (SD 78.6)

Values are mean and standard deviation or median and interquartile range. hs-CRP, high-sensitivity c-reactive protein; IQR, interquartile range;
ηp2, partial eta-squared, IL-6, interleukin-6; TNF-α. Tumour necrosis factor alpha; IL-1β, interleukin-1 beta; DROM, derivatives of reactive
oxidative metabolites; cu, Carratelli units SD, standard deviation. a P-values for two-factors repeated measures ANOVA; b results from log
natural transformed data; c Greenhouse-Geisser correction (Mauschly’s test P=0.037, Epsilonb =0.727).
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Figure 4-3. Serum concentration of inflammatory biomarkers before and after a HFHE meal
challenge in control and intervention groups (n=16). Values are median and error bars are 1st
and 3rd quartile. hs-CRP, high-sensitivity c-reactive protein, IL, interleukin, TNF, tumour
necrosis factor. *P<0.05 (Wilcoxon signed-tank test); † P=0.095 at 0h and P=0.099 at 2h
(Wilcoxon signed-tank tests).

4.4Discussion
The intake of food anthocyanins with a HFHE meal challenge was able to attenuate the
potential detrimental effects on both vascular and microvascular function, and on the
inflammatory response. Compared to the control arm, participants had a significant higher
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postprandial FMD and some of the parameters of microvascular function, and significant lower
concentration of postprandial hs-CRP, with a trend for lower IL-6 levels when allocated in the
anthocyanins intervention arm. Several outcomes presented a significant time effect from the
fasted state to the post-prandial measures, confirming that a single HFHE meal is a sufficient
challenge to induce some negative vascular and inflammatory responses that are not apparent
in the fasted state. Importantly, our findings indicate that food-based anthocyanins may confer
protection against cardiovascular and inflammatory insults caused by a typical HFHE
‘Western’ diet in older overweight, though otherwise healthy, adults.
The endothelium plays a major role in vascular homeostasis and its implications in the
development of atherosclerosis and CVD are well established(288,289). Flow-mediated
dilatation is a non-invasive measurement of endothelium function that has been associated with
CVD risk prediction(243,274). A meta-analysis of 23 studies, including 14,753 subjects, found
an overall 8 % reduction in CVD risk (RR= 0.92; 95%CI: 0.88; 0.95) for each percentage
increase in FMD(274). In the present study, food anthocyanins induced a slightly increase in
the postprandial FMD, while a decline was observed in the control arm. Participants had a
1.14% higher post-prandial FMD when allocated in the anthocyanins intervention. The ability
of anthocyanins to prevent the reduction in FMD caused by a HFHE meal challenge suggests
that there are benefits for cardiovascular health in older adults that consume a high fat diet;
however, the extrapolation of such results has to be cautious, considering the difference
between FMD assessed in the fasted and in the postprandial state are still not elucidated.
Although a 1.14% change may be considered small in healthy, normal weight young adults,
this magnitude of effect is of higher clinical significance for individuals in the present study,
who had a BMI >30kg/m2 and were aged >65 years, two factors related to impaired brachial
artery FMD(42,284,290). In the current study, the postprandial difference of 1.14% represents
a 36.7% higher FMD in the anthocyanin compared to the control arm. Similar findings were
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observed in a double-blind, randomized, crossover study (conducted in 23 male participants,
aged 46y SD 1.9, BMI of 27.6 kg/m2 SD 0.4) that investigated postprandial effects of an açaí
smoothie following a HFHE meal challenge compared to a control smoothie matched by
macronutrients and vitamin C(229). In that study, the intervention arm was provided more than
a twofold (493mg) quantity of anthocyanins than that provided in the current trial but a similar
improvement was observed in postprandial FMD after 2h (1.4% vs 0.4% for intervention vs
control smoothie; P = 0.001)(229). The immunomodulatory(21,23) and antioxidant
effects(23,125,268,271) of anthocyanins, as well as their capacity to upregulate eNOS mRNA
and NO synthesis(126,144,269,270), are the proposed mechanisms to exert this vascular
protective effect against the potential pro-inflammatory and oxidative stress state caused by the
HFHE meal. However, NO is a highly reactive molecule with a short half-life, which
complicates its direct measurement(291), and the evaluation and implication of its metabolites
remains challenging in vascular biology research(292). Concerning the peak shear rate, there
were no significant changes between treatment arms before and after the HFHE meal challenge.
Participants had an identical peak shear rate before the HFHE meal, followed by a slightly
postprandial decrease in both conditions.
In additional to effects on macrovascular function, we observed significant changes for
microvascular reactivity tests. Flow-mediated dilatation and PORH both rely on measuring the
transient increase in blood flow following the release of a brief occlusion; however, while FMD
assesses changes in diameter of the brachial artery induced by shear stress in the artery
wall(293), PORH assesses the cutaneous perfusion in the microvasculature, in this case in areas
of the skin of the forearm(96). In the present trial, both the PV and PORHmax parameters were
reduced after the high-fat meal challenge in both groups, but there was a significantly lower
reduction when anthocyanins were consumed with the meal, indicating a preventative effect of
anthocyanins in HFHE meal-induced changes in these parameters. Unlike FMD, the effects of
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anthocyanin consumption on LSCI microvascular parameters and CVD outcomes have not yet
been explored in larger studies. To our knowledge, this is the first study to report the results of
LSCI microvascular parameters along with FMD following a dietary intervention. Our findings
suggest that underlying mechanisms associated with the observed effects might be due to
common mechanisms between different vascular beds. The mechanisms underlying the
vascular reactivity in the PORH test are still being elucidated, but many mediators seems to
contribute to vasodilation and although most of these responses are endothelial-dependent, NO
and COX pathways do not appear to exert significant influences(102,103). The major
contributors for peak and time course of this microvascular reactivity are the sensory nerves
through an axon reflex response(95). The endothelium-derived hyperpolarizing factors
(EDHF) are also involved, including large-conductance calcium-activated potassium channels
(BKCa) stimulated by epoxyeicosatrienoic acids(93,104). Therefore, we also utilised LSCI
technology with iontophoresis of acetylcholine to assess a more specific endothelial
microvascular reactivity response related to NO availability(96). However, the cutaneous
perfusion following iontophoresis of acetylcholine was not altered in either of the study arms.
This may be in keeping with the finding that the NO response associated with endothelial
function decreases with age, while other pathways are preserved(294–296).
The inflammatory response is a fundamental component of atherosclerosis and is
related to the development of CVD,(190,277) with low grade continuous inflammation
occurring in association with adiposity(297) and aging (“inflammaging”)(298). Higher proinflammatory cytokine concentrations are also associated with decreased health-related quality
of life in older adults(299). For these reasons, the target population for the current study was
older adults who were overweight or obese. The ability to suppress a persistent inflammatory
state is important to attenuate the progress of atherosclerotic disease(277,278). A large number
of in vitro and animal studies(21,121,127,139) provide insight into these mechanisms related
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to the anti-inflammatory actions of anthocyanins. These include: (1) modulation of arachidonic
acid metabolism, in which lipid mediators that regulate inflammation (e.g. prostaglandins and
leukotrienes) are modulated by anthocyanins through inhibition of the key enzymes
cyclooxygenases and lipoxygenases; (2) decreased activity of the NF-κB pathway, which is a
transcription factor responsible for triggering and regulating inflammatory processes that lead
to the expression of pro-inflammatory cytokines and enzymes; (3) suppression of acute proinflammatory genes that regulate inducible nitric oxide synthase (iNOS), an enzyme
responsible for moderating some of the production of nitric oxide (NO). hs-CRP has emerged
as a major marker of vascular inflammation playing a direct role in promoting endothelial
dysfunction(65,66) and clinical CVD events(67,68,297). In the present trial, we found a
significant interaction effect between time and treatment for serum hs-CRP. Breaking down
this simple effect, we showed no significant influence of time and a significantly lower hs-CRP
concentration at the 4h post-prandial time point in the anthocyanin arm, as well as a trend for
lower concentrations at the fasted state and at the 2h post-prandial time point. An ability of
food-based anthocyanins to reduce hs-CRP concentrations in a population with risk factors
such as advanced age and high BMI, could be of major clinical benefit regarding attenuation
of the “inflammaging” process and chronic low-grade inflammation.
A systematic review of the literature examining the postprandial inflammatory response
to a HFHE meal challenge reported consistent robust increases in IL-6 across studies, while
IL-1β and TNF-α did not appear to transiently and/or robustly change in the postprandial
period(244). Among the six studies(37,231,233–236) that evaluated the effect of food
anthocyanins on post-prandial IL-6

concentrations, three studies(37,231,236) reported

significant reductions in postprandial concentrations when compared to the control group. In
the present trial, no significant main or simple effects were evident for serum concentration of
IL-6; however, a trend was observed in the main effect of treatment, as well as significantly
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lower IL-6 concentration at the 4h post-prandial time point (P=0.009). IL-6 has a high
expression on vascular endothelium(64) and although IL-6 possess both pro- and antiinflammatory properties(300), it is an independent contributor to variations in endotheliumdependent vasodilatation(301). Our results demonstrate changes associated with food-based
anthocyanins on hs-CRP and IL-6 concentrations, which combined could indicate reduced
vascular inflammation. Such findings may have positive implications in the progression of
atherosclerosis and CVD events in this high risk group. Further studies are required to better
elucidate the different clinical implications between fasted and post-prandial serum
concentration of such biomarkers. Similar to other studies(244), serum concentrations of IL1β and TNF-were not altered after the HFHE meal challenge by any treatment. Only a small
number of studies (one(231) out of four(37,231,233,234)) that investigated TNF-α response to
a meal challenge found that the anthocyanins prevented a postprandial rise of concentrations,
while no significant effects were found for IL-1β in these studies(37,231,233,234).
Serum DROM was evaluated in the present trial as a marker of oxidative stress. DROM
is increased in patients with coronary artery disease and is also associated with cardiovascular
events, thus could provide clinical benefits for risk stratification of coronary artery disease
where higher DROM place a person at greater risk(302). We found a significant time effect in
serum concentrations of DROM, indicating postprandial oxidative stress induced by the HFHE
meal; however, no significant difference between treatment arms was found. This same
response was observed for systolic and diastolic blood pressure, as well for total cholesterol
and triacylglycerol. Similar to our findings, no significant changes in postprandial systolic
blood pressure were reported in 3 studies(229,238,239) following a food anthocyanin
intervention, except for one study that found a reduction in diastolic blood pressure(239). A
large number of studies(231–240) that evaluated postprandial total cholesterol and
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triacylglycerol also reported no changes, while only two studies found a reduction in
triacylglycerol(233,239) concentrations and total cholesterol(231,239).
The urinary analyses demonstrated higher concentrations of total anthocyanins and
hippuric acid biomarkers in 24h urine following consumption of the intervention and control
juices, confirming the uptake and metabolism of these compounds from the anthocyanin-rich
plum juice. The absence of anthocyanins in the urine corresponding to the control arm confirms
the anthocyanins dietary restriction during the 4-day run-in period, the lack of anthocyanins in
the control juice, as well as a sufficient wash-out period. A large variation in the excretion of
both anthocyanin and phenolic acid biomarkers reflects the large intra-individual variation in
the metabolism of anthocyanins and flavonoids46,85. The lack of significant difference between
the arms for protocatechuic acid and ferulic acid may reflect the potential presence of other
flavonoids in the background diet and in the control (apricot) juice.
Limitations in the present study include the different numbers of females and males
enrolled, thus precluding sub-analysis by gender; however, the small number of males included
in the study had similar scores to females and the exclusion of them for sensitivity analyses did
not alter the significance of any of the results. A further limitation was the impossibility to
repeat the FMD and microvascular reactivity tests in case of experimental errors (participant
movement during the tests) due to the protocol of measures being collected at specific time
points. This resulted in a small sample size reduction for the FMD and PORH test (n=1) and
the iontophoresis of acetylcholine (n=3). Concerning the evaluation of endothelium and nonendothelium mechanisms in vascular and microvascular reactivity, we were not able to conduct
nitrate-mediated dilation nor iontophoresis of sodium nitroprusside due to temporal reasons,
considering it would be not viable, if not impossible, in a postprandial study to conduct a
protocol with all of these measures. Discussion of the results is therefore based on the tests that
were conducted and the elucidated underlying mechanisms described in the literature. Another
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limitation is that there were no measures before the start of the 4 day run-in period, and despite
that there was no significant difference in baseline, the 4 day run in period might have
modulated a few parameters in the anthocyanins group, and therefore facilitating the significant
post-prandial difference between the treatment arms. On the other hand, this design simulates
a daily diet routine, in which individuals could be constantly eating random sources of
anthocyanins, or still consuming supplements or food items on a daily basis that continuously
exposes them to many bioactive compounds. This allowed us to investigate the postprandial
effect of a continuous anthocyanins stimulus, while at the same time, avoid an overestimated
effect in a ‘super controlled’ setting.
An important strength and key feature in the design of this study should be considered
for interpretation of the results, as well as for comparison with other post-prandial studies. It is
challenging to investigate a specific bioactive compound, such as a specific flavonoid, in a
clinical trial using foods as vehicles for delivery. A food item that is a rich source of a particular
flavonoid may also contain other classes of flavonoids or still other bioactive compounds, such
as other polyphenols, and/or inorganic compounds (such as nitrate) that might have similar or
synergistic effects on the outcomes to those being assessed. In order to address this issue, the
choice of the placebo food item for the control arm is an important consideration. A placebo
that is only matched in macro, or even micronutrient content, can underestimate the effects of
other bioactive compounds. In this study, we aimed to evaluate the acute effect of a high dose
of anthocyanins using Queen Garnet plum juice as the food source. In order to isolate the effect
of the anthocyanins, we chose apricot juice as the control due to its lack of anthocyanins, but
its similarly matched macro- and micronutrient content, as well as its polyphenol profile(281),
that includes flavanols (such as quercetin), catechins and epicatechins, all of which are potential
mediators of cardiovascular health(200,303–305). The choice of this control juice is novel in
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that the effects of the flavonoid subclass of anthocyanins can be isolated from other bioactive
compounds.

4.5 Conclusion
The postprandial effects of food anthocyanins improved several CVD biomarkers in
overweight older adults following a HFHE meal challenge. Potentially beneficial effects were
observed in parameters of both macrovascular and microvascular function, as well as some
inflammatory biomarkers. The HFHE meal challenge induced increases in postprandial blood
pressure, DROM, triacylglycerol and total cholesterol; however, anthocyanin consumption did
not attenuate these responses. Our findings may have a relevant role in the cardiovascular
health of this high-risk group considering the major role of the vascular endothelium and the
inflammatory response in the atherosclerosis disease and CVD events. Further studies are
required to better elucidate the clinical implications of post-prandial biomarkers of CVD.

4.6 Supplementary Material
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Figure 4-S1. Cutaneous perfusion recorded with laser speckle contrast imaging during postocclusive reactive hyperaemia.
BF, baseline flow; BZ, biologic zero; PV, peak value
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Table 4-S1. Description of Post-Occlusive Reactive Hyperaemia Microvascular Parameters
MICROVASCULAR PARAMETER
Baseline flow (BF)

Biologic zero (BZ)
Resting flow (RF)

DESCRIPTION
The most stable 15 seconds within the first 2
minutes of reading.
The most stable 3 seconds displaying the lower
values before the deflation of the cuff.
BF-BZ
Five seconds period starting from the highest

Peak perfusion value (PV)

value in the first rise (slope) after deflation of
the cuff

PORHmax
Area under the curve (AUC)

PV – RF
Area under the curve comprising of 60 seconds
after deflation of the cuff

PORHmax, post-occlusive reactive hyperaemia maximum perfusion.
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Table 4-S2. Correlations between baseline vascular parameters and inflammatory biomarkers

IL-1β

IL-6

TNF-α

hs-CRP

Peak
value
PORH
max
IONT
max
FMD

IONT
max

FMD

Peak
shear
stress

IL-1β

IL-6

TNF-α

hs-CRP

Peak value

PORH
max

Correlation Coefficient
Sig. (2-tailed)
N
Correlation Coefficient
Sig. (2-tailed)
N
Correlation Coefficient
Sig. (2-tailed)
N

1.000
.
16
.505
.046
16
.594
.015
16

.505
.046
16
1.000
.
16
.469
.067
16

.594
.015
16
.469
.067
16
1.000
.
16

-.265
.341
15
.039
.889
15
-.136
.629
15

-.052
.849
16
-.043
.875
16
-.026
.922
16

-.032
.905
16
.018
.948
16
.021
.940
16

-.480
.114
12
.161
.618
12
-.469
.124
12

.272
.326
15
.220
.431
15
.121
.666
15

.324
.238
15
-.334
.223
15
.007
.980
15

Correlation Coefficient
Sig. (2-tailed)
N
Correlation Coefficient
Sig. (2-tailed)
N
Correlation Coefficient
Sig. (2-tailed)
N

-.265
.341
15
-.052
.849
16
-.032
.905
16

.039
.889
15
-.043
.875
16
.018
.948
16

-.136
.629
15
-.026
.922
16
.021
.940
16

1.000
.
15
.434
.106
15
.209
.454
15

.434
.106
15
1.000
.
16
.944
.000
16

.209
.454
15
.944
.000
16
1.000
.
16

.123
.719
11
.336
.286
12
.413
.183
12

.064
.829
14
.461
.084
15
.421
.118
15

-.007
.982
14
.346
.206
15
.211
.451
15

Correlation Coefficient
Sig. (2-tailed)
N
Correlation Coefficient
Sig. (2-tailed)

-.480
.114
12
.272
.326

.161
.618
12
.220
.431

-.469
.124
12
.121
.666

.123
.719
11
.064
.829

.336
.286
12
.461
.084

.413
.183
12
.421
.118

1.000
.
12
-.247 a
.464

-.247 a
.464

-.443 a
.172

11
1.000
.

11
.286 a
.301
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Peak
shear
stress

N
Correlation Coefficient
Sig. (2-tailed)
N

15
.324
.238
15

15
-.334
.223
15

15
.007
.980
15

14
-.007
.982
14

15
.346
.206
15

15
.211
.451
15

11
-.443 a
.172
11

15
.286 a
.301
15

15
1.000
.
15

IL-1β, interleukin-1 beta; IL-6, interleukin-6; TNF-α. Tumour necrosis factor alpha; hs-CRP, high-sensitivity c-reactive protein; PORHmax,
post-occlusive reactive hyperaemia maximum perfusion; IONTmax, maximum perfusion following iontophoresis of acetylcholine; FMD, flowmediated dilatation.
All correlations derived from Spearman's rank correlation coefficient, unless described elsewhere.
a

Correlations derived from Pearson correlation coefficient.
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Table 4-S3. Additional data from microvascular parameters
Parameter

Group

Baseline

2h

PORH PV

Control

103.7 (SD 14.1)

88.5 (SD 14.5)

(PU) n=15

Anthocyanins

105.3 (SD 17.1)

91.3 (SD 12.6)

PORH BF
(PU) n=15

Control

42.5 (SD 5.6)

42.5 (SD 6.7)

Anthocyanins

42.6 (SD 7.5)

42.2 (SD 9.7)

PORH BZ

Control

16.2 (SD 6.0)

15.9 (SD 5.3)

(PU) n=15

Anthocyanins

15.0 (SD 4.6)

16.8 (SD 6.2)

PORH RF

Control

0.31(SD 0.07)

0.32 (SD 0.07)

(cvc) n=15 Anthocyanins

0.32 (SD 0.05)

0.31 (SD 0.08)

IONT BF

0.35 (SD 0.08)

0.36(SD 0.11)

(cvc) n=13 Anthocyanins

0.33 (SD 0.07)

0.33 (SD 0.08)

IONT PV

0.80(SD 0.23)

0.80(SD 0.28)

0.75 (SD 0.26)

0.74 (SD 0.24)

Control

Control

(cvc) n=13 Anthocyanins
AUC (PU)

Control

3968.7 (SD 437.4)

3731.3 (SD 493.3)

n=14

Anthocyanins

3941.5 (SD 591.9)

3783.9 (SD 542.5)

AUC (cvc)

Control

0.0216 (SD 0.004)

0.0222 (SD 0.003)

n=14

Anthocyanins

0.0218 (SD 0.003)

0.228 0.003)

Data are mean and standard deviation or median and interquartile range. PORH, postocclusive reactive hyperaemia; PU, perfusion units, BF, baseline flow; RF, resting flow; IQR,
interquartile range; cvc, cutaneous vascular conductance in PU/mmHG; BZ, biologic zero;
SD, standard deviation; PV, peak value; AUC, area under the curve.
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Table 4-S4. Urinary concentrations of total anthocyanins and phenolic acid biomarkers from
a 24-hour pooled urine sample from the control and intervention arms.
Intervention

Control

Within-subject
contrasts a

Total
Anthocyanins
(ng/mL)

1.86
(IQR 3.23)

0.015
(IQR 0.12)

F(1,15)=27.44,
P<0.001, ηp2=0.647

Protocatechuic
acid (ng/mL)

86.78
(IQR 362.2)

20.08
(IQR 179.65)

F(1,15)=0.680,
P=0.423, ηp2=0.043

Hippuric acid
(µg/mL)

1565.70
(SD 912.89)

1022.36
(SD 322.21)

F(1,15)=6.05,
P=0.027, ηp2=0.287

Ferulic Acid
(ng/mL)

12.04
(IQR 72.22)

40.69
(IQR 65.09)

F(1,15)=0.752,
P=0.733, ηp2=0.008

Parameter

Values are mean and standard deviation (SD) or median and interquartile range (IQR)
a

P-values from repeated measures ANOVA; ηp2, partial eta-squared;

Total anthocyanins expressed as cyanidin-3-O-glucoside equivalents (CGE)
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CHAPTER 5: Food anthocyanins decrease serum concentrations
of TNF-α in older adults with mild cognitive impairment: a
randomized, controlled, double blind clinical trial.

There are still several gaps to be addressed regarding the effects of anthocyanins on the
vascular-inflammatory axis in older adults, especially among those with neurodegenerative
diseases, such as mild cognitive impairment (MCI), a condition that shares pathological
mechanisms with CVD. This is particularly evident in older adults, as several studies support
a gradual loss of the vascular function, and a new immune-metabolic viewpoint for age-related
diseases, termed ‘inflammaging’ which is characterized by a chronic low-grade inflammation.
Therefore, the present trial aimed to evaluate the chronic effects of food anthocyanins (8 weeks)
on the microvascular function, inflammatory biomarkers and 24 h ambulatory blood pressure
(ABP) in older adults with diagnosis of MCI.
A daily high dose of fruit-based anthocyanins (201 mg) for 8 weeks reduced concentrations
of TNF-α in older adults with MCI. Anthocyanins did not alter other inflammatory biomarkers,
microvascular function or blood pressure parameters, while an overall lack of effects were
observed in the low dose (47 mg) group.
Considering the major role of the inflammatory response and vascular function in CVD and
cognitive decline, this novel data may present relevant clinical implications in this high-risk
group; however, further studies with a larger sample size and longer period of follow-up are
required to better elucidate whether these changes in inflammatory biomarkers will alter CVD
risk and progression of cognitive decline.
The majority of this chapter forms the substantive content of a published article
(Appendix D).
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5.1 Introduction
Vascular function, blood pressure and inflammation are a triad of factors relevant to the
pathogenesis of several major chronic diseases, including cardiovascular disease
(CVD)(306,307), and neurodegenerative conditions, such as mild cognitive impairment
(MCI)3,4. The endothelium can be considered an organ that regulates vascular homeostasis by
maintaining an appropriate vascular tone, platelet activity, leukocyte adhesion, and
angiogenesis. When one or more of these components is compromised due to impaired
endothelial vascular signalling, endothelial dysfunction (ED) may occur(306). In addition to
hypertension and ED, the inflammatory response mediates several CVD related underlying
mechanisms5,6. The association between concentrations of pro-inflammatory cytokines, such
as CRP, IL-6 and TNF-α, and the development of atherosclerosis and CVD is well
established5,7. There is evidence to suggest that directly targeting inflammation may be
beneficial for the secondary prevention of CVD, and that such benefits may be independent of
traditional CVD risk factors, such as cholesterol8,9. The role of inflammatory cytokines
provides a mechanism through which risk factors for atherosclerosis may alter arterial biology,
and thereby result in a systemic pro-atherothrombotic milieu8. This is particularly evident in
older adults; several studies support a new immune-metabolic viewpoint for age-related
diseases termed ‘inflammaging’, characterized by a chronic, low-grade inflammatory
response10,11. Furthermore, there is evidence that diseases of the cardiovascular system, such
as stroke, atrial fibrillation, coronary heart disease (CHD), and heart failure are linked to
cognitive decline12. A meta-analysis of 10 prospective cohort studies showed that CHD was
associated with increased risk of cognitive impairment or dementia (OR = 1.45, 95%CI = 1.21–
1.74, p<0.001)13. Several mechanisms underlying the association between CVD and cognitive
decline have been proposed: [1] shared risk factors, which might alter clearance of brain toxins
or otherwise increase neurodegeneration; [2] CVD might lead to clinical or subclinical strokes,
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leading to cognitive impairment; and [3] CVD might directly alter cerebral perfusion14. In this
context, interventions aiming to regulate the CVD risk factors are also relevant therapeutic
targets to attenuate cognitive decline.
Potential nutritional therapeutic options are emerging, with anthocyanins, a subclass of
flavonoids, showing promising benefits related mainly to immunomodulatory, vascular
signalling and antioxidant effects(21), thereby blunting the cooperative and synergistic
deleterious effects of oxidative stress and inflammation5,16. Anthocyanins are the largest class
of water-soluble plant pigments that are responsible for the blue, purple and red colour of many
fruits and vegetables, such as blueberries, blackberries, red grapes, plums and eggplants17. A
large number of in vitro and animal studies(21,317–319) provide insight into these mechanisms
related to the anti-inflammatory actions of anthocyanins. These studies also observed a
potential positive effect on vascular function through the suppression of acute proinflammatory genes that regulate inducible nitric oxide synthase (iNOS), an enzyme
responsible for moderating some of the production of nitric oxide (NO)21, as well as attenuating
endothelium‐dependent dysfunction by anthocyanins metabolites20.A meta-analyses of
randomized clinical trials (RCT) observed an improvement in vascular reactivity measured by
flow-mediated dilation (FMD) among 6 studies ranging from one week to six months of
intervention, with anthocyanin daily doses of 12 to 320mg22. Concerning lipid profiles and
blood pressure, a systematic review of 12 RCT (3-24 weeks of duration and dose range of 7.35–
640 mg/day of anthocyanins) identified a significant effect only on lowering LDL-c among
diseased individuals or those with elevated biomarkers23. Both reviews22,23 did not find a doseresponse relationship in the cited RCTs, nor evidence of adverse effects of anthocyanins within
those concentrations. Therefore, the relevant concentration of anthocyanins required to produce
physiologically relevant is still to be elucidated.
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Among non-invasive techniques to measure endothelial function, Laser Speckle
Contrast Imaging (LSCI) is a relatively new technique that provides a non-invasive index of
blood flow in the microcirculation24. This technique, combined with dynamic tests such as
post-occlusive reactive hyperaemia (PORH), is able to provide information on several different
aspects of microvascular physiology25. Measuring 24-hour ambulatory blood pressure (ABP)
has several benefits over traditional single assessment, such as minimising white-coat
phenomena and masked hypertension, and demonstrating nocturnal hypertension and loss of
normal dipping patterns26. ABP monitoring is a stronger predictor of cardiovascular morbidity
and mortality than most traditional BP measuring techniques26–28.
This paper provides secondary analysis of a clinical trial that investigated the effect of
combining a cognitive training rehabilitation program with a dietary intervention focusing on
increasing anthocyanin intake in older persons with MCI. The aim of the current analysis is to
investigate the effects of a nutritional intervention consisting of 8 weeks of food-anthocyanins
on inflammatory markers associated with CVD risk factors(277,278), along with analysis of
microvascular function and 24-hour ABP in older adults with MCI.

5.2 Methods
The clinical trial was conducted according to the guidelines of the Declaration of
Helsinki, and approved by the joint University of Wollongong and Local Health District
Human Research Ethics Committee, New South Wales, Australia (HREC 2017/581). The study
was

registered

with

the

Australian

New

Zealand

Clinical

Trials

Registry

(ACTRN12618001184268). This manuscript is reporting results from the secondary outcomes,
while the primary outcome related to cognitive function will be reported elsewhere. Written
informed consent was obtained from all subjects before beginning the study procedures.
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Study Subjects
A total of 34 subjects enrolled in the study between April 2018 and November 2019.
The inclusion criteria were: 55+ years; diagnosis of MCI-amnesic type with memory
complaints, Mini Mental State Examination (MMSE) score of 24 or above, and estimated
premorbid IQ of more than 80, confirmed by clinical psychologists (ZF, SB, AP). A diagnosis
of MCI was given when an individual experienced cognitive change (typically 1 to 1.5 standard
deviation below age and education matched peers on culturally appropriate normative data) in
one of more cognitive areas that are insufficient to interfere with activities of daily living and
without progressive deterioration. All subjects were participating in a 6 week ‘Making the most
of your Memory’ rehabilitation group. Exclusion criteria were: a diagnosis of dementia;
significant neurological history, untreated hypertension or diabetes; chronic liver or renal
disease; smoking; diagnosis or self-reported gastrointestinal disorders; acute upper respiratory
tract infection; allergy to stone fruits or food colorants.

Study Design and Treatments
The study was a randomized, controlled, double-blind clinical trial conducted at the
Illawarra Health and Medical Research Institute and at the Port Kembla Hospital, NSW
Australia. On test days, participants attended the research facility for the study procedures after
a 12 hour overnight fast (Figure 5-1). Briefly, the PORH test (microvascular reactivity) and
blood collection were completed before provision of a standardized breakfast (minimal
anthocyanin-containing cereals, milk, bread, butter and anthocyanin-free fruit jam), followed
by collection of data including socio-economic status, anthropometry, medication use and
dietary intake.
The usual diet was assessed using a 3-day food record that participants were instructed by a
dietitian to complete at home (Table 5-1) and analysed using Foodworks 10 (Xyris Software,
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Australia), which includes the Australian Food Composition Database 2019(325). The
anthocyanins content was calculated using the ‘PhenolExplorer’ polyphenol food composition
database(206). Participants were instructed to maintain their usual diet throughout the course
of the study.
Participants were fitted with a 24-hour ambulatory blood pressure monitor which was
collected from their home the following day. Participants were randomly allocated to one of
three dietary interventions (250 ml/day): a) low-anthocyanins Queen Garnet Plum (QGP) juice;
b) high-anthocyanins QGP juice; c) apricot juice (control). Juice was supplied weekly to
participants when they attended the memory clinic. The duration of the dietary intervention
was 8 weeks, after which time participants returned to the research facility for the final data
collection. Compliance was measured by requesting the empty bottles from participants.
Block randomization (3x3) was conducted by a researcher independent to the data
collection or enrolment of participants using a computer generated randomization sequence.
Blinding strategies included colouring of control juice, as well as advertising and consenting
participants to a “fruit juice study” without providing information on which fruit was being
investigated.
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Figure 5-1. Study design and procedures. PORH, post-occlusive reactive hyperaemia; ABP,
ambulatory blood pressure; QGP queen garnet plum.

Table 5-1. Dietary intake of participants at baseline, assessed using 3-day food records.
Control

Low
anthocyanins

High
Anthocyanins

All

14

9

6

29

2170.4 SD

2072.1 SD

2040.8 SD

2113.1 SD

745.1

495.8

177.2

580.4

Protein (g)

103.2 SD 38.6

95.0 SD 28.6

88.9 SD 10.5

97.7 SD 31.3

0.634

Fat – total (g)

86.7 SD 35.9

72.1 SD 26.4

72.8 SD 17.5

79.3 SD 30.1

0.453

Saturated fat (g)

35.9 SD 18.1

29.8 SD 13.0

31.0 SD 8.6

33.0 SD 14.9

0.608

Carbohydrates (g)

227.3 SD 79.9

239.4 SD 52.0

236.4 SD 32.3

233.0 SD 62.9

0.900

Dietary fibre (g)

28.2 SD 13.4

26.5 SD 10.0

28.1 SD 7.3

27.6 SD 11.1

0.934

2619.5 SD

2468.4 SD

2082.7 SD

2461.4 SD

1434.4

567.2

397.2

1057.6

Vitamin C (mg)

90.4 IQR 99.9

76.1 IQR 59.7

Vitamin E (mg)

9.6 IQR 5.4

8.2 IQR 6.3

Vitamin A* (µg)

881.2 IQR 529.4

n
Energy (kcal)

Sodium (mg)

101.7 IQR

Pvaluea

0.880

0.599

86.7 IQR 85.6

0.546

8.3 IQR 1.5

9.0 IQR 4.8

0.441

611.5 IQR

887.7 IQR

807.7 IQR

767.5

330.5

590.7

122.5

Anthocyanins

2.7 IQR 22.5;

3.6 IQR 17.8;

1.4 IQR 5.4;

43.1 IQR 82.8;

(mg)

13.9 SD 22.9

68.1 SD 188.3

73.3 SD 101.5

43.1 SD 114.2

0.875

0.426

Values are mean and standard deviation or median and interquartile range. aP-value for one-way
ANOVA among the three treatments; * Total Vitamin A equivalents. Values obtained from the
Australian Food Composition Database 2019(325). Anthocyanins content values obtained from the
‘PhenolExplorer’ polyphenol food composition database(206).

Intervention and control juices
The low-anthocyanins QGP juice consisted of 99% fruit and 1% water that went
through a high pressure-low temperature treatment. The high-anthocyanins QGP juice was a
blend of 220g of frozen QGP with 30mL of water added. The anthocyanin content of both
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juices were analysed by the Queensland Department of Agriculture and Fisheries (DAF,
Australia) by Performance Liquid Chromatography (HPLC) and the pH differential method,
following the AOAC 2005.02 protocol. An apricot juice was chosen as the control arm due to
similar consistency, nutritional content and flavonoid content(282) to the QGP juice, but
without anthocyanins. Food dyes (red and blue) were added to the apricot juice to closely
approximate the colour of the QGP juice. The total anthocyanins content for the 250 mL bottle
of low-anthocyanins QGP juice was 48 mg based on the HPLC method and 44 mg based on
the pH differential method, while the total anthocyanins content for the 250 mL bottle of
untreated QGP juice was 201 mg based on the HPLC method and 207 mg based on the pH
differential method. Additional nutritional information of the fruit juices can be found in the
supplementary material (Table 5-S1).

Blood samples
Pre and post (baseline and 8 weeks) fasted plasma and serum samples were collected
in the morning, following the microvascular reactivity test, and then stored at -80 °C, prior to
analysis. IL-1β, IL-6 and TNF-α were analysed in a Luminex 200 using a Human High
sensitivity T cell magnetic bead panel kits (Merck Millipore, Billerica, MA, USA). High
sensitivity CRP was analysed on a BK400 automated chemistry analyser using a
immunoturbidometric assay (Biobase, Shandong, China).

24-hour ambulatory blood pressure
The 24-hour ambulatory blood pressure was measured using an automated Welch Allyn
ABPM 7100 (Welch Allyn, NSW, Australia). Participants were fitted with the device and
appropriate instructions were provided(322). Participants were asked to record any moderate
or intense physical activity. Criteria for measurements errors include the exclusion of the
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following measures: 70 mmHg ≤ SBP ≤ 250 mmHg and 30 mmHg ≤ DBP ≤ 130 mmHg.
Daytime blood pressure was defined as 09-21h and night-time as 11-05h. The “dipping” pattern
was calculated using a ratio of night-time/daytime blood pressure(322).

Microvascular function
Participants were rested in a quiet, controlled temperature room 23 °C ±1, in a supine
position for 15 minutes. Blood pressure was measured before the PORH test procedure using
a Welch Allyn Connex 6700 Vital Signs Monitors (Welch Allyn, NSW, Australia), according
to clinical guidelines(283). Microvascular cutaneous vascular reactivity was measured by using
LSCI (Pericam PSI System, Perimed AB, Järfälla, Sweden), The baseline perfusion was
measured in the volar side of the left forearm for 2 minutes, followed by the PORH test: an
arterial occlusion was maintained for 3 minutes using a BP cuff around the upper arm inflated
to a pressure of 50-60 mmHg above systolic BP reading; after the BP cuff was released, the
PORH response was recorded for 3 minutes. The following parameters were extracted: baseline
flow (BF), biological zero (BZ) and peak value (PV). The PV was obtained with a 5 second
“time of interest” starting from the highest value after deflation of the cuff(326). RF was
calculated as BF – BZ. The maximum PORH perfusion (PORHmax) was calculated as PV –
RF (Supplementary Figure 5-S1 and Table 5-S2. By international convention all parameters
are expressed in arbitrary Perfusion Units (PU). Microvascular flow parameters were then
transformed to cutaneous vascular conductance (CVC) by dividing mean arterial pressure to
yield CVC in PU/mmHg. This PORH protocol is routinely performed in our laboratory; with
intra-subject coefficients of variation of 7.7% for PV and 11.4% for PORHmax. Additional
LSCI data combined with the PORH test are listed in the supplementary material
(Supplementary Table 5-S3).
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Statistical Analyses
Data are presented in mean and standard deviation (SD) or median and interquartile
range according to data distribution. Natural log transformation was used to normalize the data,
where appropriate. Differences in the baseline demographics among the treatment groups were
investigated by one-way ANOVA and chi-squared tests. Outliers were graphically inspected
and exclusions were conducted with Z-scores >2.5 or modified Z-scores >3.5. A two-way
mixed [1 between-subject factor with 3 levels (treatment) and 1 within-subject with 2 levels
(time)] ANOVA was used to investigate the outcomes and significant effects were followed by
corrected post-hoc pairwise comparisons(327,328). Parameters with significant baseline
between-group imbalances (IL-6 and IL-1β) were further inspected using ANCOVA(329,330).
The Kruskal-Wallis test was used to inspect results from ANOVA tests conducted with data
with normality concerns. SPSS (version 25 SPSS Statistic Subscription, IBM, Chicago, IL,
USA 2019) was used for all statistical analyses. Significance was accepted at alpha p<0.05,
and non-significant p values between p=0.05-0.099 were considered a trend in the data. Posthoc power analysis were conducted for each parameter that had a significant result or trend.

5.3 Results
A total of 47 participants were assessed for eligibility and 31 participants (19 female
and 12 male) out of 34 enrolled participants completed the trial (Figure 5-S2). Two withdrawals
were related to the participants reporting that the study was too onerous and one withdrawal
was related to an underlying gastrointestinal condition that made the juice consumption
unviable. Baseline mean age and BMI of participants were 75.3 (SD 6.9) years and 26.1 (SD
3.3) kg/m2, respectively. Additional baseline demographics are listed in Table 5-2.
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Table 5-2. Baseline demographics
Control

Low
anthocyanins

High
Anthocyanins

All

n

14

10

7

31

Gender (M/F)

5/9

6/4

1/6

12/19

0.043

Age (years)

74.9 (SD 7.8)

76.1 (SD 6.7 )

75.1 (SD 6.1)

75.3 (SD 6.9)

0.875

BMI (kg/m2)

25.2 (SD 3.1)

27.1 (SD 2.3)

26.6 (SD 4.7)

26.1 (SD 3.3)

0.377

Hypertensionb

5 (35.7%)

4 (40%)

4 (57%)

13 (41.9%)

0.637

Day SPB (mm
Hg)

127.9 (SD 17.9)

128.1 (SD 13.9)

128.5 (SD 16.9)

128.1 (SD 15.9)

0.997

Day DPB (mm
Hg)

78.4 (SD 10.0)

78.6 (SD 8.7)

80.2 (SD 12.5)

78.9 (SD 9.9)

0.928

SPB night/day
ratio

0.89 (SD 0.04)

0.90 (SD 0.09)

0.98 (SD 0.08)

0.92 (SD 0.08)

0.112

DPB night/day
ratio

0.89 (SD 0.09)

0.88 (SD 0.09)

0.95 (SD 0.12)

0.91 (SD 0.10)

0.362

P-valuea

BMI, body mass index; SPB, systolic blood pressure; DPB, diastolic blood pressure. aP-value for oneway ANOVA or chi-square test among the three treatments; b Participants with controlled hypertension
taking anti-hypertensive drugs.

Inflammatory biomarkers
A significant time and treatment interaction effect was found for serum concentrations
of TNF-α [F(2,27)=7.739, P=0.002, ηp2=0.364] with post-hoc analysis indicating a power of
99.2% The breakdown of this interaction showed a lower TNF-α in the high anthocyanins
group (7.60 pg/mL SD 3.18) vs controls (11.00 pg/mL SD 3.51) after 8 weeks of intervention
(P=0.047, independent t-test) (Figure 5-2a). Regarding serum concentrations of IL-6, there was
a significant treatment effect (P=0.013), a trend towards an effect of time (P=0.096) and a trend
for an interaction effect [F(2,21)=2.933, P=0.075, ηp2=0.218]; however, post-hoc analysis
indicated a power of 44.6%. Baseline IL-6 was higher in the high anthocyanins group when
compared to the low anthocyanins group or controls (P<0.001 and P=0.009, respectively,
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independent t tests), but between-group differences were not significant after 8 weeks of
intervention (P>0.05) with a 36.6% decrease in IL-6 levels in the high anthocyanins group from
baseline to 8 weeks (Figure 5-2b). An ANCOVA adjusting for baseline imbalances identified
no significant treatment effect (P>0.05). The values of IL-1β were natural log transformed to
approximate a normal distribution. There were significant time and treatment effects (P=0.022
and 0.038), and a trend for an interaction effect [F(2,27)=2.972, P=0.068, ηp2=0.180], however,
post-hoc analysis indicated a power of 42.3%. Similar to IL-6, baseline serum concentration of
IL-1β was higher in the high anthocyanins group, compared to the low anthocyanins group or
controls (P=0.025 and P=0.019, respectively, Mann-Whitney test), but not significant between
groups after treatment (P>0.05), with a 23.3% decrease in IL-1β observed in the high
anthocyanins group over time (Figure 5-2c). A Kruskal-Wallis test confirmed that differences
between treatment groups at baseline (P=0.028) were no longer significant after 8 weeks of
treatment (P=0.153). An ANCOVA adjusting for baseline imbalances identified no significant
treatment effect (P>0.05).

There was no interaction effect [F(2,25)=1.146, P=0.334,

ηp2=0.084], nor time or treatment effects (P>0.05) for serum concentration of CRP (Figure 52d). Analyses conducted with natural log transformed data or with the Kruskal-Wallis test for
non-parametric raw data confirmed no effects on CRP serum concentrations (P>0.05). There
were no gender differences in baseline concentrations of TNF-α (P=0.931), IL-6 (P=0.061),
IL-1β (P=0.233) and hsCRP (P=0.895).
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Figure 5-2. Serum concentration of inflammatory biomarkers before and after 8 weeks intervention.
Values are mean and error bars are standard deviation (A and B) or median and 1st and 3rd quartile (C
and D). TNF, tumor necrosis factor; IL, interleukin; CRP, c-reactive protein. A) time*treatment effect
(P=0.002); *HighAntho vs Control (P=0.047, independent t-test). B) No significant treatment effect
between groups (P>0.05); *HighAntho vs LowAntho (P<0.001, independent t-test); C) No significant
treatment effect between groups (P>0.05); *HighAntho > Control (P=0.019, Mann-Whitney test)
*HighAntho > LowAntho (P<0.025, Mann-Whitney test) D) No significant changes or differences
between groups (P>0.05).
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24-hour ambulatory blood pressure
There was no significant interaction, treatment or time effects on any of the 24-hour
ambulatory systolic and diastolic BP parameters (daytime, nocturnal and 24-hour, and dipping
patterns) (Table 5-3). Based on the classification of dipping ratios(322) of <0.9 and >0.8 for
‘normal dipping’, <1.0 and >0.9 for ‘reduced dipping’, and >1.00 for ‘no dipping and rising’,
there were several changes between treatments. The mean systolic and diastolic BP dipping
pattern of controls changed from ‘normal dipping’ at baseline to ‘reduced dipping’ after the
intervention, and the systolic BP dipping pattern of the high anthocyanins group changed from
‘reduced dipping’ at baseline to ‘no dipping and rising’ after the intervention. There were no
gender differences for any baseline 24-hour ambulatory systolic and diastolic BP parameters
(all P’s>0.05)
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Table 5-3. 24-hour ambulatory blood pressure measures before and after treatment in control and intervention groups
Parameter

Day SPB

Day DPB

24h SPB

24h DPB

Nocturnal SBP

Nocturnal DBP

Group

n

PRE

POST

Control

9

126.3 (SD 14.6)

125.2 (SD 11.9)

LowAntho

8

127.7 (SD 14.8)

129.3 (SD 16.9)

HighAntho

7

127.4 (SD 14.7)

123.7 (SD 17.2)

Control

9

79.9 (SD 10.9)

79.9 (SD 9.1)

LowAntho

8

78.5 (SD 9.3)

81.3 (SD 9.5)

HighAntho

7

80.2 (SD 12.5)

77.6 (SD 8.1)

Control

9

121.4 (SD 12.9)

123.1 (SD 9.6)

LowAntho

8

123.2 (SD 11.0)

126.0 (SD 14.3)

HighAntho

7

129.3 (SD 19.9)

125.8 (SD 16.4)

Control

9

75.9 (SD 9.3)

78.4 (SD 8.3)

LowAntho

8

74.6 (SD 8.4)

78.8 (SD 10.4)

HighAntho

7

80.0 (SD 13.8)

76.9 (SD 10.0)

Control

9

113.6 (SD 10.5)

117.5 (SD 8.9)

LowAntho

8

114.9 (SD 11.9)

115.0 (SD 14.2)

HighAntho

7

126.4 (SD 27.1)

126.9 (SD 22.4)

Control

9

71.0 (SD 8.4)

73.4 (SD 9.8)

Timea

Treatmenta

Time x treatmenta

0.595

0.911

F(2,21)=0.453, P=0.642,
ηp2=0.041

0.962

0.970

F(2,21)=0.610, P=0.553,
ηp2=0.055

0.818

0.745

F(2,21)=1.573, P=0.231,
ηp2=0.130

0.529

0.928

F(2,21)=1.463, P=0.254,
ηp2=0.122

0.510

0.284

F(2,21)=0.324, P=0.727,
ηp2=0.005

0.623

0.651
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LowAntho

8

68.6 (SD 9.9)

72.3 (SD 14.1)

HighAntho

7

71.9 (SD 19.1)

74.5 (SD 13.4)

Control

8

0.89 (SD 0.04)

0.93 (SD 0.08)

LowAntho

8

0.90 (SD 0.09)

0.89 (SD 0.08)

HighAntho

7

0.98 (SD 0.08)

1.03 (SD 0.17)

Control

9

0.89 (SD 0.09)

0.92 (SD 0.08)

LowAntho

8

0.88 (SD 0.09)

0.88 (SD 0.09)

HighAntho

7

0.95 (SD 0.12)

0.96 (SD 0.12)

F(2,21)=0.470, P=0.632,
ηp2=0.043

SPB night/day
ratio

0.308

0.103

F(2,20)=0.559, P=0.581,
ηp2=0.053

0.555

0.236

F(2,21)=0.067, P=0.935,
ηp2=0.006

DPB night/day
ratio

Values are means and standard deviation. SPB, systolic blood pressure; DPB, diastolic blood pressure; ηp2, partial eta-squared. a P-values for two-factor mixed
ANOVA.
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Microvascular function
No significant time or treatment effects were observed in the microvascular parameter ‘peak
value’ in CVC. A trend towards an interaction effect was found [F( 2,24)=2.678, P=0.089, ηp2=0.182];
however, post-hoc comparisons showed no significant effect of time nor treatment. There was no
significant interaction effect [F(2,24)=0.309, P=0.737, ηp2=0.025], nor time or treatment effects
(P>0.05) in the maximum perfusion following the PORH test (PORHmax). There were no gender
differences in baseline BF (P=0.549), BZ (P=0.858), RF (P=0.451), PV (P=0.675) and PORHmax
(P=0.884) in CVC. A full description of all microvascular parameters in PU and CVC (PU/mmHg) are
presented in the supplementary material (Table 5-S3).

Figure 5-3. Microvascular reactivity parameters before and after 8 weeks intervention. Values are mean
and error bars are standard deviation. CVC, cutaneous vascular conductance in PU/mmHg; PORHmax,
post occlusive reactive hyperaemia maximum perfusion. No significant differences between groups
(P>0.05).
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5.4 Discussion
Consumption of anthocyanins provided in the QGP juice for 8 weeks decreased the
serum concentrations of TNF-α in older adults diagnosed with MCI. This effect was only
observed in the intervention group that received the higher dose (201 mg/day) of anthocyanins.
Other outcomes, including other inflammatory biomarkers, parameters of microvascular
function and 24-hour ABP measures, remained unchanged in both treatment groups compared
to controls.
The major finding in the present trial was the significant decrease in serum
concentration of TNF-α in the high-anthocyanins intervention group. TNF-α is a cytokine with
a wide range of pro-inflammatory activities that is primarily produced by macrophages,
endothelial cells, and smooth muscle cells of atherosclerotic arteries(64). TNF-α may influence
the atherosclerotic process by causing metabolic perturbations and by increasing the expression
of surface leukocyte adhesion molecules, chemokines and enhancing the production of other
cytokines and growth factors. High concentrations of TNF-α have been associated with
premature coronary artery disease, acute myocardial infarction, peripheral arterial disease, and
congestive heart failure(277). The magnitude of reduction of TNF-α observed with the high
dose of anthocyanins in this trial [2.86 pg/mL, from 10.46 (SD 2.84) to 7.60 (SD 3.18) pg/mL]
may have important clinical implications considering the predictive role of TNF-α in CVD
events supported by previous studies. For example, in a case-cohort study comprising 105 CAD
cases and 638 individuals randomly selected from a cohort of 5,404 participants aged 35–74
years (mean follow-up of 6.1 years), TNF-α was significantly and independently associated
with CAD (adjusted HRs=1.87;1.31–2.66)(331). Furthermore, there is evidence from largescale prospective studies, such as a cohort of 2225 participants (70-79 years old) without
baseline CVD that were assessed for incident coronary heart disease, stroke and congestive
heart failure events during an average follow-up of 3.6 years. In that cohort, TNF-α was
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significantly associated with coronary heart disease (per TNF-α SD increase: RR, 1.22; 95%
CI, 1.04 to 1.43) and congestive heart failure (per TNF-α SD increase: RR, 1.59; 95% CI, 1.30
to 1.95) events(76). The beneficial outcomes reported in such studies were found for
differences in TNF-α, which supports the clinical significance of the reductions observed in
our study in older adults.
Despite a reduction in concentrations of IL-6 (36.6%) and Il-1β (23.3%) in the group
receiving the high-anthocyanins treatment, these changes were no longer significant after
adjusting for baseline imbalances between groups. These two interleukins are fundamental
components of atherosclerosis, related to CVD(190,277). IL-6 is highly expressed by the
vascular endothelium and the pharmacological inhibition of IL-6 can improve endothelial
function(332). Concerning the clinical significance of the magnitude of effect found in the high
anthocyanins intervention in the present trial, a significant reduction of 2.08 pg/mL represents
a change from baseline of approximately 2 SD [5.68 (SD 1.24) pg/mL at baseline to 3.60 (SD
0.97) pg/mL after the treatment]. Other studies have reported hazard ratios of 1.80 according
to each 1-SD increase in IL-6 for risk of first-ever cerebrovascular events in individuals with
vascular risk factors, but without any pre-existing CVD(333). Furthermore, in a meta-analysis
of 17 prospective studies investigating clinical coronary outcomes (i.e., myocardial infarction
or coronary death), an odds ratio of 1.61 (95% CI 1.42–1.83) was found per 2 SD increase in
baseline IL-6(334).
IL-1β synthesis is significantly upregulated after cardiovascular events such as
myocardium infarction, as well as in advanced plaque formations in atherosclerosis disease;
thus, it has been investigated as a therapeutic option in secondary and tertiary prevention of
CVD(335). Local stimuli in the plaque induces the generation of active IL-1β through the
action of a molecular assembly known as the inflammasome(336). The convincing links
between IL-1β to pro-inflammatory diseases, such as atherosclerosis indicates this cytokine as
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a potential therapeutic target to improve cardiovascular outcomes(336). In support of this, an
anti-IL-1β therapy was investigated in a large randomized, double-blind, placebo-controlled
trial of 10,061 patients (median follow-up of 3.7y) with a history of myocardial infarction and
CRP ≥ 2 mg/L. Treatment with canakinumab (anti-IL-1β monoclonal antibody) led to 15%
reduction in major adverse CVD events (p=0.007)(313). Furthermore, a meta-analysis
including 6 cohort studies with 1,855 CVD cases and 18,745 non-cases with follow-up times
between 5-16y investigated the role of Interleukin-1 receptor antagonist (IL-1RA), which
counter-regulates IL-1β as an endogenous inhibitor in vivo by blocking the binding site for IL1β, and incident CVD(337). A pooled standardized hazard ratio (95% CI) for incident CVD of
1.11 (1.06–1.17) was found after adjustment for age, sex, anthropometric, metabolic, and
lifestyle factors (P<0.0001)(337). A lack of studies regarding the magnitude of change in IL1β concentration and CVD prediction makes it complex to extrapolate the clinical significance
of our findings. The significant treatment effect showed a reduction of 0.140 pg/mL [0.600
(IQR 1.065) pg/mL at baseline and 0.460 (IQR 0.215) pg/mL after treatment] in the high
anthocyanins group, representing a 23.3% reduction from baseline. Overall, our results,
combined with the strong evidence pinpointing a relationship between inflammatory markers
and CVD suggest that food-derived anthocyanins may be an important potential therapeutic
treatment for reducing inflammation and promoting subsequent health benefits. Another
feature of the present trial is that all participants were diagnosed with MCI; therefore, such
health benefits may have potential implications in attenuating the advance of cognitive decline,
considering that a number of studies support the association between neuroinflammation and a
decline in cognitive function(338–340). Several studies support that CVD are associated with
increased risk of cognitive impairment and dementia(314–316,341,342).
The changes observed in concentrations of TNF-α were not accompanied by changes
in vascular outcomes, either in parameters derived from the 24h ABP measurements or
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microvascular assessment. The observed changes in mean systolic and diastolic BP dipping
pattern are not clinically relevant considering that the ratios were borderline compared to the
classification thresholds and had relatively high standard deviations. It has been suggested that
the cutaneous microcirculation may mirror generalized systemic vascular dysfunction(343),
and continuous high frame assessment of skin perfusion over wide areas measured through
LSCI provides strong reproducibility for vascular challenges(344,345). Based on the ability of
anthocyanins to exert beneficial physiological effects as antioxidant and anti-inflammatory
compounds, we proposed that treatment might improve the vascular reactivity measured using
the PORH test. Mechanisms underlying the vascular reactivity response in the PORH test are
still being elucidated; however, the findings of the present study suggest that reduction in serum
TNF-αmay not affect microvascular reactivity in older adults. The use of the LSCI in
nutritional intervention studies is relatively new, and there are no published reference values
for predicting any condition, nor values that have an established clinical significance in
vascular biology literature. A recent study from our group found a positive acute effect
(postprandial) of anthocyanins in attenuating vascular and inflammatory responses to a high
fat high energy meal challenge in overweight older adults(346). An improvement for both
microvascular and macrovascular function was observed in that study, as assessed by PORH
test combined with LSCI and FMD, respectively.
Limitations of our study include the variation in sample size and gender between
treatment groups. Forty two percent of participants were hypertensive; however, this is
reflective of the overall prevalence of 45.2% in Australians aged 75 years and older(347) and
values did not significantly differ between the treatment groups. The limited sample size
hindered the ability to conduct sub-analysis by sex or prevalence of hypertension, and may
have influenced the baseline between-group imbalances in IL-6 and IL-1β concentration
despite randomization. It should be noted that RCTs conducted in participants with MCI have
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a complex recruitment process, and that the sample size of the present study was larger than
that in 44% of included studies in a systematic review of treatments for MCI(348). A key
feature in the design of this study was the placebo chosen for the control group. Investigation
of a specific bioactive compound, such as anthocyanins, in a clinical trial using foodstuffs as
the vehicle of delivery is challenging. Foods that are rich in a particular flavonoid sub-class
may also contain other classes of flavonoids or other bioactive compounds, such as other
polyphenols, and/or inorganic compounds (such as nitrate) that might have similar or
synergistic effects on the outcomes assessed. We aimed to evaluate the effect of two different
doses of anthocyanins using differently processed juice as the food source. A potential
limitation that may have led to the absence of effects in the low dose group is that the average
mean intake of anthocyanins in the usual diet of participants was similar to the intervention per
se (68mg compared to 48mg). In order to isolate the effect of anthocyanins from other
bioactives, apricot juice was provided as the control due to its lack of anthocyanins, but its
similarly matched macro- and micronutrient content, as well as its polyphenol profile(206),
including flavanols (such as quercetin), catechins and epicatechins, all of which are potential
mediators of cardiovascular health(200,303–305).

5.5 Conclusion
A daily high dose of fruit-derived anthocyanins for 8 weeks decreased serum
concentrations of TNF-α in older adults diagnosed with MCI. This change was not
accompanied by effects on other inflammatory biomarkers, 24h ABP or microcirculation
function, and no effects were observed in the low anthocyanin dose treatment group.
Considering the major role of the inflammatory response in CVD and cognitive decline, our
finding suggest that a regular high intake of anthocyanins may have clinical implications in
this high-risk group; however, further studies with a longer follow-up and larger sample size
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are required to better elucidate if these changes in concentrations of TNF-α will alter CVD risk
and progression of cognitive decline.

5.6 Supplementary Material
Table 5-S1. Description of Post-Occlusive Reactive Hyperaemia Microvascular Parameters
MICROVASCULAR PARAMETER
Baseline flow (BF)

Biologic zero (BZ)
Resting flow (RF)
Peak perfusion value (PV)
PORHmax

DESCRIPTION
The most stable 30 seconds within the first 2 minutes
of reading.
The most stable 3 seconds displaying the lower
values before the deflation of the cuff.
BF-BZ
Five seconds period starting from the highest value
in the first rise (slope) after deflation of the cuff
PV - RF

PORHmax, post-occlusive reactive hyperaemia maximum perfusion
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Table 5-S2. Nutrition information of the test meal and fruit juices (250 mL)
Lowanthocyanins
QGP juice

Highanthocyanins
QGP juice

Apricot juice

Energy (kcal)

113

98

96

Protein (g)

0.7

0.6

0.7

Fat – total (g)

< 0.1

< 0.1

< 0.1

Saturated fat (g)

< 0.1

< 0.1

< 0.1

Carbohydrates (g)

23.1

22.2

22.2

Dietary fibre (g)

2.9

4.4

4.0

7

6

2

Vitamin C (mg)

0.3

0.3

1.2

Anthocyanins1 (mg)

46.7

200.8

03

Anthocyanins2 (mg)

43.7

206.8

03

Sodium (mg)

1

High Performance Liquid Chromatography; 2pH differential method; 3Phenol-explorer23. Remaining
values were obtained from the Australian Food Composition Database 201924.
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Table 5-S3. Post-occlusive reactive hyperaemia parameters
Parameter

PV (pu)

PV (cvc)

PORH (cvc)

RF (cvc)

BZ (pu)

BF (pu)

Group

n

PRE

POST

Control

11

96.4 (SD 29.3)

93.5 (SD 22.0)

LowAntho

9

85.9 (SD 10.2)

82.2 (SD 12.6)

HighAntho

7

99.4 (SD 16.9)

101.4(SD 19.6)

Control

11

1.02 (SD 0.26)

1.01 (SD 0.21)

LowAntho

9

1.00 (SD 0.13)

0.90 (SD 0.15)

HighAntho

7

1.00 (SD 0.26)

1.07 (SD 0.25)

Control

11

0.55 (SD 0.22)

0.53 (SD 0.22)

LowAntho

9

0.42 (SD 0.15)

0.36 (SD 0.09)

HighAntho

7

0.56 (SD 0.24)

0.50 (SD 0.18)

Control

11

0.29 (SD 0.06)

0.31 (SD 0.07)

LowAntho

9

0.39 (SD 0.09)

0.38 (SD 0.07)

HighAntho

7

0.28 (SD 0.08)

0.37 (SD 0.18)

Control

11

17.4 (SD 9.3)

15.7 (SD 6.9)

LowAntho

9

16.2 (SD 6.6)

14.4 (SD 3.9)

HighAntho

6

15.2 (SD 2.9)

18.9 (SD 4.9)

Control

11

44.8 (SD 12.3)

44.9 (SD 14.2)

Timea

Treatmenta

Time x treatmenta

0.565

0.637

F(2,24)=0.418, P=0.663,
ηp2=0.034

0.598

0.637

F(2,24)=2.678, P=0.089,
ηp2=0.182

0.084

0.149

F(2,24)=0.309, P=0.737,
ηp2=0.025

0.200

0.047

F(2,24)=1.403, P=0.265,
ηp2=0.105

0.971

0.827

F(2,24)=3.369, P=0.051,
ηp2=0.219

0.134

0.564
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LowAntho

9

49.9 (SD 6.7)

49.0 (SD 7.4)

HighAntho

6

44.0 (SD 8.3)

53.9 (SD 16.1)

F(2,24)=2.751, P=0.084,
ηp2=0.187

Data are mean and standard deviation. PV, peak value; ηp2, partial eta-squared ;PORH, post-occlusive reactive hyperaemia; RF, resting flow; BZ, biologic
zero; pu, perfusion units; BF; baseline flow; cvc, cutaneous vascular conductance
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Figure 5-S1. Cutaneous perfusion recorded with laser speckle contrast imaging during postocclusive reactive hyperaemia. BF, baseline perfusion; BZ, biologic zero; PV, peak value
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Figure 5-S2. Consort 2010 Flow diagram
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CHAPTER 6: Conclusions and recommendations

6.1 Overview of core findings

The studies presented in this thesis utilised different study design methodologies to
address the central research questions concerning the role of dietary intake of flavonoids and
anthocyanins on vascular function, inflammation and other cardiovascular disease risk factors.
Following an extensive exploration of the literature, gaps were identified that guided the design
and conduct of all studies. The availability of resources, expertise of the research team
collaborators and access to healthcare services in the local area were also considered in order
to maximize efficiency of the body of work. This approach covered domains of: a)
Epidemiological evidence: analytical work conducted in national representative cohort of
Australian women: b) Knowledge syntheses: systematic literature review of randomized
clinical trials; and c) Experimental evidence: conduct of two clinical trials to assess the acute
and chronic effect of anthocyanin nutritional interventions in older adults.
The first gap identified was a lack of data from the Australian population regarding the
association between the dietary intake of flavonoids and incidence of hypertension.
Epidemiological evidence suggests that a higher dietary flavonoid intake is associated with a
reduced risk of several chronic diseases, including hypertension. However, different dietary
patterns and cuisines between populations affects the amounts and types of flavonoid-rich
foods consumed, while differing lifestyle factors and life expectancy also influence the
contribution of flavonoids to the incidence of hypertension and other chronic diseases.
Moreover, the flavonoid content of foods is likely to be influenced by seasonality and differ
between geographic areas. Therefore, a study was developed to investigate the association
between intake of flavonoids and their subclasses, and incidence of hypertension among
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Australian women in two age cohorts. Findings from this population-based prospective study
showed an association between a higher dietary intake of flavonoids and lower incidence of
hypertension. In the middle-aged cohort, higher intakes of the flavonoid subclasses, flavones,
isoflavones and flavanones, found mainly in orange and orange juice, apples and soy milk,
were associated with a reduced risk of hypertension among middle-aged women followed-up
over 15 years. In the younger, reproductive-aged cohort, a higher intake of total flavonoids and
flavanols, attributed mainly to orange juice, red wine, apples and onions, were associated with
a reduced risk of hypertension over a 12 year follow-up period. These findings contribute to
the current knowledge in his field, which may be used in nutritional messages and policies
aiming to improve the cardiovascular health of women at these two different life stages.
Interestingly, in two other similar studies (119,185) that found a reduction in incident
hypertension in other countries, the benefits were attributed to other groups of flavonoids, such
as flavonols and anthocyanins. This confirms a need to conduct studies in different regions
because of variations in cultural and socio-economic characteristics that influence dietary
patterns. Taken together, such findings suggest that nutritional messages and policies aiming
to improve the cardiovascular health through increased consumption of dietary flavonoids may
vary from population to population, as well as between different ages ranges.
The epidemiological study had a general approach regarding the classes of flavonoids,
while the other studies that composed this Thesis had a scope focused in clinical nutrition, and
advanced into a more specific investigation of one class of flavonoids, the anthocyanins.
Additionally, although blood pressure and hypertension were addressed in all of these studies,
a variety of parameters related to CVD were further investigated. Among studies that evaluate
the effects of anthocyanins on CVD risk factors and associated biomarkers, a number of studies
addressed the potential acute effects of anthocyanins in studies using a HFM challenge;
however, such finding were not yet collated and synthetized. This gap led to the second study

186

of this Thesis, a systematic literature research that was conducted focusing in knowledge
synthesis of the postprandial effects of anthocyanins on CVD risk factors in HFM studies. A
total of 13 eligible studies were included and beneficial effects of anthocyanins were reported,
with most promising results indicating attenuation of deleterious postprandial effects on
oxidative stress and antioxidant status, triacylglycerol and total cholesterol concentrations,
vascular endothelial function and inflammatory biomarkers. Post-prandial changes in blood
pressure and lipoproteins were least affected by anthocyanins. The systematic literature review
identified beneficial effects of acute dietary anthocyanin interventions on CVD risk factors
following a HFM challenge; however, due to the heterogeneity in changes of some parameters
identified between the studies, further studies are required in order to advance the current
knowledge of the underlying mechanisms between post-prandial imbalances and CVD
incidence and progression, and to investigate how these imbalances are attenuated by bioactive
compounds such anthocyanins.
Based on the findings from the systematic literature review, another gap that was
identified was a need for a more robust investigation of vascular function in the postprandial
state, which along with the immune response, is an important predictor for CVD risk. This is
particularly evident in older adults, as several studies support a gradual loss of the vascular
function, and a new immune-metabolic viewpoint for age-related diseases, termed
‘inflammaging’ which is characterized by a chronic low-grade inflammation. Additionally,
excessive adiposity at all ages is associated with an up-regulation of a pro-inflammatory state,
as the accumulation of adipose tissue mass promotes the secretion and release of inflammatory
mediators. This process also leads to chronic low-grade inflammation that is driven by a
nutrient excess and/or overnutrition and has the same mechanisms as those underpinning
“inflammaging”. Therefore, a clinical trial was designed in the same setting of investigating
the postprandial effects of anthocyanins following a HFHE meal challenge; however the
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novelty was related to evaluation of both macro and microvascular parameters by combining
classical and novel techniques with the latest imaging technologies, such as the flow-mediated
dilatation (FMD) and the Laser Speckle Contrast Imaging (LSCI). In addition to vascular
function assessments, classical CVD biomarkers such as lipid profile and blood pressure, and
inflammatory biomarkers were also evaluated. To our knowledge, this is the first study to
conduct this type of protocol in studies with nutritional interventions. The findings supported
the postprandial effects of food anthocyanins in improving several CVD biomarkers in
overweight older adults following a HFHE meal challenge. Potentially beneficial effects were
observed in parameters of both macrovascular and microvascular function, as well as some
inflammatory biomarkers. The HFHE meal challenge induced increases in postprandial blood
pressure, diacron reactive oxygen metabolites, triacylglycerol and total cholesterol; however,
anthocyanin consumption did not attenuate these responses. Such results corroborated with
findings from the systematic literature review, and also advanced knowledge concerning the
postprandial vascular regulation and how the effects exerted by anthocyanins can be observed
in different vascular beds. Our findings contribute new evidence regarding the potential
protective effect of dietary anthocyanins on vascular function and inflammatory responses,
parameters that have a major role on atherosclerotic disease and CVD events.
Considering there were still several gaps to be addressed regarding the longer term
effect of anthocyanins in this vascular-inflammatory axis in older adults, another clinical trial
was conducted to investigate the chronic effects (8 weeks) of two different doses of foodanthocyanins on inflammatory markers associated with CVD risk factors, along with analysis
of microvascular function and 24-hour ABP. This study was also conducted in older adults, but
the aim was to investigate such parameters in individuals that had a diagnosis of Mild Cognitive
Impairment, a neurodegenerative condition that shares pathological mechanisms with CVD. A
daily high dose of fruit-derived anthocyanins for 8 weeks decreased serum concentrations of
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TNF-α. These changes were not accompanied by effects on other inflammatory biomarkers
(IL-6, hs-CRP and IL-1β), 24h ABP or microcirculation function, and no effects were observed
in the low anthocyanin dose treatment group. Considering the major role of the inflammatory
response in CVD and cognitive decline, our findings suggest that a regular high intake of
anthocyanins may have clinical implications in this high-risk group; however, further studies
with a longer follow-up are required to better elucidate whether this change on the i will alter
overall CVD risk and/or progression of cognitive decline.
Overall, the findings from all four studies suggest that flavonoids and anthocyanins
have an important role as a potential non-pharmacological treatment option to improve vascular
health and reduce cardiovascular risk.

6.2 Strengths and limitations
The specific methodological strengths and limitations of each study have been
addressed in-depth in each of the research chapters. However, more general aspects of the
thesis will be addressed in this section.
Firstly, for the epidemiological aspect, the main strength of this study was the
representative sample of Australian women across two age cohorts, the prospective design, and
repeated measures over time. The statistical approach of using generalized estimated equations
allowed for adjustments of key confounding factors. Potential confounders were extensively
explored in our models, as there was access to a wide range of demographic, hypertension risk
factor and dietary intake variables. The large sample size allowed for a stepwise regression
with bidirectional elimination in order to create the models for such adjustments, therefore
avoiding multicollinearity and overfitting of the model. Recruitment of participants was
proportional to the population size in all Australian states, thereby enabling generalizability of
the study findings to Australian women generally. However, a few limitations were present
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such as the absence of men in this cohort and the use of self-reported data for hypertension.
Moreover, the FFQ used may lack detail about some flavonoid-rich food sources due to it being
developed over two decades ago, and it may not have included relevant high-flavonoid food
items that have increased in popularity over this period, such as blackberries, cherries,
blueberries and raspberries. This could have led to an underestimation of anthocyanin intake,
as the mean intake in the present study was 4.7 mg/day in the middle-aged and 5.0 mg/day in
the reproductive-aged cohort, compared to 24.2 mg/day reported in 2019 in the overall
Australian population from a nationally representative sample that used two 24-hr recalls as
the method of dietary assessment (222). This may have hindered a more robust overall message
from the Thesis, considering that all other three studies focused in this specific flavonoid
subclass.
The most notable challenge and limitation of conducting the systematic literature
review was to address a wide range of CVD-related biomarkers assessed in this type of acute
clinical trial. We had originally considered conducting a meta-analyses for the various
outcomes included in the review, particularly for those outcomes that were most frequently
reported. However, the major variation in reporting of the included meal challenge studies,
presentation of data according to varying postprandial time points, and the use of different
methodologies to measure outcome variables rendered the possibility of meta-analysis or other
pooled analyses as unfeasible. However, the narrative analysis remains valuable. Another
source of heterogeneity in the included studies may have resulted from the variability in the
macronutrient and energy content of the HMF challenges, particularly regarding the types of
fat, as well as the format in which the meals were delivered.
Despite these limitations, all included studies were conducted in young and middleaged adults (mean age ranging from 20.2 to 46.9y), but there were differences in mean BMI
between studies (two studies included participants with BMI<25kg/m2 [34,40], while six
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targeted those with BMI between 25 and 30kg/m2 [26,29–31,36,39] and three included
participants with BMI>30kg/m2 [33,35,38]). Another feature in the design of this type of study
is that tests are conducted over multiple time periods following the HFM challenge, thereby
raising a concern that the number of false positive findings may be inflated. For this reason,
the interpretation of results found for only one or a few time points, and that were not sustained,
had to be interpreted with caution. Still, parameters that have been used in included studies to
investigate oxidative stress and antioxidant status represented a wide range of analytical
methods, and there is no formal mechanism to establish consensus regarding the optimal
biomarkers to use in such nutritional interventions (259,261). The main strength of the
systematic literature review was to present the body of evidence to date in a clear and concise
way, as well as discussing and suggesting which results need to be further investigated and
identifying gaps that require further elucidation. The latter was what guided the design of the
clinical trial included in Chapter 4.
A key feature of the two studies that comprised the experimental evidence part of this
thesis was the ability to evaluate microcirculatory functioning using a cutting edge technology,
the Laser Speckle Contrast Imaging (LSCI) method. Assessment of the microcirculation has
been performed for decades, but the LSCI method is the first one to provide excellent
reproducibility to assess skin microvascular reactivity (97). The main methodological strength
of the acute study that evaluated postprandial effects of anthocyanins in older adults following
a HFM challenge was the inclusion of a more robust evaluation of the vascular function, by
exploring both macro and microvascular parameters by combining classical (FMD) and novel
techniques (LSCI). To our knowledge, this is the first study to conduct this type of protocol in
a nutritional intervention study. Although this innovative design allowed us to explore
macrovascular and microvascular function, a few limitations need to be highlighted. It was not
possible to repeat the FMD and microvascular reactivity tests in case of experimental errors,
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such as a participant movement during testing, due to the protocol of measures being collected
at specific time points. Concerning the evaluation of endothelial and non-endothelial
mechanisms in vascular and microvascular reactivity, we were not able to conduct nitratemediated dilation nor iontophoresis of sodium nitroprusside due to the time limit between
measures, considering it would be not viable, if not impossible, in a postprandial study to
conduct a protocol with all of these measures. Another strength that can be attributed to both
the acute and longer clinical trials was the choice of the control intervention. It is challenging
to investigate a specific bioactive compound, such as a specific flavonoid, in a clinical trial
using foods as vehicles for delivery. A food item that is a rich source of a particular flavonoid
may also contain other classes of flavonoids, or still other bioactive compounds such as other
polyphenols and/or inorganic compounds (such as nitrate), that might have similar or
synergistic effects on the outcomes to those being assessed. In order to address this issue, the
choice of the placebo food item for the control arm is an important consideration. A placebo
that is only matched in macro, or even micronutrient content, can underestimate the effects of
other bioactive compounds. In both studies, we aimed to evaluate the acute effect of
anthocyanins using Queen Garnet plum juice as the intervention food source. In order to isolate
the effect of anthocyanins, we chose apricot juice as the control due to its lack of anthocyanins,
but its similarly matched macro- and micronutrient content, as well as its polyphenol profile
(281), that includes flavanols (such as quercetin), catechins and epicatechins, all of which are
potential mediators of cardiovascular health (20,303,305,349). The choice of this control juice
allowed the effects of only anthocyanins to be isolated from other bioactive compounds.
Concerning the second clinical trial that was conducted in older adults with a diagnosis of MCI,
the small sample size was its main limitation. In addition to recruitment being slower than
expected due to difficulties recruiting this patient group, and difficulties in ensuring a definite
clinical diagnosis of MCI, the trial had to be cut short due to COVID-19 restrictions that
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prevented face-to-face data collection. The smaller sample size of the final clinical trial has
probably introduced issues of insufficient power and possibility of Type II error.
Overall, the main strength of this thesis is that all studies were highly connected to each
other. The epidemiological study, answered a more general research question using data from
a nationally representative cohort study, while the research questions were more narrowly
focused in the experimental clinical trials. The systematic literature review and the first clinical
trial addressed similar research outcomes. Both clinical trials shared several important features
such as: food-based intervention of anthocyanins; microcirculation assessment using LSCI
technology; evaluation of inflammatory biomarkers; and were conducted in older adults. The
combination of studies presented in this thesis together helps address the main research
questions in a complementary manner.

6.3 Future research and recommendations
Findings from this thesis have contributed novel findings to advance knowledge of this
topic, but have also highlighted new areas for further research.
In the epidemiological approach of investigating the association of dietary intake of
flavonoids in the Australian population, further studies with a similar methodology, but in
different populations with varying outcomes are recommended. For example, a national
representative study investigating the incidence of hypertension among Australian men is still
lacking. Likewise, data on the incidence of other CVD and related conditions and their
associations with the dietary intake of flavonoids are also needed. Considering that the dietary
intake, in terms of sources of flavonoids, vary according to many factors over time, it is
recommended that such analyses need to be conducted from time-to-time in different
populations, using an appropriate and updated dietary intake assessment method for accurate
estimation of dietary intake. Still, the possibility of evaluating blood, urine and faecal samples,
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and measures of vascular function along with an epidemiological analyses, provide an
important link between experimental and epidemiological evidence and would help elucidate
the mechanisms underlying the dietary intake of flavonoids and incidence of various disease
states.
At the clinical level, a number of key points and recommendations for future research
are highlighted below:
•

The choice of the intervention and placebo is an important consideration in order to
compare and generalise conclusions across studies. As the evidence of the effects of
anthocyanins to prevent and treat certain conditions is increasing, future studies will
need to investigate specifically which types of anthocyanins exert these effects, as well
as identify the synergistic effects of nutrients and food matrices that may be
contributing to observed effects. There is also a need to focus on methodologies to
stabilise or reduce degradation of these bioactive compounds in foods during
processing and handling. In cases where the research question aims to explore the
effects of a specific bioactive compound, a placebo choice that isolates this compound
is recommended, in order to avoid non-specific effects of other polyphenols or nutrients
such as dietary fibre and nitrate concentration.

•

The assessment of postprandial parameters as CVD risk factors is still relatively new
and less explored when compared to fasting measures. Although the findings from the
systematic literature review and the clinical trial presented in Chapter 4 showed
improvements in a variety of biomarkers associated with CVD, future studies should
explore whether such changes will impact on CVD incidence and progression, and how
these measures may differ from fasting measures. In other words, determine how the
fasting and postprandial flow-mediated dilatation scores differ in prediction values for
later CVD events.
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•

The use of the LSCI technology to assess microvascular function has increased in recent
years; however, this remains an exploratory field, and further studies that include this
outcome measure are required in the context of CVD research. There is a need to
standardize the vascular reactivity tests protocols, in order to allow better comparison
between studies and improve reproducibility of such tests within and between studies.
Moreover, studies with larger sample sizes are required to investigate the association
between these new microvascular parameters and other already established measures
of vascular function, such as the gold-standard FMD, as well to investigate the
association with other traditional and related CVD biomarkers.

•

In studies that evaluate risk factors that are shared between CVD and neurodegenerative
conditions such as in the clinical trial presented in Chapter 5, a longer nutritional
intervention and follow-up period would be recommended in order to investigate if the
improvements of such risk factors will reduce the overall incidence of CVD events and
attenuate further cognitive decline over time.

6.4 Conclusion
The studies included in this thesis have addressed several gaps related to the role of
dietary intake of flavonoids and anthocyanins on vascular function, inflammation and other
cardiovascular disease risk factors. This body of research was conducted across three levels of
evidence: Epidemiological evidence; Knowledge syntheses; and Experimental evidence. This
was achieved by utilising a wide range of scientific methods in the medical sciences field,
especially in nutritional epidemiology and clinical nutrition. From secondary data analysis, to
the identification, selection and critical appraisal of relevant primary research, and the design
and execution of original clinical trials, a vast array of interpersonal and laboratory skills,
statistical methods and forms of presenting results were utilized.
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Collectively, the four studies included in this thesis have resulted in novel findings that
contributed to the advance of the knowledge in this field, as well as highlighting what is still
have to be addressed, and identified new gaps to be explored in future studies. In a broader
context, this research strengthen the concept that bioactive compounds, as part of diet or as a
nutritional intervention, may have positive impact in health outcomes and help to attenuate the
burden and incidence of chronic diseases.
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